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ABSTRACT!
 
Early stage prostate cancer is highly manageable using definitive radical 
prostatectomy and/ or radiotherapy techniques. Unfortunately, for some men, 
transition to castrate-resistant prostate cancer is both inevitable and incurable with 
few life-extending therapies available. Therefore, there is an urgent need for novel 
agents to improve the oncological and survival outcomes for these last-resort patients. 
One such modality may be α1-adrenoceptor antagonists. Clinically, some of these 
drugs reportedly increase benign and cancerous prostatic apoptosis. In vitro studies 
indicate that this anticancer effect occurs via !1-adrenoceptor independent 
mechanisms. However, the cytotoxic profile of these drugs have yet to be fully 
characterised, including whether these agents may be useful in improving anticancer 
treatment efficacy.  To address the gaps in literature, the relative cytotoxic potencies 
and underlying cell death mechanisms (apoptosis and autophagy) were determined for 
six !1-adrenoceptor antagonists on castrate-sensitive and castrate-resistant prostate 
cancer cells. Molecular mechanisms were explored using immunoassays. The effects 
of these drugs were also investigated on normoxic or hypoxic irradiated prostate 
cancer cells to mimic outer and inner portions of a solid tumour. In an adjunct study, 
comparisons between the cytotoxic profile of doxazosin and the chemotherapeutic 
mitomycin c were made in an in vitro model of bladder cancer intravesical therapy. 
Overall, prazosin and doxazosin were found to be equipotent and were the most 
potent of all investigated drugs by inducing apoptosis and/or autophagy in a cell type-
dependent manner. This cytotoxic effect was attributed to decreased mTOR/p70S6K 
signalling coupled with increases in p27 and p38 mitogen-activated protein kinase. 
Prazosin was also found to selectively radiosensitise hypoxic prostate cancer cells.  
This effect was characterised by increased reactive oxygen species and suppression of 
HIF-1! accumulation, further implicating mTOR-signalling as an underlying 
cytotoxic mechanism. Exploration of additional novel uses of these drugs revealed 
that doxazosin was 6-times more toxic than mitomycin C on bladder cancer cells in 
modelling of intravesical therapy. Taken together, these findings indicate that 
prazosin/doxazosin have potent cytotoxic actions in prostate cancer cells that are 
characterised by induction of apoptosis and autophagy, possibly by inhibition of the 
mTOR-signalling cascade. This is the first report of radiosensitising effects of these 
 ii 
drugs in prostate cancer cells, suggesting that these agents may have novel clinical 
benefits for patients undergoing radiotherapy. Likewise, the preliminarily findings of 
this thesis suggest that these drugs may be a novel alternative intravesical treatment 
option for bladder cancer and warrants further investigation. 
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INTRODUCTION!
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1.1! HUMAN!PROSTATE:!ANATOMY!AND!FUNCTION!
 
The prostate is an exocrine gland of the male reproductive system, which sits anterior 
to the rectum and inferior to the urinary bladder, surrounding the urethra. The prostate 
is considered to be comprised of three zones (peripheral, translational and central) and 
one fibromuscular zone referred to as the “stroma” (Fine and Reuter, 2012). 
 
Briefly, the primary function of the prostate is to secrete alkaline fluid, which makes 
up a portion of semen.  Prostatic fluid consists of several enzymes, including the 
prostate specific antigen (PSA), a protease secreted by prostatic epithelial cells that 
acts to reduce the viscosity of semen to improve sperm motility (National Health and 
Medical Research Council, 2013).  Additionally, the prostate contracts to prevent 
urine from escaping the urinary bladder or entering the seminal vesicles during 
ejaculation or urination (U.S. National Library of Medicine, 2012). 
1.2!PROSTATE!CANCER!
!
INCIDENCE(
Prostate cancer is the most commonly diagnosed male cancer in the world and 
accounts for approximately 30% of all newly diagnosed cancers in Australia (Bray et 
al., 2013, Australian Institute of Health and Welfare, 2014) (Figure 1.1). The mean 
age at diagnosis in Australia is 68.2 years old (Figure 1.2). As shown in Figure 1.3, 
the age-standardised incidence rate of prostate cancer has increased between 1982 and 
2007, with estimates of approximately 18,140 new cases in 2016 (Australian Institute 
of Health and Welfare, 2012).  Of note, prostate cancer incidence appeared to increase 
drastically in the early 1990’s with the introduction of PSA testing.  As a direct result 
of PSA testing, more prostate cancers were detected and diagnosed earlier, giving a 
false sense of increased incidence when in fact these men would have been diagnosed 
at a later time upon the presentation of symptomatic disease in the pre-PSA era.  It is 
currently estimated that 1 in 7 Australian men are at risk for developing prostate 
cancer before the age of 85 (Australian Institute of Health and Welfare, 2013, 
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Australian Institute of Health and Welfare, 2014). Interestingly, a recent retrospective 
review of autopsy studies identified a significantly higher incidence of prostate cancer 
than previously thought (Bell et al., 2015). Overall, it was reported that approximately 
59% of men had prostate cancer by the time they reached their eighth-decade of life. 
The disparity between reported incidence by the Australian Institute of Health and 
Welfare (AIHW) statistics and the recent findings is likely due to the characteristic 
slow growth of early stage prostate cancer tumours that are often asymptomatic for 
many years.  In essence, the AIHW statistics represent the risk of being diagnosed, 
not necessarily the risk of developing prostate cancer.  
 
There are regional and ethnicity differences amongst prostate cancer incidence 
amongst Australian men. Aboriginals and Torres Straight Islanders are less likely than 
other Australian men to be diagnosed with prostate cancer.  Interestingly, men living 
in moderately remote areas are at a lower risk, whereas men residing in very remote 
areas are at a greater risk for being diagnosed with prostate cancer than those living in 
other locations (Australian Institute of Health and Welfare, 2013). One study reported 
in 2005 that men residing in regional or remote areas were 16% less likely to undergo 
PSA testing compared to the rest of the Australia (Coory and Baade, 2005). In a 
subsequent study conducted in 2011, the same authors reported that there was no 
significant improvement in prostate cancer diagnosis between men in rural compared 
to men residing in urban areas (Baade et al., 2011).  These findings indicate that 
despite technological advances and improved access to healthcare, there are 
unidentified factors that contribute to the regional inequalities in prostate cancer 
diagnosis with in Australia that remain to be explored further. While only speculative, 
differences in prostate cancer incidence amongst geographical locations in Australia 
may be in part to regional differences in diet, social norms and access to healthcare 
(discussed in more detail below).  
 
Inequalities in prostate cancer incidence also exist between men of other ethnic 
backgrounds. One recent retrospective chart review evaluated prostate cancer 
incidence amongst American men with Asian-Pacific background (Chao et al., 2016). 
The authors reported a greater incidence of advanced prostate cancers amongst Asian 
Indian/Pakistani, Filipino, Hawaiian and Pacific Islanders (odds ratio = 1.37, 1.38, 
1.70 and 1.90, respectively) compared to non-Hispanic white males. While data on 
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diet and social norms of these men is not available, it can be speculated that many of 
these men would have been subject to westernised diet influences controlling for this 
typical confounding factor. This suggesting that genetic variations between ethnicities 
may play a significant role the apparent disparity in prostate cancer incidence 
amongst Asian-Pacific men compared their White male counterparts.  
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Figure'1.1.'Global'map'illustrating'the'most'prevalent'male'cancers'across'184'countries.'The'top'nine'male'cancers'in'the'world'are:'
prostate'(blue,'111'countries),'colorectal'(red,'25'countries),'stomach'(green,'14'countries),'Kaposi'sarcoma'(brown,'11'countries),'lip'and'
oral'cavity'(orange),'bladder'(pink),'lung'(gold),'liver'(yellow)'and'nonEHodgkin’s'lymphoma'(light'blue)'(Bray'et'al.,'2013).'Image'
reprinted'with'permission'from'copyright'holder.'
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Figure' 1.2.' Incidence' of' prostate' cancer' in' Australia' according' to' age' groups'
(Australian'Institute'of'Health'and'Welfare,'2015)'
 
 
 
 
'
Figure'1.3.'Age'standardised'prostate'cancer'incidence'(number'of'new'cases)'per'
100,000' Australian' males' between' years' 1983' –' 2011.' (Australian' Institute' of'
Health'and'Welfare,'2015).''
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'MORTALITY'
Prostate cancer is the second most common cause of cancer-specific death, and the 
fourth leading cause of death amongst Australian men (Australian Institute of Health 
and Welfare, 2013, Australian Institute of Health and Welfare, 2014). Over more than 
two decades, between 1968 and 2012, prostate cancer mortality decreased by a 
modest ~8% (36 deaths to 28 deaths per 100,000 males, respectively) (Figure 1.4). 
Importantly, this downward trend is expected to continue, with an estimated 26 deaths 
per 100,000 Australian men in 2020 (Australian Institute of Health and Welfare, 
2013).  However, the risk of cancer-specific mortality differs between ethnicity and 
regional demographics.  For example, in the United States, African-American men are 
twice as likely to die as a result of prostate cancer compared to Caucasians.  
Furthermore, mortality rates are ten-times greater for African-Americans than men 
residing in Asian countries (Higgins, 1975, Newman, 1996). In Australia, a recent 
retrospective study identified a higher 5-year mortality rate amongst aboriginal men 
compared to non-aboriginal men (17.5% vs. 11.4%, respectively), with aboriginal 
men nearly 50% more likely to die from the disease. This difference is likely 
attributed to differences in treatment choice, with one-third of aboriginal men 
choosing to forgo treatment for local prostate cancer (Rodger et al., 2015).  
 
ECONOMIC'BURDEN'
Between 2008 and 2009, the economic burden of prostate cancer has tripled since 
1994, and costs Australians over $349 million dollars annually (Australian Institute of 
Health and Welfare, 2013, Marks et al., 2010). However, the actual cost to the 
Australian community are likely to be significantly greater as the majority of 
estimates do not incorporate the costly end-of-life treatments, which include more 
frequent hospitalisations, palliative care and hospice (Roehrborn and Black, 2011). 
Furthermore, as prostate cancer survival rates are increasing, more men are likely to 
require long term follow-up and/or maintenance therapy which represents additional 
economic burden.   
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Figure' 1.4.' Prostate' cancerGspecific' mortality' in' Australia' between' years' 1968' –'
2012'(Australian'Institute'of'Health'and'Welfare,'2015).  
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RISK'FACTORS''
The most common factors associated with increased risk of prostate cancer include 
positive family history, African American decent, high basal levels of PSA and, most 
importantly, advancing age. One study evaluated the prostates of men who underwent 
a radical cysto-prostatectomy for advanced bladder cancer, with no prior suspicions of 
prostate cancer (Pignot et al., 2015). Overall, 21.4% of men (518 of 2424) aged 
between 41.5 and 95.6 years were found to have prostate cancer in their tissue 
specimen, which was strongly correlated with age increasing age. Both prostate 
cancer incidence (percent of evaluated prostate glands) and percent of cancers with 
Gleason score ≥ 7 was found to increase with age, from 15% and 0% amongst 50-59 
age group to 31% and 37% in men 75 years or older, respectively.  
 
Other risk factors linked to prostate cancer incidence may include hypertension and 
metabolic syndrome (Bhindi et al., 2015). To date, no clear association has been made 
between prostate cancer incidence and typical independent risk factors for cancer such 
as history of tobacco smoking, weight gain/ obesity (Ho et al., 2014, Ohwaki et al., 
2015).  
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PROGNOSTIC'FACTORS''
There are no currently defined clinical predictors of disease progression and overall 
survival, although there is strong evidence to suggest that high Gleason scores (≥ 8 – 
10) are correlated with poorer survival outcomes (Rusthoven et al., 2014). One study 
identified significant differences between Gleason scores (7 vs. 8, 8 vs. 9, and 9 vs. 
10) in predicting cancer-specific survival, suggesting that there is a relative stepwise 
decrease in survival at 4 years with increasing Gleason scores (Rusthoven et al., 
2014).  
 
Interestingly, life style factors, such as cigarette smoking, and those leading to obesity 
and hypertension, may also be linked to disease progression and poor survival 
outcomes. While not established predictors of prostate cancer diagnosis, cigarette 
smoke and obesity are positively correlated with increased disease aggression, shorter 
duration to biochemical recurrence and higher mortality (Ho et al., 2014, Moreira et 
al., 2014, Moller et al., 2015). Furthermore, patients with uncontrolled and untreated 
hypertension had an increased risk for biochemical recurrence after RP compared to 
those who received treatment for controlled or uncontrolled hypertension (Ohwaki et 
al., 2015, Asmar et al., 2013).  
!
DIETARY'FACTORS'
The protective or adverse effect of the consumption of fatty acids, vitamins, calcium, 
fruits and vegetables on prostate cancer risk remains unclear (Lin et al., 2015). 
However, a previous literature review of meta-analyses and clinical trials identify 
associations between dietary patterns and prostate cancer risk (Lin et al., 2015). 
Retrospective studies identified a higher risk amongst individuals consuming a 
Westernised diet, whereas Asian and Mediterranean diets were associated with 
reduced prostate cancer risk (Ambrosini et al., 2008, Kapiszewska, 2006). A growing 
body of evidence including pre-clinical, retrospective and prospective clinical studies 
indicates a negative correlation between number of cups of coffee/day and risk, 
recurrence, and fatality of prostate cancer (Lu et al., 2014). Of particular interest, one 
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study identified an inverse correlation between solar radiation and prostate cancer 
incidence amongst Australian men (Loke et al., 2011). These findings have been 
attributed to increased vitamin D production as a result of greater sun exposure, which 
was been postulated to have a protective effect against prostate cancer.  However, the 
evidence between vitamin D and risk of prostate cancer is mixed, with pre-clinical 
and retrospective studies identifying a higher and lower risk (Schenk et al., 2014), 
whereas clinical trials have determined no benefit of vitamin D supplementation.  
 
CARCINOGENESIS'
The development of prostate cancer is a lengthy process that typically unfolds over 
the course of ten years or more. The development of pre-neoplastic lesions known as 
high-grade prostatic intraepithelial neoplasia (HGPIN) (Sakr et al., 1994) is the only 
known pre-cursor to prostate cancer.  Similar to prostate cancers, HGPIN is most 
commonly found in the peripheral zone of the prostate, distantly followed by the 
transition and central zones. Evidence suggests HGPIN contains similar genetic and 
molecular abnormalities as early invasive prostate cancers; HGPIN incidence 
increases with age and is more common amongst African American men (Sakr et al., 
1996), and HGPIN is frequently identified within surgically removed prostates for 
prostate cancer treatment. 
 
Clinical significance of HGPIN diagnosis and is still unclear, however identification 
of unilateral or bilateral multifoci HGPIN is associated with a 48.1 and 57.8% risk for 
being diagnosed with prostate cancer five years following initial biopsy (Lee et al., 
2010b).   Unfortunately, there are no current clinical parameters that may help 
identify which men with HGPIN histological findings have the highest risk 
developing prostate cancer (Clouston and Bolton, 2012a, Clouston and Bolton, 
2012b). 
 
Chromosomal or molecular abnormalities may tip the scale from pre-neoplastic 
HGPIN to invasive carcinoma of the prostate (Abate-Shen and Shen, 2000). Most 
commonly, the loss of one or more regions on chromosomes 8p, 10q and 13q, 
specifically areas which code for tumour suppressors genes may play a pivotal role in 
the development of prostate cancer.  For example, loss of functional PTEN (10q) and 
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Rb (13q) (retinoblastoma) tumour suppressor proteins, which negatively regulate 
proliferation, is frequently absent from prostate cancer tissues and cell lines (Abate-
Shen and Shen, 2000, van Bokhoven et al., 2003), leading to uncontrolled 
proliferation and tumour growth. 
 
PROSTATE'CANCER'TREATMENT'
An overview of typical progression of prostate cancer through various treatment 
modalities is show in Figure 1.10 at the end of this section. 
!
SCREENING!
Today, there is no population-wide screening protocol for early detection of prostate 
cancer in men (Heidenreich et al., 2011). A growing number of clinical studies 
indicate screening is positively correlated with reduced incidence of mortality 
compared to standard care (Schroder et al., 2009, Schroder et al., 2012). However, 
urological societies have concluded the economic, physical, and emotional burden 
from intensive screening regimen and high incidence of false-positives offsets the 
marginal increase in diagnosis and survival rates (Heidenreich et al., 2011).  
 
DIAGNOSIS!
Prostate cancer is diagnosed using a multi-study approach employing the use of 
digital rectal examination (DRE), prostate specific antigen (PSA) and transrectal-
ultrasound (TRUS) guided biopsies (Heidenreich et al., 2011). Relative serum PSA 
levels are considered the “gold standard” for detection and are strongly correlated 
with the increased risk of prostate cancer (Heidenreich et al., 2011). In contrast to 
previous practice, PSA kinetics known as PSA “velocity” or “doubling time” have not 
been shown to have significant predictive benefits in identify men at risk of prostate 
cancer compared to PSA levels alone (O'Brien et al., 2009, Heidenreich et al., 2011).  
 
The current recommended PSA threshold is ≥ 4.0 ng/ml (Heidenreich et al., 2008, 
Heidenreich et al., 2011). Nearly all prostate cancers are detected by PSA serum 
levels, with half of cases utilizing both DRE and PSA testing. In contrast, only 5% of 
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prostate cancers are detected by DRE alone (Baade et al., 2012a). In the presence of 
inconclusive DRE or PSA levels, the patient risk factors are taken into consideration 
to determine if further work up is required. Where indicated, patients undergo 
diagnostic TRUS or transperineal laterally-directed biopsy for histopathological 
examination (Heidenreich et al., 2011). 
 
Of particular note, the use of PSA testing is not without controversy. As mentioned 
previously, there was a dramatic increase in prostate cancer incidence in with the 
introduction of PSA testing in the early 1990’s leading to earlier detection, 
particularly in men with asymptomatic disease. This poses the issue of over-diagnosis 
and thus potential over-treatment of asymptomatic cancers, many of which would 
passively exist without life-limiting consequences. For example, one recent Australian 
study found that nearly three-quarters (73%) of Australian men diagnosed with 
prostate cancer presented to their health care provider with other non-cancer related 
concern (Baade et al., 2012a).  Over-treatment as a result of over-diagnosis is 
problematic in that it subjects men to unnecessary treatment that may impact quality 
of life. On the contrary, PSA testing may. An Australian conducted review of PSA 
testing (± DRE) in asymptomatic men concluded there is no evidence to suggest a 
benefit or negative impact relating to cancer-specific and all cause-mortality, 
compared to no PSA testing. On the contrary, PSA testing was associated with 
reduced occurrence of metastatic disease at diagnosis (National Health and Medical 
Research Council, 2013), providing an opportunity to treat early disease where 
curative treatments, such as surgery, are most effective.   
!
!
!
STAGING!
Prostate cancer is staged using the common tumour, node, and metastasis 
classifications outlined by the Union International Contra Cancer 2002 guidelines 
(Wittekind et al., 2002). Additionally, a Gleason score is given as measure of disease 
aggression and prognosis (Xu and Zhou, 2014). The Gleason score is on a scale 
ranging from 2 to 10, with 10 being the most aggressive, and is obtained by 
summation of the two most common grades (1-5) amongst biopsy specimens.  
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The combination of DRE, PSA levels, magnetic resonance imaging, tumour grade and 
number of positive foci are used to for local staging (T-staging). In Australia, early 
stage or local disease is defined as T1-T2; whereas locally advanced or high-risk 
prostate cancer is defined as diagnosis of clinical stage of T3 – T4 cancer and/or 
early-stage (T1-T2) with serum PSA levels > 20 ng/ml  (Australian Cancer Network 
Management of Metastatic Prostate Cancer Working Party, 2010).  
 
Prostate cancers with moderate to high Gleason scores are at greater risk of involving 
surrounding or distant lymph nodes. Accurate lymph node staging (N-staging) via 
extended lymphadenectomy is primarily reserved for men who are considering 
curative treatment options. Staging for skeletal metastasis (M-staging) is indicated for 
men with PSA levels greater than 20 ng/ml and tumours with minimal differentiation 
(Heidenreich et al., 2008). 
 
!
LOCAL!TREATMENT!
Local treatment strategies are determined on an individual basis taking into account 
disease stage and life expectancy. For patients with less than 10 years of life 
expectancy or low stage cancer, are often recommended for active surveillance. 
Active surveillance (or watchful waiting) involves careful follow-up in which 
treatment is postponed until disease advancement may impede the patient’s quality of 
life (Heidenreich et al., 2008, Heidenreich et al., 2011).   
 
Patients that have 10 years or greater life expectancy with organ-confined disease are 
commonly recommended for radical prostatectomy (RP), external-beam radiation 
therapy, or brachytherapy (Heidenreich et al., 2011). However, for Australian men, 
initial treatment choice is impacted by several factors such as age, proximity to 
treatment centre, and socioeconomic status (Baade et al., 2012b).  
'
Surgical'treatment'
Radical prostatectomy (RP) is the only treatment option with significant long-term 
survival benefits compared to other more conservative therapies (Bill-Axelson et al., 
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2011), including radiation therapy (Shao et al., 2013) for men with early-stage 
disease. While RP best serves men with organ-confined disease, those with locally 
advance disease may also benefit from RP (Heidenreich et al., 2008), with one study 
identifying survival rates of 95% and 90% at 5 and 10 years, respectively (Ward et al., 
2005).  However, this delicate procedure carries the risk of impotence and 
incontinence, which may adversely affect quality of life (Barry et al., 2012).  
'
Radiation'therapy'
!
External!beam!radiation!therapy!
Radiation therapy (dose of ≥ 72-81 Gy) is considered a curative treatment option for 
patients with a life expectancy of greater than 5-10 years who are diagnosed with 
local/ early-stage (T1-T2) or locally advanced disease (clinical stage T3-T4), as well 
as those who are unfit for surgery (Heidenreich et al., 2008). In Australia, limited 
field radiotherapy is the primary treatment used to minimise toxicity. However, whole 
pelvic radiotherapy, including para-aortic nodes, may be indicated in some patients 
with high-risk disease.  In contrast, 3D conformal radiotherapy allows the radiation 
field to be shaped to the prostate by CT imaging, therefore allowing highly-targeted 
radiation and minimise toxicity to the surrounding tissues or organs (Australian 
Cancer Network Management of Metastatic Prostate Cancer Working Party, 2010).  
 
In Australia, men with locally advanced disease are recommended to receive dose-
escalation of ≥ 74 Gy, if tolerable, using 3D conformal techniques (Australian Cancer 
Network Management of Metastatic Prostate Cancer Working Party, 2010). Although 
the clinical or survival benefit of radiotherapy alone for this group remains unclear, 
there is a marked improvement in overall survival when radiotherapy was combined 
with hormonal therapy (Widmark et al., 2009). Furthermore, the combination of 
radiotherapy with neo-adjuvant and long term adjuvant hormonal modulation (2 
years) significantly improved 5-year biochemical disease free survival in men with 
locally advanced disease (Heidenreich et al., 2008).  
 
Post-operative adjuvant radiotherapy of the tumour bed, particularly in the case of 
positive surgical margins, is well known to have important oncological and survival 
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benefits for locally advanced prostate cancer. Three separate prospective randiomised 
clinical trials (SWOG8794, EORTC2291 and ARO 92-02) evaluated the clinical 
effect of adjuvant radiotherapy following RP for men with locally advanced disease 
(Heidenreich et al., 2008, Swanson et al., 2008, Wiegel et al., 2009). All three trials 
reported improved time to PSA-progression free survival, with two of the three trials 
demonstrating improved locoregional (i.e. tumour site and associated areas) treatment 
response and radiographic disease-free progression in RP patients who received 
adjuvant radiotherapy compared to the observation groups. Furthermore, the data 
from the SWOG8794 trial demonstrated marked improvement in overall survival 
amongst the adjuvant radiotherapy treatment arm (74% compared to 66% at 12 years 
follow up) (Swanson et al., 2008). As a result of these three trials, the American 
Urological Association (AUA) and ASTRO strongly recommend the use of adjuvant 
radiotherapy in men with high-risk pathological findings, including seminal vesicle 
involvement, following RP to reduce the risk of biochemical relapse and potentially 
improve survival outcomes (Thompson et al., 2013).   
 
Brachytherapy!
Men with early stage, intermediate risk prostate cancer with baseline good prostate-
specific lower urinary tract symptoms (LUTS) may be candidates for brachytherapy 
(Heidenreich et al., 2008). Brachytherapy is the permanent or temporary implantation 
of a radioactive “seed” in the prostate gland to deliver high doses of radiation to the 
cancer, while minimising toxicity to adjacent tissues and organs (Australian Cancer 
Network Management of Metastatic Prostate Cancer Working Party, 2010)). On one 
hand, permanent transperineum brachytherapy involves the surgical placement of 
multiple radioisotope (Iodine-125). Where as a temporary implant brachytherapy 
involves the placement of radioactive compounds (usually Iridium-92) into the 
prostate via the urethra (Australian Cancer Network Management of Metastatic 
Prostate Cancer Working Party, 2010).  
 
In locally advanced disease, there is little clinical evidence demonstrating superiority 
of brachytherapy over surgery or external beam radiotherapy with regards to 
oncological or survival parameters (Australian Cancer Network Management of 
Metastatic Prostate Cancer Working Party, 2010). However, in some cases the 
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combination of low-dose radiotherapy and high-dose brachytherapy may provide 
clinical benefit.  
!
ANDROGEN@DEPRIVATION!THERAPY!
The use of androgen-deprivation therapy (ADT) is indicated in early-stage hormone-
responsive with symptomatic, locally advanced (clinical stage T3-4), or metastatic 
disease (Grimm et al., 2002, Australian Cancer Network Management of Metastatic 
Prostate Cancer Working Party, 2010). Additionally, ADT is also indicated for men 
who by preference or due to comorbidities, choose to forgo curative treatment 
options, and opt for pharmacological management of their disease (Australian Cancer 
Network Management of Metastatic Prostate Cancer Working Party, 2010). As its 
name suggests, ADT capitalises on the androgen-dependence of prostate cancer 
growth by suppressing testosterone production to castrate levels (< 50 ng/dl) or by 
inhibiting the survival-promoting actions of the androgen receptor (described in detail 
below).  
 '
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AndrogenGdependence'of'prostate'cell'growth'and'proliferation'
As shown in Figure 1.5, the main circulatory androgen testosterone is primarily 
synthesised (~95%) by the testes and regulated by gonadotropin-releasing hormone 
(GnRH)-mediated pituitary stimulation and subsequent lutenising hormone (LH) 
release (Feldman and Feldman, 2001, Debes and Tindall, 2002, Chen et al., 2009, 
Lamb and Neal, 2013). LH acts on the Leydig cells of the testes to induce synthesis of 
testosterone. In contrast,  approximately five percent of endogenous testosterone is 
produced by the adrenal glands in response to the corticosteroid-adrenocorticotropic 
hormone pathway (Lamb and Neal, 2013). Non-malignant and malignant prostate cell 
proliferation is regulated by testosterone-androgen receptor (AR) interactions. In 
prostate cells, testosterone crosses the cell membrane and is enzymatically converted 
to dihydrotestosterone (DHT) by 5α-reductase. DHT binds to cytosolic AR triggering 
dimerization and activation by phosphorylation (Feldman and Feldman, 2001). The 
activated AR translocates to the nucleus where it binds to androgen response elements 
in the promoter region of DNA stimulating transcription of target genes to induce 
protein synthesis (Geller et al., 1987), PSA secretion, cell proliferation and survival 
(Feldman and Feldman, 2001).  In the context of prostate cancer, blocking of 
androgen-mediated AR signalling through suppression of androgen synthesis or direct 
inhibitory actions on AR, ADT indirectly triggers prostate cancer cell death (Westin 
et al., 1995, Kimura et al., 2001), leading to rapid decline in both PSA (< 0.5 ng/mL) 
and tumour growth (Choueiri et al., 2009).  
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'
Figure' 1.5.' Testosterone' biosynthesis' via' hypothalamoGpituitaryG' gonadal' axis'
(Lamb'and'Neal,'2013).'Image'reprinted'with'permission'from'copyright'holder.'
'
'
Clinical'use'of'ADT''
In addition to surgical castration (orchiectomy), ADT is achieved centrally and/or 
peripherally through GnRH agonists (referred to as lutenising hormone releasing 
hormone [LHRH] agonist) or anti-androgens, respectively (Heidenreich et al., 2008).  
While highly effective, prevalence of orchiectomy has significantly dropped in 
Westernised nations primarily due to the irreversible nature of the procedure  
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THE HORMONAL BASIS OF 
PROSTATE GROWTH
The hormonal basis of the prostate was first
identified by John Hunter in 1786.1
He observed that rutting mammals such as
male roe deer or moles have larger and more
mucus-rich prostates during the rutting
season. In 1876 Pelikan observed that the
males in the Skopsty sect in Russia, who
practised castration as a method of
promoting sexual purity, had prostate glands
that were the same size as those of children.2
It was not until the 1940s, however, that the
true significance of the androgen regulation
of the prostate was discovered, when Charles
Huggins reported that canine castration led
to prostate shrinkage and reduced acid
phosphatase secretion, while testosterone
injection had the opposite effect.3 He went
on to show in eight patients with prostate
cancer that orchidectomy and adrenalectomy
removed circulating androgens.4
T en in 1982 Redding and Schally
demonstrated that a gonadotrophin-
releasing hormone (GnRH) analogue,
D-Trp6, effectively reduced normal prostate
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Figure 1. Hypothalamo–pituitary–gonadal axis. Gonadotrophin-
releasing hormone (GnRH) released from the hypothalamus induces
release of gonadotrophins including luteinising hormone (LH) and
adrenocorticotrophic hormone (ACTH) from the anterior pituitary
gland. These in turn stimulate release of testosterone (T) from the
testes (>95% of total T production) and from the adrenal gland
(<5%). Testosterone is converted to its more active metabolite
dihydrotestosterone (DHT) by 5-alpha reductase. Both T and DHT 
can act as ligands to the androgen receptor (AR)
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(Connolly et al., 2012). As such, androgen-deprivation is frequently achieved using 
the LHRH agonists including leuprolide and goserelin, which act to suppress the 
gonadal-testosterone synthesis axis. In contrast, anti-androgens, including 
bicalutamide, flutamide, nilutamide and cyproterone acetate are competitive 
antagonists of AR, preventing AR-mediated transcription of survival genes.  While 
LHRH agonists are available to Australian men as a monotherapy, LHRH agonists are 
commonly prescribed in combination with anti-androgens to target both production 
and AR activity to provide a total androgen-blockade. Furthermore, anti-androgens 
mitigate the tumour promoting effects of the characteristic LHRH agonist-induced 
“flare” of testosterone production as a result of adrenal compensation (Thompson, 
2001). Unlike LHRH, prescribing limitations exist of available anti-androgens 
(nilutamide, bicalutamide and flutamide), in that all but cyproterone acetate, are only 
available for treatment of locally advanced or metastatic disease when prescribed in 
conjunction with LHRH analogues (Australian Cancer Network Management of 
Metastatic Prostate Cancer Working Party, 2010). 
 
While ADT may be used as a primary treatment modality for locally advanced or 
metastatic prostate cancer with contraindications or due to treatment preference, ADT 
is particularly effective in conjunction with definitive (curative) treatments such as RP 
and/ or radiotherapy for locally advanced or high-risk prostate cancer. As briefly 
touched on previously, combination ADT and radiotherapy has been shown to have 
significant survival benefits in men with locally advanced disease (Widmark et al., 
2009). Similarly, short course neoadjuvant and adjuvant ADT with radiation therapy 
provided a survival benefit over radiotherapy alone in men with either intermediate- 
(Jones et al., 2011) or high-risk disease (Koie et al., 2014). Survival benefits of 
androgen-deprivation is not just limited to radiotherapy, as results from a small scale 
clinical study found that three-year overall survival was not different between groups 
receiving neo-adjuvant ADT prior to definitive RP or radiotherapy (Koie et al., 2014). 
 
Controversy exists with regard to the timing of ADT in locally advanced disease. 
While generally considered safe, continual use of ADT predisposes men to a plethora 
of quality of life-limiting effects affecting such as cardiovascular disease, 
hypertension, weight gain and obesity, metabolic syndrome, diabetes, osteoporosis 
and decline in cognitive abilities (Mohler, 2014).  It is well documented that many 
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prostate cancers progress slowly; therefore one must wonder if subjecting elderly men 
to the adverse side effects of ADT pays off with significant survival benefit.  The 
choice between immediate or delayed ADT is more clear-cut in the context of 
metastatic disease, particularly in symptomatic cases, as immediate induction of ADT 
provides significant improvement in relative risk of prostate-cancer specific mortality 
(17% reduction) compared to delayed ADT regimens (Loblaw et al., 2007, Mohler, 
2014). However, in some circumstances, ADT has been reported to negatively impact 
non-cancer-specific mortality (15% increase), and consequently fail to provide an 
overall survival benefit (Loblaw et al., 2007, Mohler, 2014).  To balance the 
therapeutic benefits and quality of life-limiting side effects, many oncologists 
successfully employ intermittent ADT via employing immediate, yet, short term 
androgen-deprivation to drive disease to remission, and using subsequent cycles of 
androgen-deprivation upon presence of biochemical recurrence or clinically 
measurable disease. Two separate systematic reviews of available clinical studies, 
inclusive of both phase II and III trials, uncovered similar oncological and survival 
benefits between continual and intermittent ADT, with the side effect profile favoring 
intermittent treatment protocols (Abrahamsson, 2010, Magnan et al., 2015). This 
suggests, that intermittent ADT may be a viable alternative to classical continuous 
androgen-deprivation treatment regimens, with improved tolerability and quality of 
life parameters, particularly in sexual potency. Additionally, reduction in adverse side 
effects associated with intermittent treatment may improve non-cancer- and cancer-
specific overall survival outcomes. However this remains to be fully elucidated in a 
randomised prospective clinical trial.  
 
BIOCHEMICAL!RECURRENCE!
Generally, a consecutive rise in PSA following definitive local therapy such as 
radiotherapy or RP is considered to be biochemical recurrence of prostate cancer. 
However, debate exists surrounding the precise PSA threshold to be considered 
recurrence following curative treatments. A review of the literature suggests a PSA 
level > 0.2 – 0.6 ng/mL above nadair in men with or without intact prostates may be 
clinically appropriate (Stephenson et al., 2006).  However, several independent 
institutions have suggested the use of tailored definitions of biochemical recurrence 
based on clinicopathologic stratification of prostate cancers into low-, intermediate- 
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and high-risk groups (Taplin, 2003, Morgan et al., 2014). Importantly, the American 
Society for Therapeutic Radiology and Oncology (ASTRO) has made it clear in their 
guidelines for the interpretation of PSA rise following radiotherapy that an increase in 
PSA alone does not necessarily translate to clinical recurrence, therefore does not 
justify additional treatment in every context. The ASTRO are also point out that there 
are no current definition of biochemical failure which has been linked to better or 
worse treatment or survival outcomes (1997). 
 
Unfortunately, an estimated one-fifth of men will experience disease recurrence 
following curative treatment modalities. In the context of RP, an estimated 19% of 
men will experience biochemical treatment failure (Freedland et al., 2005). Similarly, 
between 23 - 34%, of men receiving definitive radiotherapy will experience a rise in 
PSA levels, however, time to biochemical failure is less clear (Kupelian et al., 2002, 
Zumsteg et al., 2015). Of these men, an estimated 34% will develop appreciable 
clinical metastasis (Pound et al., 1999). However, it appears that the time to from 
biochemical relapse (PSA rise) to measureable disease progression is somewhat 
worse for those treated with definitive radiotherapy; with an estimated 5.4 years to 
distant metastasis compared to 8 years in RP treated tumours (Zumsteg et al., 2015, 
Pound et al., 1999).  
 
Depending on several factors, including but not limited to; comorbidities, prior 
treatment history, extent of local or distant metastasis, Gleason score or PSA levels at 
diagnosis, patients may undergo salvage RP or radiotherapy, induction of first-line or 
second-generation ADT, or a combination of one or more therapies. Retrospective 
and clinical studies report better prognoses following salvage RP or radiotherapy, 
with these salvage treatments favoring lower Gleason score and PSA serum levels at 
biochemical treatment failure (Chade et al., 2011, Trock et al., 2008). Specifically, a 
moderately sized multi-institute clinical study identified a significant three-fold 
increase in cancer-specific survival, as well as an improved overall survival benefit 
when salvage external beam radiotherapy was employed following RP failure, 
particularly within two years of biochemical relapse. Furthermore, PSA doubling time 
was a prognostic marker for prostate cancer-specific survival, and survival benefit 
was only observed in men with PSA doubling times less than six months (Trock et al., 
2008).  Further biochemical failure following local salvage therapies is often treated 
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with ADT. In the event of disease progression during first-generation ADT 
(bicalutamide, flutamide, cyproterone acetate, etc.), the disease is considered to have 
transition to the incurable and often fatal variant known as castrate-resistant prostate 
cancer.     
 
TRANSITION'TO'CASTRATIONGRESISTANT'DISEASE'
While the use of ADT is very effective for most men in reducing prostate tumour 
growth, there exists a caveat. Unfortunately, for many men disease progression during 
or after ADT is inevitable, facilitated by restoration of AR survival signaling through 
various mechanisms described below (Yuan and Balk, 2009). ADT failure indicates 
transition from castration-sensitive to castration-resistant prostate cancer (Mottet et 
al., 2011). Castration-resistant prostate cancer was previously, however, incorrectly 
referred to as androgen-insensitive, androgen-independent or hormone-refractory. It is 
now known that despite failure of anti-androgens, AR signaling continues to promote 
prostate cancer growth and survival (described in further detail below). 
 
Castration-resistant prostate cancer (CRPC) is commonly defined by rising PSA 
levels, despite castrate-levels of testosterone, in the presence of either symptomatic 
disease or radiographic evidence of disease progression (Scher et al., 2008, Saad and 
Hotte, 2010). It remains to be elucidated whether the transition to CRPC is a natural 
progression of the disease or provoked by ADT. Unfortunately, it appears the use of 
ADT is a double-edge sword. Firstly, it reduces testosterone to castrate levels, rapidly 
inducing tumour regression and palliation of symptoms. However, ADT may select 
for prostate cancer cells containing mutations that allow these cells to evade therapy 
and continue to proliferate under low levels of testosterone (Steinkamp et al., 2009, 
Chen et al., 2009). In contrast to what was previously known, true androgen-
independence is rare and most CRPCs maintain AR signaling activity despite ADT 
failure (Attard et al., 2009, Wang et al., 2009).  
 
Several mechanisms for the establishment of CRPC have been described including 
AR overexpression, hypersensitivity, up-regulation of alternate survival mechanisms 
or intratumoural androgen production (Tilley et al., 1996, Feldman and Feldman, 
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2001, Steinkamp et al., 2009, Yuan and Balk, 2009, Eikenberry et al., 2010, Sun et 
al., 2010). One pre-clinical study evaluating the impact of testosterone (and DHT) on 
prostate cancer cell growth through mathematical modeling demonstrated that in fact 
low levels of circulating testosterone (or DHT) selects for cells containing aberrant 
AR expression, and therefore may contribute to ADT failure and disease progression 
(Eikenberry et al., 2010).  
 
Of particular importance are AR mutations in the ligand-binding domain (LBD) and 
splice variants devoid of LBD. In the first instance, LBD mutations may lead to 
“promiscuous” or decreased specificity for other ligands, including anti-androgens. 
This promiscuous agonistic activity has been demonstrated clinically in men 
experiencing rising PSA levels despite receiving anti-androgen therapy (Small and 
Srinivas, 1995, Culig et al., 1999). In this case, PSA levels soon decline following 
drug withdrawal, suggesting a switch from antagonist to agonist in these prostate 
cancers. This observation is known as “anti-androgen withdrawal syndrome”. More 
recently, truncated AR splice variants lacking a LBD were found to be constitutively 
active, participate in survival signaling, and is unaffected by ADT (Sun et al., 2010). 
These LBD-lacking AR splice variants have also been isolated clinically and 
correlated to risk of progression (Zhang et al., 2011) 
 
More recently, intratumoural synthesis of androgens (primarily DHT) has been shown 
to be a novel mechanism for evading central and/or peripheral androgen-deprivation. 
Previous literature suggest in response to ADT, prostate tumour cells express a gain-
of-function mutation in 3beta-hydroxysteroid dehydrogenase type 1 (3βHSD1) either 
by selective pressure of ADT or through adaptation mechanisms. The function of 
3βHSD1 is to catalyse the synthesis of DHT from dehydropiandrosterone (an adrenal-
synthesised steroid) (Chang et al., 2013) thereby driving AR-signaling in the absence 
of circulating testosterone.   
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TREATMENT!FOR!CASTRATION@RESISTANT!DISEASE!
'
SecondGgeneration'antiGandrogens'
As previously mentioned, prostate cancer is typically considered to be castration-
resistant (CRPC) following first generation ADT failure. It is now known that ligand-
dependent AR signaling remains an important aspect of CRPC progression so may 
still be responsive to further hormonal manipulation. The new second generation 
ADT agents, enzalutamide and abiraterone acetate may be useful as the primary 
treatment for CRPC. Previously in the United States and Australia, these drugs were 
only approved as a salvage therapy following chemotherapy-treatment failure. 
However, the FDA recently expanded both enzalutamide and abiraterone acetate 
treatment indications to include chemotherapy-naïve men with castrate-resistant 
disease (Ning et al., 2015, D'Amico, 2014). Following suit, the TGA has made similar 
changes to the abiraterone acetate treatment indications in Australia, although no 
modification to the enzalutamide treatment indications have been made to 
date.(Australian Therapeutic Goods Administration, 2014) 
 
Enzalutamide'
Enzalutamide (Xtandi®, previous known as MDV3100) has been designed to 
overcome the low binding affinity and agonistic activity of the widely used AR 
receptor antagonists (Figure 1.6). Unlike first generation AR antagonists such as 
bicalumatide, enzalutamide targets AR signaling by directly preventing AR nuclear 
translocation and subsequently, transcription of survival promoting genes (Tran et al., 
2009).  This novel mechanism has shown significant efficacy in vitro, in vivo, and in 
clinical settings with few reported side effects (Tran et al., 2009, Scher et al., 2010).  
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Figure'1.6.'Chemical'structure'of'enzalutamide'
 
 
Of particular importance, the PREVAIL trial uncovered a significant delay in disease 
progression, and subsequently, initiation of chemotherapy amongst chemo-naïve men 
treated with enzalutamide compared to placebo (Beer et al., 2014). In this trial, it was 
found that duration to initiation of chemotherapeutics was 28.0 months compared to 
10.8 months for enzalutamide versus placebo treatment arm. Importantly, 
enzalutamide treatment reduced the risk of death by nearly 30%, and improved 
overall survival by 2.2 months compared to placebo. However, whether enzalutamide 
may be beneficial as a first-line therapy in ADT-naïve men remains to be fully 
explored. A recent and ongoing phase II clinical trial, investigated PSA response as a 
result of enzalutamide mono-therapy for up to 25 weeks (Tombal et al., 2014). The 
preliminary findings of this trial reported a >80 % reduction in PSA levels for 62 of 
67 enrolled subjects (92.5%), with few adverse side-effects.  To date, no further 
clinical trials are planned.  
 
Abiratrone'acetate'
Abiraterone acetate is a highly selective and irreversible inhibitor of CYP17, which is 
an important rate-limiting enzyme for the production of estrogen and testosterone 
(Figure 1.7). In chemotherapy naive men with metastatic CRPC disease, abiraterone 
plus demexathasone resulted in ≥ 50% reduction in PSA levels for the majority of 
patients with a mean of 225 days until PSA progression (Attard et al., 2009). In a 
related, more recent clinical trial, radiographic progression free survival time was 
two-fold greater (16.5 months) in the abiraterone-prednisone group compared to 
placebo (8.5 months) (Ryan et al., 2013).  Like enalutamide, abiraterone was 
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previously only approved for use following docetaxel-failure; however, both the US 
FDA and the Australian TGA have revised the treatment indications to include men 
who have not received prior chemotherapy.  
 
 
 
Figure'1.7.'Chemical'structure'of'abiraterone'acetate'
 
Chemotherapy'
Chemotherapy is indicated in patients with recurrent prostate cancers with extensive 
asymptomatic or symptomatic metastases that are no longer responsive to hormonal 
manipulation (Heidenreich et al., 2008).  For years, chemotherapy has been employed 
only as a palliative measure. Following the TAX327 clinical trial in 2004, docetaxel 
(75 mg/m2 every 3 weeks) became the first chemotherapeutic to improve overall 
survival and quality of life for men with CRPC (Tannock et al., 2004). In mid-2005, 
docetaxel-prednisone was approved by the TGA as first-line treatment for CRPC, and 
subsequently added to the pharmaceutical benefits scheme.  
 
Docetaxel is a semi-synthetic derivative of paclitaxel and is a member of the taxane 
class of chemotherapeutic agents. The chemical structure of docetaxel is shown in 
Figure 1.8. Similar to other taxanes, the anti-neoplastic activity of docetaxel is 
achieved primarily through microtubular stabilization and disruption of essential 
cellular activities.  Microtubules are cytoskeletal fibers comprised of intertwined α 
and ! tubulin subunits, which undergo polarization and depolarization in regulating 
important cellular processes such as mitosis and cell cycle progression. Taxanes 
disrupt microtubule dynamics by binding the β-tubulin subunit resulting in 
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stabilization and increased polymerization. This leads to inhibition of mitosis by 
inducing G2/M phase cell cycle arrest and subsequently triggering apoptotic cell death 
(Mackler and Pienta, 2005, Perez, 2009).  In addition, it is thought that that docetaxel 
exerts a pro-apoptotic effect by inhibiting Bcl-2. Briefly, Bcl-2 is a member of the 
pro-survival class of proteins involved in the regulation of apoptosis. Docetaxel-
induced stabilization of microtubules induces inactivation of Bcl-2, thereby 
preventing interaction with pro-apoptotic proteins, such as Bax. Free pro-apoptotic 
proteins induce the activation of the caspase cascade and downstream apoptosis 
(Mackler and Pienta, 2005). Recent findings suggest that taxanes may also target AR-
mediated survival signaling (Zhu et al., 2010, Darshan et al., 2011). As previously 
mentioned, AR translocation and binding to androgen response elements in the 
nucleus are important events in prostate cancer survival. In vitro exposure to 
paclitaxel inhibited androgen-sensitive and –insensitive AR nuclear translocation and 
DNA-binding activity, which was dependent on microtubule stabilization (Zhu et al., 
2010, Darshan et al., 2011).  
 
Prior to the adoption of docetaxel, mitoxantrone was the cytotoxic agent of choice for 
late stage metastatic CRPC. However, mitoxantrone provided little survival benefit 
and was considered primarily a palliative measure (Denmeade and Isaacs, 2002).  In 
the early 1990s, clinical trials of single-agent docetaxel demonstrated an overall mean 
survival of 27 months in chemotherapy-naïve patients (Picus and Schultz, 1999). 
Later, a head-to-head clinical trial (TAX327) demonstrated superior efficacy of 
docetaxel over mitoxantrone, providing men with a 3-month survival benefit and 
improved quality of life (Tannock et al., 2004). However, the survival benefit is not 
without side effects. As reported by Tannock et al. (2004), the most prevalent side 
effects affecting 10% of patients or more included neutropenia, hypersensitivity, 
neuropathy, nail toxicities, and fluid retention.  
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Figure'1.8.'Chemical'structure'of'the'taxaneGbased'docetaxel'
'
'
Sequencing'of'enzalutamide,'abiraterone'acetate'and'docetaxel'for'CRPC'
Interestingly, several clinical studies suggest the treatment sequence of enzalutamide, 
abiraterone, docetaxel and cabazataxel may impact duration of disease response in 
furture treatments. For example, prior treatment with abiraterone acetate may impair 
docetaxel efficacy. A small, single institution study reported a significantly higher 
risk of docetaxel treatment failure (PSA and radiographic) amongst men previously 
treated with abiraterone acetate, compared to those who did not receive prior 
abiraterone acetate treatment (Schweizer et al., 2014). In contrast, a separate small 
scale study evaluating the efficacy of either enzalutamide or docetaxel following 
abiraterone acetate-treatment failure, found than both docetaxel and enzalutamide had 
similar clinical activity post-abiraterone (Suzman et al., 2014).  Furthermore, the anti-
neoplastic effects of enzalutamide in CRPC settings was diminished following prior 
treatment with  abiraterone  or docetaxel, and prior treatment with both abiraterone 
and docetaxel further suppressed disease response to enzalutamide (as measured by 
PSA kinetics, PSA-progression free survival) (Cheng et al., 2015).  Unfortunately, no 
large scale randomised clinical trial has yet to report on appropriate sequencing of 
these drugs for the management of CRPC.   
!
!
 !
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TREATMENT!OF!DOCETAXEL@RESISTANT!TUMOURS!
Disease progression as a result of docetaxel-based treatment failure may occur within 
6-8 months (Mottet et al., 2011) and is commonly attributed to intrinsic or acquired 
drug resistance (Zhang et al., 2015b). Following occurrence of docetaxel-resistance, 
second-line chemotherapy regimens are limited. The taxane-based chemotherapeutic 
agent cabazitaxel (Jevanta ®) is currently the prescribed first-line therapy in docetaxel 
refractory CRPC in Australia. The chemical structure of cabazitaxel is shown below 
in Figure 1.9. In clinical trials, cabazitaxel demonstrated modest superiority to 
mitoxatrone, the commonly used second line docetaxel-refractory CRPC, and 
improved survival by 2.4 months (de Bono et al., 2010). The first-line efficacy of 
cabazitaxel compared to docetaxel in men with metastatic CRPC remains to be 
established. However, a large multi-national clinical trial is underway to demonstrate 
superiority of cabazitaxel over docetaxel for first-line CRPC therapy (Sanofi, 2011).  
 
 
 
Figure'1.9.'Chemical'structure'of'the'docetaxel'analogue'cabazitaxel'
 
 
While the anti-cancer mechanisms of cabazitaxel remain to be fully investigated, 
early studies suggest a combination of tubulin-binding and efflux-resistance underlie 
cabazitaxel-mediated toxicity.  Unlike docetaxel and paclitaxel, cabazitaxel has poor 
affinity for P-gp efflux pumps (Paller and Antonarakis, 2011). As a result, cabazitaxel 
is able to escape efflux-mediated cancer cell survival mechanisms and maintain 
cytotoxic intracellular concentrations for up to 96 h (Vrignaud et al., 2013).  
Furthermore, cabazitaxel is able to cross the blood-brain barrier; however, the clinical 
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implications of this unique property have yet to be fully investigated (Paller and 
Antonarakis, 2011).  
 
As a monotherapy, abiraterone acetate and enzalutamide provide modest increases in 
progression free and overall survival compared to placebo in men with docetaxel-
refractory CRPC. Specifically, abiraterone-prednisone treatment extended 
progression-free and overall survival by 2 and 3.9 months (de Bono et al., 2011).  
Enzalutamide was slightly better than abiraterone, with an observed 3.3 and 4.8 
month increase in disease-free and overall survival compared to placebo, respectively 
(Scher et al., 2012). More recently, enzalutamide following sequential docetaxel and 
abiraterone treatment failure was evaluated in a small-scale trial. Response to 
enzalutamide following docetaxel and abiraterone was only modest, with a median 
survival of 7.1 months from initiation of treatment (Schrader et al., 2013).  
 32 
  
Figure'1.10.'Flow'diagram'of'the'natural'progression'of'prostate'cancer'through'available'treatment'modalities'in'Australia'
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1.3$ ALPHA1)ADRENOCEPTORS!
 
Adrenoceptors (also known as adrenergic receptors) are members of the G protein-
coupled receptor (GPCR) superfamily. Adrenoceptors (ADRs) are stimulated by 
endogenous catecholamines such as epinephrine and norepinephrine, and exogenous 
agonists such as phenylephrine (Alexander et al., 2011). As illustrated in Figure 1.11, 
the ADR family can be broken down into α and beta subtypes with several homologous 
isoforms including α-1 (A, B, and D), -2 (A, B, and C), and β-1, 2, and 3 (Cotecchia, 
2010). Of note, pharmacological studies have identified a functional variant of the α1A-
subtype known as α1L, due to its low affinity towards α1-ADR antagonists, prazosin 
and RS17053 (Davis et al., 2015). Despite this, the agonist noradrenaline was found to 
not discriminate between the α1A- and α1L-subtypes as the affinities of these drugs are 
reportedly similar between subtypes (Ford et al., 1997).  
 
While all adrenergic receptors play an important role in regulating human tissue 
homeostasis, the focus of this review will primarily cover α1-ADRs as these receptors 
pertain specifically to the topic of this study.  α1-ADR are commonly found in many 
human tissues such as neural, cardiac, vascular, renal, urinary, and prostate and are 
known to modulated many functions including neurotransmission, cardiac homeostasis, 
vasoconstriction and smooth muscle contraction (Cotecchia, 2010, Andersson, 2002).  
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Figure!1.11.!Adrenergic!receptor!subtype!classification!
 
ALPHA1&ADR)INNERVATION)OF)THE)HUMAN)PROSTATE)
In the human prostate, differences exist in the localisation and expression of the three 
α1-ADR isoforms.  The α1A-ADR isoform (previously identified as α1C) makes up 
approximately 70% of the prostatic α1-ADRs, which are primarily found in the stromal 
region (Price et al., 1993).  The α1D-ADR isoform is also found in the prostate stroma 
as well as the innervating prostatic blood vessels (Walden et al., 1999).  In contrast, α1B-ADR is localised to the glandular epithelium (Walden et al., 1999).  Prior evidence 
suggests that the distribution of the three isoforms change with advancing chronological 
age and subsequently the onset of prostatic hyperplasias (White et al., 2013). One study 
reported increased a six-fold increase in α1-ADR mRNA expression in the hyperplastic 
prostate, specifically α1A and α1D subtype mRNA (Nasu et al., 1996). In contrast, the 
overall receptor expression and localisation remained unchanged between the normal 
and hyperplastic prostate (Walden et al., 1999).  The α1L-subtype has also been 
reported to be an important mediator of prostatic contraction suggesting this phenotypic 
α1A-varient may be important for therapeutic BPH interventions (Morishima et al., 
Adrenergic Receptors 
G protein-coupled receptors (GPCR) 
α β 
1 2 1 2 
A, B, D A, B, C 
3 
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2010). Overall, it is unknown whether the altered isoform mRNA levels and receptor 
isoform localisation contributes to BPH pathogenesis or occurs secondary to the 
development of hyperplasia.  
 
Similar to BPH, receptor localisation and expression appears to be altered in prostate 
cancer tissues. Unlike normal prostate epithelium which expresses few α1-ADRs, 
prostate cancer epithelia have been reported to express functional α1A-ADR (Thebault 
et al., 2003, Jensen et al., 2009), as well as increased mRNA levels of α1B and α1D 
isoforms (Tseng-Crank et al., 1995). It remains unclear whether α1-ADRs have a role in 
promoting prostate carcinogenesis remains unclear. However, α1-ADRs have been 
identified to play a role in cellular proliferation (Thebault et al., 2003, Munaron et al., 
2004, Thebault et al., 2006) and therefore may be exploited by neoplasms. In contrast, 
the expression of alpha1L in prostate cancer has yet to be reported. 
 
 
ALPHA1&ADR&MEDIATED)CELLULAR)PROLIFERATION)
Signal transduction by activated α1-ADR begins with the activation of receptor-coupled 
G proteins. α1-ADRs primarily interact with Gq/11. However, α1-ADRs demonstrate 
subtype-dependent selectivity in G protein-coupling. The G proteins disassociate from 
the membrane bound receptor where it activates phospholipase C (PLC) and RhoA/Rho 
kinase pathways. PLC indirectly triggers release of intracellular stores of Ca2+ mediated 
by inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). The release of 
intracellular Ca2+, activates ion channels, promoting influx of extracellular Ca2+. 
Activation of α1-ADRs by their agonists also results in the opening of receptor-operated 
calcium channels within the plasma membrane and subsequent influx of Ca2+ ions. In 
addition to mediating Ca2+ release, DAG activates protein kinase C (PKC), which 
participates in signaling cascades with many important downstream regulators of cell 
survival and proliferation (Graham et al., 1996, McFadzean and Gibson, 2002). 
 
Calcium signaling appears to play a central role in carrying out α1-ADR-regulated 
cellular proliferation (Thebault et al., 2003, Munaron et al., 2004, Thebault et al., 2006). 
Calcium serves as an ubiquitous inhibitor or activator of various cytosolic targets, 
including calmodulin (Munaron et al., 2004).  Calmodulin (also known as calcium-
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modulated protein) is a calcium-binding protein, which acts as a secondary messenger 
promoting activation of enzymes and kinases. Ca2+:calmodulin complex has been 
shown to promote PKC-mediated activation of epidermal growth factor receptor 
(EGFR) and subsequently the mitogen-activated protein kinase (MAPK) extracellular 
regulated kinase (ERK) 1/ 2 (Tebar et al., 2002). ERK1/2 activation is well known to 
contribute to cellular proliferation and/ or death in a cell type- and stimulus-specific 
manner. Furthermore, aberrant ERK1/2 activity is frequently linked to development of 
many cancers (Zelivianski et al., 2003, Carey et al., 2007) including prostate (Price et 
al., 1999), which may be mediated by α1-ADRs (Graham et al., 1996).  
 
In human prostate cancer cells, chronic α1-ADR stimulation by phenylephrine (PE) or 
norepinephrine (NE) resulted in increased proliferation (Thebault et al., 2003, Liou et 
al., 2009) triggered by PLC/ DAG-mediated influx of extracellular Ca2+, with no 
reported role for IP3-mediated release of intracellular stores of Ca2+ (Thebault et al., 
2006). Mechanisms underlying α1-ADR-mediated proliferation have been suggested to 
involve upregulation of membrane-bound transient receptor potential canonical 6 
(TRPC6) expression, Ca2+/calmodulin/calcineurin-mediated activation of NFAT 
(nuclear factor of activated T-cells), and modulation of cell cycle regulator expression 
(Thebault et al., 2006). In a related study, TRPC6-mediated Ca2+ entry was strongly 
correlated with androgen-sensitive prostate cancer survival and proliferation (Lehen'kyi 
et al., 2007), which may be regulated by upstream α1-ADR activation. Interestingly, AR 
may regulate TRPC6 expression and subsequently Ca2+ influx-mediated proliferation 
(Lehen'kyi et al., 2007).  Genetic knock down of AR reduced protein levels of TRPC6 
and resulted in decreased Ca2+ intracellular influx (Lehen'kyi et al., 2007).  From these 
findings, one can conclude that α1-ADRs contribute, to some degree, to prostate cancer 
proliferation in vitro. 
 
 $
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1.4$ ALPHA1)ADR$ANTAGONISTS$
 
Alpha1-ADR antagonists (also referred to as ‘blockers’) are commonly used in clinical 
practice to treat hypertension and more recently, the urodynamic symptoms associated 
with benign prostate hyperplasia (BPH). In BPH, α1-ADR antagonists block receptor 
activation to relax the prostatic smooth muscle thereby improving rate of urine flow and 
other associated lower-urinary tract symptoms (LUTS) (Jepsen and Bruskewitz, 1998, 
Gillenwater et al., 1995).  
 
There are regional differences in the commonly prescribed α1-ADR antagonists for 
BPH.  In the United States, the non-selective doxazosin and terazosin are the most 
commonly prescribed α1-blockers due to their relatively long half-life (Vincent et al., 
1983, Sonders, 1986) and clinically significant improvement in BPH-related LUTS. 
Furthermore, these drugs have been associated with fewer adverse drug-related 
cardiovascular side effects, compared to prazosin (Lepor et al., 2012).  However, in 
Australia, the short acting and non-selective prazosin is clinically favored over other α1-
blockers primarily due to the rapid mitigation of LUTS. At the present time, the TGA 
has yet to approve definitive use of this drug for treatment of BPH and instead is only 
indicated for pre-operative treatment only (Australian Therapeutic Goods 
Administration, 2015).  The highly selective tamulosin, also offer significant reduction 
in BPH-related LUTS symptoms, however, at a cost of ejaculatory dysfunction making 
this α1-ADR antagonists undesirable for some men (Lepor et al., 2012). Depending on 
impact to quality of life and affordability, α1-ADR antagonists may be combined with 
5α-reductase inhibitors, such as finasteride and dutasteride (Woo et al., 2011). These 
drugs act to reduce prostatic volume and prevent disease progression via inhibition of 
the conversion of testosterone to DHT (as shown previously in Figure 1.5). Together, 
these drugs have been reported to provide long-term synergistic improvement BPH-
associated LUTS, and in turn, delay surgical interventions (McConnell et al., 2003, 
Roehrborn et al., 2010).  
 
In the late 1990s, monotherapy with α1-ADR antagonists were suggested to provide 
long-term clinical benefits that could not be explained solely by acute prostatic 
relaxation (McConnell et al., 1998, Lukacs et al., 1999, Michel et al., 2000). In further 
support, a more recent study uncovered a large proportion of men (70 %), which 
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experienced continued improvement of BPH-associated LUTS following 
discontinuation of α1-ADR antagonists (Yokoyama et al., 2007).  
 
NOVEL)ANTI&TUMOUR)ACTIVITY)OF)Α1&ADR)ANTAGONISTS)
Over the last fifteen years, quinazoline-based α1-ADR antagonists such as doxazosin 
and prazosin have demonstrated significant potential in either preventing or treating 
prostate cancer. Clinically relevant doses (nM range) of quinazoline α1-ADR 
antagonist-induced cell death were identified to primarily target cancerous cells 
(Benning and Kyprianou, 2002) with minimal toxicity in non-cancerous cells (Chon et 
al., 1999, Hui et al., 2008, Benning and Kyprianou, 2002). Potential therapeutic benefit 
is further exemplified in vivo models demonstrating prostate cancer regression 
(Kyprianou and Benning, 2000), reduced tumour vascularity (Pan et al., 2003) and 
decreased incidence of prostate and renal cancer metastasis (Chiang et al., 2005, 
Sakamoto et al., 2011). While α1-ADR activity might contribute to prostate cancer 
proliferation, the cytotoxic effects of these antagonists are known to occur independent 
of α1-ADR antagonism in pre-clinical models (Benning and Kyprianou, 2002). The 
potential anticancer actions of α1-ADR antagonism are further explored later in this 
thesis (Chapter 7).  
 
In clinical settings, retrospective studies conducted by Harris et al. and Martin et al. 
showed a reduced incidence of prostate (Harris et al., 2007) and bladder cancer (Martin 
et al., 2008), respectively, in men treated with quinazoline-based α1-ADR antagonist.  
Interestingly, the non-quinazoline naftopidil has also been retrospectively reported to 
decrease prostate cancer incidence and increased prostate cancer apoptosis (Yamada et 
al., 2013).  Likewise, men treated with terazosin displayed a similar increase in 
apoptotic cells, as well as a reduction in tumour vascularity in both bladder and prostate 
cancer tissue specimens (Keledjian et al., 2001, Tahmatzopoulos et al., 2005). However, 
the mechanisms contributing to the anticancer effects of these drugs have yet to be fully 
characterised. Furthermore, the cell death (autophagy) and molecular mechanisms 
contributing α1-ADR antagonist-mediated cytotoxicity remains to be fully explored. 
Elucidation of these mechanisms may provide insight as to whether these drugs may be 
useful alone or concurrently with anticancer therapies to mitigate prostate cancer or 
improve treatment efficacy. 
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SUMMARY$!
 
Prostate cancer is a significant global public health concern, and in Australia, 1 in 7 men 
will be diagnosed with prostate cancer before the age of 85. While early-stage prostate 
cancer is highly manageable and even curable, few treatment options exist for advanced 
disease. Despite recent addition of cabazitaxel, enzalutamide and abiraterone acetate, 
these agents have shown only modest benefit and many men experience disease 
progression within months. The ferocity of prostate cancer is further exemplified with 
the occurrence of treatment-dependent selection for malignant cells containing survival-
enhancing mutations. Therefore, new and novel agents are needed to continue to “out-
smart” prostate cancer thereby increasing overall survival and quality of life.  
 
Pharmacological treatment with α1-ADR antagonists are by far the most common 
treatment option used to improve BPH- associated LUTS.  Additionally, men 
undergoing radiotherapy for prostate cancer are often prescribed α1-antagonists either 
prophylactically or concurrently to reduce treatment-induced LUTS. Of particular 
interest, some of these drugs possess novel-anti cancer effects, particularly amongst 
prostate cancers, in pre-clinical and in retrospective clinical settings. While 
monotherapy with α1-ADR antagonist at safe doses are unlikely to be effective against 
prostate cancer, treatment with these drugs may reduce the incidence of prostate cancer 
(Harris et al., 2007) and delay disease progression, particularly in the transition from the 
castrate-sensitive to castrate-resistant forms. Furthermore, these agents, when combined 
with current prostate cancer treatments, may have synergistic actions and in turn 
improve treatment efficacy, or restore sensitivity to existing treatment in resistant 
prostate cancers.  
 
This study investigated the relative cytotoxic potencies, cell death mechanisms, 
molecular mechanisms of various α1-ADR antagonists on prostate cancer cell lines.  
Furthermore, the potential synergistic activity of these antagonists in combination with 
radiation therapy and chemotherapy was investigated. The findings from this thesis will 
provide important insight into the development of novel therapies for men diagnosed 
with prostate cancer.  
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1.5$ AIMS$
 
The overall of aim of this thesis was to investigate the cytotoxic effects of various α1-
ADR antagonists on in vitro models of castrate-sensitive and castrate-resistant prostate 
cancer cells.  
 
Using castrate-sensitive (AR-positive) LNCaP and castrate-resistant (AR-negative) PC-
3 cells, the specific aims were to:  
 
1.! Determine the relative potency and cell death mechanisms (autophagy and 
apoptosis) of various α1-ADR antagonists (Chapter 3). 
 
2.! Uncover the underlying molecular mechanisms contributing to α1-ADR 
antagonist-mediated prostate cancer cytotoxicity (Chapter 4).  
 
3.! Investigate potential radiosensitising actions of α1-ADR antagonist in hypoxic 
and normoxic conditions and the underlying mechanisms underlying this 
(Chapter 5). 
 
4.! Further explore novel uses of α1-ADR antagonists in treatment of urogenital 
cancers. 
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CHAPTER$2:$
GENERAL$METHODS$
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CELL$LINES$
 
All cells used were obtained from the American Tissue Culture Collection (ATCC, 
Mannassas, VA, USA) and were grown and maintained according to ATCC guidelines.  
 
HUMAN!PROSTATE!CANCER!LNCAP!CELLS!
The LNCaP prostate carcinoma cell line was initiated from lymph node metastases in a 
50-year old Caucasian male. LNCaP cells express functional androgen receptor (AR). 
However molecular characterisation studies have revealed a missense mutation at locus 
T877, causing binding promiscuity of AR to other steroid ligands including 
bicalutamide. LNCaP cells express normal p53 and secrete PSA (van Bokhoven et al., 
2003). The LNCaP cells were used as a model of early, castration-sensitive prostate 
cancer (Figure 2.1).  
 
 
Figure! 2.1.! Morphology! and! growth! pattern! of! human! androgen! receptorGpositive!
(castrateGsensitive)! LNCaP! prostate! cancer! cell! line.! ! Cells! were! fixed! and! stained!
with! crystal! violet! as! described! below.! Images! were! taken! using! an! Evos! ®! Cell!
Imaging! Systems! (Thermo! Fischer! Scientific).! Length! of! calibration! bar! is! equal! to!
400!µm.!
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HUMAN!PROSTATE!CANCER!PCG3!CELLS!
The PC-3 prostate carcinoma cell line was isolated from bone metastasis of grade IV 
prostate cancer in a 62-year old Caucasian male (Kaighn et al., 1979). PC-3 cells are 
androgen-insensitive as this cell line does not express AR, and therefore were 
considered to be a model of CRPC (Figure 2.2). Additionally, these cells express non-
functional truncated p53 (van Bokhoven et al., 2003). 
 
 
 
Figure! 2.2.! Morphology! and! growth! pattern! of! human! ARGnegative! (castrateG
resistant)!PCG3!prostate! cancer! cells.! PCG3! cells!were! fixed!and! stained!with! crystal!
violet,! as! described! below.! Images! were! captured! using! an! Evos®! Cell! Imaging!
System!(ThermoGFischer!Scientific).!Length!of!calibration!bar!is!equal!to!400!µm.!
 
!
HUMAN!PROSTATE!MYOFIBROBLAST!WYMPG1!STROMAL!CELLS!
The non-cancerous stromal AR-positive WYMP-1 cells were isolated from the normal 
prostate of a 54 year-old Caucasian male and were immortalised by plasmid delivery of 
viral SV40 DNA sequence (Bello et al., 1997, Webber et al., 1999). To date, !1-ADR 
subtype expression profile remains unknown. WPMY-1 cells were used to model 
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effects of prostate cancer-stromal interactions via indirect 2D co-cultures as described in 
the relevant sections of Chapter 6. 
HUMAN!BLADDER!CANCER!T24!CELLS!
The human bladder transitional (urothelial) cell carcinoma T24 cell line was used 
briefly throughout Chapter 6. The reader is referred to the relevant methods section in 
Chapter 6 for further details.  
 
CELL$CULTURE$$
CHEMICALS!AND!SOLUTIONS!
Chemicals and solutions that were routinely used for growth and maintenance of 
cultured cells are detailed in Table 2.1. 
GROWTH!MEDIUM!AND!MAINTENANCE!!
LNCaP cells were grown in RPMI 1640 culture medium containing L-glutamine and 
phenol red, and supplemented with 10 % foetal bovine serum (FBS), 10 mM HEPES, 
1500 mg/L sodium bicarbonate, and 1% gentamicin solution. PC-3 cells were grown in 
Ham’s F-12K culture medium containing L-glutamine and phenol red, and 
supplemented with 10% FBS and 1% gentamicin solution.  
 
For the relevant sections of this thesis (Chapter 6), WPMY-1 cells were grown in high 
glucose Dulbeccos’s Modified Eagle’s Media culture medium containing phenol red, L-
glutamine, sodium pyruvate and sodium bicarbonate, and supplemented with 5 % FBS 
and 1% gentamicin solution. T24 cells were grown in McCoy’s A5 modified growth 
medium containing L-glutamine and sodium bicarbonate and supplemented with 10 % 
FBS and 1% gentamicin solution. 
 
All cells were maintained at 37C in a humidified incubator with 5% CO2 and 95% air. 
For all experiments, cells were harvested upon reaching 80-90% confluency. Only cells 
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≤ 30 passages were used. Unless stated otherwise, all experiments were conducted in 
respective complete culture medium. 
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Table 2.1. Cell culture chemicals and solutions 
Solution / Chemical Use Working conc. Supplier Cat. No. 
RPMI-1640 culture 
medium 
LNCaP cell 
culture - 
Life 
Technologies 11875 
Ham’s F12 Kaighn’s 
(F12-K) culture 
medium 
PC-3 cell 
culture - 
Life 
Technologies 21127 
Dulbecco’s Modified 
Eagle’s Medium 
(DMEM) 
WPMY-1 cell 
culture - Sigma-Aldrich D6429 
McCoy’s A5 modified 
medium T24 cell culture - Sigma-Aldrich M9309 
Poly-L-Lysine 
Coat LNCaP 
tissue flasks 
and plates 
0.10% Sigma-Aldrich P4707 
Gentamicin (50 
mg/ml) Antibiotic 1% 
Life 
Technologies 15750 
Fetal Bovine Serum 
(FBS) 
Supplement 
culture medium 5 – 10% Bovogen SFBS-F 
HEPES 
Supplement 
LNCaP culture 
medium 
100 mM Life Technologies 15630 
Sodium bicarbonate 
Supplement 
LNCaP culture 
medium 
100 mM Sigma-Aldrich 25080 
Trypsin-EDTA 
(0.25%) 
Detachment of 
cells 0.25% 
Life 
Technologies 25200 
Dulbecco’s phosphate 
buffered saline 
(DPBS) (10X) 
Sub-culturing 
of WPMY-1 
cells 
1X Sigma-Aldrich D8537 
Phosphate Buffered 
Saline (PBS) (10X) 
Sub-culturing 
LNCaP, PC-3 
and T24 cells 
1X (diluted 
in sterile 
dH20) 
Sigma-Aldrich P5493 
DMSO 
Cryo-
preservation 
freeze medium 
5% Sigma-Aldrich D2438 
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SUBGCULTURING!TECHNIQUE!
For all work with cells, strict aseptic technique was adhered to. Briefly, spent culture 
medium was removed and the cell monolayer was washed with 1X phosphate buffered 
saline (PBS) (LNCaP and PC-3). Cells were incubated at 37°C for 1-5 minutes with 
0.25% trypsin-EDTA for detachment from tissue-culture flask. Trypsin was inactivated 
by the addition of culture medium containing FBS (> 5%), and trypsin was removed by 
centrifugation of cells. Cells were then re-suspended in desired amount of culture 
medium to achieve a split ratio between 1:6 and 1:3.  
 
Prior to seeding of LNCaP cells, tissue-culture flasks and experimental plates or petri 
dishes were pre-coated with 0.1% poly-L-lysine for 15 minutes, rinsed with sterile 
deionized H20, and allowed to dry overnight in the tissue culture hood. Spare poly-l-
lysine coated flasks/plates were stored at 4C for up to 7 days.  
!
CRYOPRESERVATION!AND!RESTORATION!
Stocks of LNCaP, PC-3, WYMP-1 and T24 cells were generated and preserved in 
liquid nitrogen. For LNCaP and PC-3 cell lines, freeze medium contained 5% DMSO 
dissolved in respective complete culture medium, whereas WPMY-1 and T24 freeze 
medium consisted of cell line-specific culture medium supplemented with 15% or 10% 
FBS, respectively. Cells were detached and washed as previously described; however, 
after centrifugation, cells were re-suspended in freeze medium at a density of 
approximately 2.0x106/mL. One mL of cell suspension was aliquoted in 
cryopreservation vials, and was cooled at approximately -1°C per minute using a Mr. 
Frosty (Nalgene®) in a -80°C freezer. After 24 h, vials were transferred to liquid 
nitrogen for indefinite storage. After 24 h, one vial of cells was restored to check 
viability and sterility. 
 
Restoration of cryopreserved cell lines was accomplished by rapidly thawing cells in a 
37°C water bath upon removal from liquid nitrogen storage. Freeze medium containing 
DMSO was removed by centrifugation, and the cell pellet was re-suspended in fresh 
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complete growth medium and seeded in a T-25 flask. Cells were monitored visually for 
attachment, growth patterns and sterility. 
 
TRYPAN$BLUE)EXCLUSION$ASSAY$
 
Cell counts were conducted using the trypan blue-exclusion assay.  Trypan blue is a dye 
that is impermeable to living health cells, but is able to permeate the cell membranes of 
dead cells. Living cells appear clear with a dark blue border and dead cells appear dark 
blue. Based on this principle, cell counts and cell viability were determined using 0.4% 
trypan blue mixed 1:1 with cells in suspension. Cells were either counted manually 
using a haemocytometer, or by the automated Countess® cell counter (Life 
Technologies). For all experiments, cell viability was ≥ 95%. 
 
RESAZURIN$REDUCTION$ASSAY$
 
Resazurin is a stable, non-toxic, and non-fluorescent blue dye. In the presence of 
cellular metabolic activity, resazurin is reduced to form resorufin, a pink highly 
fluorescent product. The rate of reduction of resazurin to resorufin directly correlates 
with cell number, as shown in Figure 2.3, and is a reliable indicator of cellular viability 
in the presence of cytotoxic chemicals (Anoopkumar-Dukie et al., 2005a, Czekanska, 
2011). The resazurin reduction assay was used throughout this study as an index of cell 
viability or survival. 
 
A resazurin stock solution (440 µM) was made from dry powder in sterile PBS then 
sterile filtered using a 0.2 µm pore syringe filter. Aliquots of stock solution were stored 
at 4C for up to 6 months. Immediately prior to use, resazurin stock solution was 
diluted 1:10 in complete culture medium for a final concentration of 44 µM. 
 
The resazurin reduction assay was carried out as previously described (Anoopkumar-
Dukie et al., 2005a). Briefly, cells were seeded as a monolayer at sub-confluent 
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densities to allow for exponential growth throughout the duration of the experiments. 
Cells were incubated for 24 h (PC-3, WPMY-1 and T24) or 48 h (LNCaP) to allow for 
adhesion prior to treatment. Following desired incubation or treatment time, spent 
culture medium above the cells was removed and replaced with culture medium 
containing 44 µM resazurin and incubated at 37°C between 0.5 – 4 h depending on cell 
type and density. After an appropriate incubation time, fluorescence (excitation: 530 
nm; emission: 590 nm) was measured using a Modulous Microplate multimode reader 
(Promega). Unless stated otherwise, the resazurin reduction assay was conducted in 
triplicate over three or more independent experiments.  
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Figure! 2.3.! Linear! relationship! between! PCG3! [A]! and! LNCaP! [B]! cell! number! and!
resazurin! reduction! to! the! fluorescent!by!product! resorufin.! [C]!A! representative!
image! of! cell! densityGdependent! reduction! of! resazurin! to! resorufin! (cell! density!
increases!left!to!right).!!!
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DRUGS$AND$STOCK$SOLUTIONS$
 
The drugs commonly used throughout this study are listed below in Table 2.2. Stock 
solutions were made up aseptically from dry powder dissolved in DMSO (" 0.2% in cell 
culture), except for prazosin where drug was made up in sterile deionized H20 (dH2O). 
No appreciable cytotoxicity was observed with DMSO concentrations used throughout 
this thesis. To ensure DMSO had no confounding effects, all experiments using drugs 
dissolved in DMSO was matched with an appropriate DMSO vehicle control. 
 
Immediately prior to treatment, 2X working concentrations were made in pre-warmed 
complete culture medium and diluted 1:2 in cell culture medium on the plate to yield 
final concentrations of 0.01 – 100 µM. 
 
! !
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Table!2.2.!Commonly!used!drugs!and!their!stock!concentrations,!storage!conditions!
and!supplier!details.!
Drug / 
Reagent 
Actions Stock 
(mM) 
Solvent/ 
Vehicle 
Storage Supplier Cat. No. 
Alfuzosin 
HCl 
Non-selective 
!1-ADR 
antagonist 
100 DMSO < -20C; 
30 days 
Selleck 
Chemicals 
S1409 
Doxazosin 
mesylate 
Non-selective 
!1-ADR 
antagonist 
50 DMSO < -20C; 
30 days 
Sigma-
Aldrich 
D9815 
Prazosin HCl 
Non-selective 
!1-ADR 
antagonist 
1 dH2O 
2-8C; 7 
days 
Sigma-
Aldrich 
P7791 
Silodosin 
Selective 
!1A-ADR 
antagonist 
100 DMSO < -20C; 
30 days 
LKT 
Laboratories 
S3346 
Terazosin 
HCl 
Non-selective 
!1-ADR 
antagonist 
100 DMSO < -20C; 
30 days 
Selleck 
Chemicals 
S2059 
Tamsulosin 
HCl 
Selective 
!1A/D-ADR 
antagonist 
50 DMSO 
< -20C; 
30 days 
Sigma-
Aldrich 
T1330 
Dimethyl 
sulfoxide 
(DMSO) 
Solvent; 
Freeze 
medium 
N/A N/A 21C Sigma-
Aldrich 
D2438 
CRYSTAL$VIOLET$$
 
Staining with crystal violet was conducted to examine the morphology of the prostate 
cancer cells. Traditional methodology for fixing and staining cells was used but in a 
simplified form. After the desired incubation or treatment time, culture medium above 
the cells was removed and replaced with methanol (100 %) containing 0.5% w/v crystal 
violet. Cells were incubated on ice for 15 minutes prior to rinsing gently with water.  
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Fixed cells were allowed to air dry completely before being examined under phase 
contrast microscopy using an Evos ® Cell Imaging System (Thermo-Fischer Scientific).  
 
ANALYSIS$
 
Statistical testing was conducted throughout this thesis, which is detailed in the relevant 
sections of each chapter. In general, GraphPad Prism (version 6 for Mac OS X, San 
Diego, USA) was used to generate all graphical representations and statistical analyses. 
A p-value of < 0.05 was considered statistically significant.  
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CHAPTER$3:$
RELATIVE$CYTOTOXIC$POTENCIES$AND$CELL$
DEATH$MECHANISMS$OF$ALPHA1)ADR$
ANTAGONISTS$
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3.1$ $ BACKGROUND$
 
ANTICANCER!EFFECTS!OF!ALPHA1GADR!ANTAGONISTS!
Alpha1-ADR antagonists have generated significant interest amongst researchers for 
their novel urogenital (Hui et al., 2008, Gan et al., 2008, Sakamoto et al., 2011, Gotoh 
et al., 2012) anticancer activity in vitro and in vivo, particularly against prostate cancer 
(Kyprianou and Benning et al., 2000, Chaing et al., 2005, Lin et al., 2007). Doxazosin 
was first of the α1-ADR antagonists to be identified by as having cytotoxic properties. 
In 1997, Yang et al. demonstrated decreased weight accompanied by prostatic 
cytotoxicity in a BPH murine model (Yang et al., 1997). Shortly after, similar findings 
were uncovered in human BPH specimens (Kyprianou et al., 1998, Chon et al., 1999) 
and human vascular (Hu et al., 1998) and bladder (Austin et al., 2004) smooth muscle 
cells (SMCs). Later, doxazosin-induced cytotoxicity was reported to extend to 
malignant cells including prostatic (Kyprianou and Benning, 2000, Partin et al., 2003), 
cervical (Gan et al., 2008), breast (Hui et al., 2008), and renal (Sakamoto et al., 2011). 
Likewise, other quinazoline-based α1-ADR antagonists such as prazosin and terazosin, 
were also found to possess cytotoxic actions (Kyprianou and Benning, 2000, Partin et 
al., 2003, Lin et al., 2007).  
 
In contrast, the non-quinazoline antagonist, tamsulosin, reportedly lacks the cytotoxic 
capacity of its quinazoline-containing antagonist cousins. The inability of tamsulosin to 
induce cancer cell cytotoxicity (Benning and Kyprianou 2002) has since been 
generalised to all non-quinazoline-based antagonists, giving rise to the notion that 
antagonist-induced toxicity occurs via quinazoline-dependent mechanisms (Kyprianou 
and Benning, 2000, Benning and Kyprianou, 2002, Partin et al., 2003). However, little 
is known with regards to the anticancer potential of other !1-ADR antagonists such as, 
alfuzosin and the non-quinazoline silodosin. The comparisons of the chemical structures 
of investigated α1-ADR antagonists are shown in Table 3.1. 
 
Recent findings challenge the central dogma to α1-ADR antagonists-induced toxicity, 
indicating that quinazoline-dependency and receptor antagonism-independent 
mechanisms are not absolute. The non-quinazoline antagonists labedipinediol-A (Liou 
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et al., 2009) and naftopidil (Gotoh et al., 2012) displayed comparable cytotoxicity to 
doxazosin or prazosin against prostate cancer cells.  Furthermore, irreversible inhibition 
of α1-ADRs partially blocked labedipinediol mediated toxicity, suggesting receptor 
antagonism-dependent and independent mechanisms (Liou et al., 2009).  
  
 59 
Table!3.1.!Chemical!structures!of!commonly!used!α1G
subtype!selective!ADR!antagonists!
Alfuzosin 
 
Doxazosin 
 
Prazosin 
 
Silodosin 
 
Terazosin 
 
Tamsulosin 
 
 
 
)
CELL)DEATH)MECHANISMS)
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Apoptosis!
Apoptosis, or type I programmed cell death, was first described by Kerr and colleagues 
in 1972 and is characterised by several morphological and biochemical changes 
including cell shrinking, membrane blebbing, and DNA fragmentation (Kerr et al., 
1972). Apoptosis occurs in multicellular organisms as a mechanism for homeostasis and 
elimination of neoplastic cells.  Anomalies in apoptotic machinery prevent cells from 
being eliminated in response to apoptotic stimuli and are commonly associated with the 
development of carcinomas (Kerr et al., 1994). 
 
Apoptosis can occur via intrinsic or extrinsic mechanisms, as shown in Figure 3.1. The 
intrinsic or “mitochondrial-dependent” apoptotic pathway is initiated in response to 
intracellular stimuli such as DNA damage or endoplasmic reticulum stress. This triggers 
activation of pro-apoptotic members of the Bcl-2 protein superfamily such as Bad, Bax, 
Bim, and Bid.  The apoptotic signal is negatively regulated by pro-survival proteins 
including Bcl-2 and Bcl-xL, which bind to inhibit pro-apoptotic protein activity. Free, 
unbound, pro-apoptotic proteins stimulate mitochondrial cytochrome c release and 
formation of the apoptosome. The apoptosome consists of cytochorome c and apoptosis 
protease activating factor 1 (Apaf-1), which activates caspase-9. Caspase-3 becomes 
activated by caspase-9 and participates in activation of downstream effector caspases. In 
contrast, the extrinsic apoptotic pathway begins with ligand-mediated activation of 
membrane bound death receptors. Upon activation, the receptor recruits several 
components of the death-inducing signaling complex (DISC). The inactivated form of 
Caspase-8, pro-caspase-8, becomes activated by DISC-mediated cleavage. Caspase-8 
activates caspase-3, triggering activation of the caspase cascade and ensuing apoptotic 
cell death (Taylor et al., 2008).  
 
The!role!of!apoptosis!in!prostate!cancer!
As mentioned previously, apoptosis is an important mechanism regulating tissue 
homeostasis and loss of normal apoptotic signaling mechanisms are known to 
contribute to carcinogenesis.  Cancer cells maintain functional apoptotic machinery but 
employ numerous strategies to evade traditional apoptotic signals including contact-
inhibition and detachment. Anticancer therapies such as ADT, chemotherapy and 
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radiotherapy exploit the residual apoptotic mechanisms leading to cancer cell death and 
tumour regression.  However, neoplasms eventually acquire further anti-apoptotic 
mechanisms, presumably through treatment-dependent selection, which are responsible 
for disease recurrence or progression. For example, altered expression of the anti- and 
pro-apoptotic proteins, such as Bcl-2 and Bax, are partially responsible for ADT failure 
(Raffo et al., 1995, Yang et al., 2003), radioresistance (Khor et al., 2007) and docetaxel-
resistance (DiPaola and Aisner, 1999, Lebedeva et al., 2000).  
 
 
Figure!3.1.!Extrinsic!(A)!and!Intrinsic!(B)!apoptotic!pathways. 
 
Apoptotic!effect!of!α1GADR!antagonists!in!prostate!cancer!
Exposure of androgen receptor (AR)-positive and AR-negative prostate cancer cell lines 
to cytotoxic concentrations of doxazosin, prazosin, or terazosin has been reported to 
trigger apoptotic cell death in vitro (Partin et al., 2003, Lin et al., 2007, Kyprianou et al., 
2000, Garrison and Kyprianou, 2006). Interestingly, these effects were also observed in 
rodent models (Papadopoulos et al., 2013, Chiang et al., 2005) and in human tissue 
specimens from resected prostates (Kyprianou et al., 1998, Keledjian et al., 2001). 
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Consistent with findings of apoptotic activity in vitro, the non-quinazoline naftopidil 
was also reported to have pro-apoptotic effects in prostate cancer specimens from men 
treated with this drug (Yamada et al., 2013).  
 
In addition to targeting the prostate cancer cells directly, the apoptotic effect of α1-
antagonists is also seen amongst endothelial cells in vitro (Keledjian et al., 2005). In a 
previous study, doxazosin was able to induced apoptosis in human umbilical vein 
endothelial cells (HUVEC), and as a result prevented cell migration, invasion, adhesion 
and overall endothelial tube formation in response to angiogenic factors (Keledjian et 
al., 2005). This endothelial cell apoptotic effect has also been observed in vivo and in 
clinical settings, where it has been reported that treatment with quinazoline-based 
doxazosin and terazosin reduced tumour vascularity in mice (Pan et al., 2003) and 
humans (Keledjian et al., 2001, Tahmatzopoulos et al., 2005), respectively. 
 
Quinazoline-based α1-ADR antagonist-induced prostate cancer apoptosis has been 
reported to primarily involve transforming growth factor beta (TGF-β) and Smad 
signaling, activation of IκBα, and subsequent inhibition of the survival transcription 
factor NfκB (Partin et al., 2003). However, a growing body of evidence suggests 
apoptotic cell death may occur by other intrinsic (Lin et al., 2007) and extrinsic 
mechanisms (Partin et al., 2003, Garrison and Kyprianou, 2006) including, 
mitochondrial-dependent activation of caspase cascade (Lin et al., 2007) and Fas-
associated death domain (FADD) activation (Garrison and Kyprianou, 2006). 
Additional signaling mechanisms underlying α1-ADR antagonist-induced prostate 
cancer apoptosis will be detailed further in Chapter 4.   
 )
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AUTOPHAGY)
Macrophagy (herein referred to as ‘Autophagy’) is a catabolic process in which a cell 
triggers “self-eating” to recycle unneeded organelles and other cellular components. The 
induction of autophagy is most commonly viewed as a survival mechanism in the 
presence of various stimuli including nutrient starvation, hypoxia, and metabolic stress 
(Dalby et al., 2010). In a growth state, autophagy is typically inhibited. Binding of 
growth factors to their respective receptors triggers activation of phosphoinositide 3-
kinase PI3K / Akt / mammalian target of rapamycin (mTOR) and subsequently inhibits 
autophagy by negative regulation of Ulk complex.  In the presence of autophagic 
stimuli, mTOR is inhibited, freeing Ulk complex to initiate autophagy. As shown in 
Figure 3.2, autophagy is carried out in five distinct stages: membrane isolation, 
elongation, completion (sequestration), maturation (fusion), and degradation (Kondo et 
al., 2005). Activated by Ulk complex, PI3K associates with beclin-1 to convert 
phosphatidylinositol to phosphatidylinositol 3-phosphate (PI3P), which functions to 
recruit other autophagy-related proteins to the phagopore. The conjugation of 
autophagy-related proteins, Atg5 and Atg12 in the phagopore recruits microtubule-
associate light chain 3 (LC3). Atg5-Atg12 facilitates the conversion of LC3 from 
isoform I to II, a hallmark of late stage autophagy.  In the final stages, the 
autophagosome, containing sequestered cellular components, matures via H+ -ATPase 
acidification and fusion with lysosomes forming an autolysosome. In the final stage, 
degradation is carried out by lysosomal hydrolases and resulting macromolecules are 
released into the cytosol (Kondo et al., 2005).   
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Figure! 3.2.! The! autophagy! pathway! (Greenfield! and! Jones,! 2013).! Figure! reprinted!
with!permission!from!copyright!holder.!
!
Autophagic!(Type!II)!programmed!cell!death!
In recent years, autophagy has been identified to play a role in a type of programmed 
cell death known as Type II or autophagic cell death. This notion remains controversial 
amongst researchers, questioning whether autophagy occurs secondary to other forms of 
programmed cell death, either as a preventative or adaptive measure to cytotoxic 
stimuli, rather than driving programmed cell death (Shen et al., 2012, Shimizu et al., 
2014).  Despite the critics, it has been proposed that the primary hallmark of autophagic 
cell death is whether inhibition of autophagy by pharmacological or genetic knockdown 
is able to protect against cell death (Shen and Codogno, 2011, Shimizu et al., 2014). 
!
Role!of!autophagy!in!cancer!
Cancer is well characterised to involve up-regulation of autophagy mechanisms to 
provide a survival advantage in harsh environmental conditions not well suited to 
normal non-cancerous cells. Modulation of autophagy to enhance sensitivity to 
cytotoxic agents or radiotherapy or to overcome treatment resistance has become of 
significant interest to the scientific community. Of particular importance, ADT 
treatment failure may in part be due to the up-regulation of autophagic mechanisms to 
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maintain survival signaling and to protect cells in the absence of androgens (Li et al., 
2008a, Boutin et al., 2013).  Likewise, the development of chemoresistance may be an 
incidental by-product of autophagy-mediated “housekeeping”, by eliminating treatment-
induced damaged organelles to mitigating intracellular stress (Mohammad et al., 2015) 
and evading apoptosis. Together, these concepts set the stage for an interesting, yet 
difficult scenario. While ADT is particularly effective in treating early stage prostate 
cancer, androgen-deprivation drives the transition from androgen/AR- to autophagy-
mediated survival signaling (Boutin et al., 2013), eventually leading to ADT-failure and 
disease progression. The ADT-mediated acquisition of autophagic survival mechanisms 
may confer resistance to chemotherapeutics, which are often the first line treatment for 
hormone-refractory disease.  
 
In current medicine, many therapies have been employed to induce autophagic cell 
death in cancer cells including tamoxifen and γ-irradiation.  Likewise, autophagy 
inhibitors also have shown efficacy in various cancers where autophagy provides a 
survival advantage, such as treatment with the autophagy inhibitor 3-methyladenine (3-
MA), in breast, colon, cervical, and prostate cancers (Kondo et al., 2005). In prostate 
cancer, autophagy is reported to have a cell-type dependent paradoxical effect; 
contributing to both survival (Li et al., 2008a, Wu et al., 2010b, Bennett et al., 2013, 
Shin et al., 2013, Pickard et al., 2015) and cell death in response to various toxic stimuli 
including chemotherapeutics (Pickard et al., 2015). 
 
Autophagy!and!α1GADR!antagonists!
The role of autophagy in quinazoline-based α1-ADR antagonist-mediated toxicity, 
particularly in prostate cancer cells, remains to be fully explored.  Autophagic response 
to α1-ADR antagonists was first reported by Yang et al (2011). Prazosin was found to 
induce autophagy in rodent cardiac cells, which was evidenced by autophagic vacuole 
formation and LC3 conversion (Yang et al., 2011b). However, prazosin induced cell 
death was not dependent on autophagic machinery, but was suggested to involve cross 
talk with apoptotic pathways (Yang et al., 2011b). More recently, a potential role for 
autophagy in doxazosin-induced prostate cancer cell death was uncovered (Pavithran 
and Thompson, 2012). Using transmission electron microscopy, the authors reported 
that toxic doses of doxazosin triggered acidic vacuole formation and lipofuscin 
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accumulation (Pavithran and Thompson, 2012). While these findings point to the 
occurrence of autophagy, its contribution to programmed cell death in response to 
antagonist-induced toxicity is unclear and further investigation is required as suggested 
by Klionsky et al. (2012).  
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SUMMARY$
 
Few studies have evaluated the relative cytotoxic potency and cell death mechanism of 
various α1-antagonists, including quinazoline- and non-quinazoline-based antagonists in 
prostate cancer cells. Additionally, there is a gap in knowledge with regards to how α1-
ADR antagonist potencies vary between prostate cancer cell lines and with duration of 
exposure. 
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3.2$ AIMS$
 
The overall aim of this study was to investigate the relative cytotoxic potency and cell 
death mechanisms (apoptosis and autophagy) of quinazoline- and non-quinazoline 
based α1-ADR antagonists in cellular models of castration-sensitive and castration-
resistant prostate cancer. 
 
 
Using AR-positive (castration-sensitive) LNCaP and AR-negative (castration-resistant) 
PC-3 cells, the specific aims of this study were to: 
 
1.! Determine the relative cytotoxic potencies of quinazoline- and non-quinazoline-
based α1-ADR antagonists following continuous 24, 48 and 72 h exposures. 
 
2.! Investigate the underlying cell death mechanisms of these α1-ADR antagonists. 
 
3.! Determine whether cell type-dependent differences exist in the cytotoxic 
potencies and cell death mechanisms. 
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3.3$ MATERIALS$AND$METHODS$
 
CHEMICALS!AND!SOLUTIONS!
Stock solutions of the autophagy inhibitor 3-MA (10 mM) were made up fresh daily 
from powder dissolved in complete culture medium containing 0.1% DMSO. 3-MA 
stock solution was diluted 1:2 in cell culture medium for a final concentration of 5 mM. 
All other chemicals and solutions (including α1-ADR antagonists) are detailed in 
Chapter 2 (General Methods). 
 
CELL!LINES!AND!TREATMENT!
Human prostate cancer cell lines LNCaP and PC-3 were seeded in 96-well plates at a 
density of 5.0x103 and 3.0x103 trypan blue-excluding cells per well, respectively. Cells 
were incubated for 24 (PC-3) or 48 h (LNCaP) for adhesion. Prior to treatment, culture 
medium above the cells was renewed. Cells were treated continuously with alfuzosin, 
terazosin, silodosin, doxazosin, prazosin (0.01 – 100 µM) or appropriate vehicle control 
and for 24, 48, or 72 h. The concentrations chosen range from therapeutic to 
supratherapeutic. The therapeutic concentrations of investigated drugs are detailed 
below in Table 3.2.   
 
 !
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Table!3.2.!Therapeutic!concentrations!of!investigated!α1GADR!antagonists!
Drug Concentration in 
human plasma [Cmax] 
Reference 
Alfuzosin 41 nM (Ahtoy et al., 2002) 
Doxazosin 33 nM (Vincent et al., 1983) 
Prazosin 52.2 – 391 nM (Jaillon, 1980) 
Silodosin 97 nM (Zhao et al., 2009) 
Tamsulosin  37.2 nM (Korstanje et al., 2011) 
Terazosin 95 - 120 nM (McNeil et al., 1991) 
 
 
  
 71 
CYTOTOXIC!POTENCY!OF! 1GADR!ANTAGONISTS!
The resazurin reduction assay was used as a measurement of cell viability and was 
conducted as detailed previously in Chapter 2 (General Methods) following desired 
treatment time.  
 
To ensure observed changes in cell viability were in fact due to cytotoxicity and not to 
change in cellular metabolic activity, the quantitative DNA-based proliferation assay 
CyQuant NF® (Life Technologies) was used according to the manufacturer’s 
instructions. Briefly, culture medium above the cells was removed and replaced with 
100 µL of CyQuant dye reagent and incubated at 37°C for 60 minutes. Fluorescence 
(excitation: 485 nm; emission 530 nm) was read using Modulous Microplate multimode 
plate reader (Promega). All CyQuant NF® experiments were conducted in duplicate 
over three independent experiments. 
 
Using the resazurin data, the concentration that resulted in 50% of maximal reduction in 
cell viability (IC50) was determined for all cell lines, drugs, and time points. 
 
CASPASEG3!ACTIVITY!ASSAY!
Apoptotic programmed cell death is carried out by activation of the caspase cascade 
initiated rom either the intrinsic (mitochondrial) or extrinsic (death receptor) pathways. 
Caspase-3 is the “universal” caspase that is activated by both intrinsic and extrinsic 
pathways, making it a good marker for apoptosis.   
 
Following 24 h treatment with alfuzosin, terazosin, tamsulosin, silodosin (30 µM), 
doxazosin, prazosin (10 and 30 µM), or appropriate vehicle control, apoptosis was 
measured using the commercially available caspase-3 fluorescence assay kit (Cat. No. 
10009135, Cayman Chemicals) according to manufacturer’s instructions. Briefly, 
immediately following treatment, plates containing cells were centrifuged at 800 x g for 
5 minutes prior to and after washing of adherent cells with assay buffer. The assay 
buffer was aspirated, and cells were lysed for 30 minutes on an orbital shaker using kit 
provided lysis buffer.  Samples were transferred to a clean 96-well black plate prior to 
addition of caspase-3 substrate solution, and incubated for 30 minutes at 37°C. 
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Fluorescence was read (excitation 485 nm; emission 530 nm) using a Modulus 
Microplate multimode plate reader (Promega).  
!
AUTOPHAGY!!
Changes in autophagy can be measured in numerous ways (Klionsky et al., 2012), with 
many assays utilising fluorometric stains of autophagic vesicles as a marker of 
autophagic activity. One such assay, the Cyto-ID Autophagy Detection kit (Cat. No. 
ENZ-51031, Enzo Life Sciences) has previously been used detect changes in vesicle 
formation specific to autophagy and correlates with the LC3-II puncta localised in the 
autophagosome (Guo et al., 2015).  In this study, the commercially available Cyto-ID 
Autophagy Detection kit was used to detect changes in autophagic vesicle formation 
following 24 h treatment with alfuzosin, terazosin, tamsulosin, silodosin (30 µM), 
doxazosin, prazosin (10 and 30 µM), or appropriate vehicle control. Increase in 
autophagy-related vesicles was measured using Cyto-ID® Autophagy Detection kit 
according to the manufacturer’s instructions. Briefly, cells were washed once with the 
buffer solution provided in kit, which was supplemented with 5% FBS to prevent cell 
detachment during washes. Cells were stained for 30 minutes at 37°C with the dual 
reagent staining solution consisting of Cyto-ID® reagent and the nuclear counterstain 
Hoechst 33342 diluted 1:1000 in phenol-red free culture medium containing 5% FBS. 
Cells were washed twice and autophagic vesicle formation was visualised by 
fluorescence microscopy using an Evos® Cell Imaging System (Thermo-Fischer 
Scientific). The Cyto-ID Autophagy Detection kit was conducted in duplicate for each 
condition over three or more independent experiments.  
 
Rapamycin, an inducer of autophagy, was used as a positive control. Cells were treated 
with 100 nM of rapamycin for 24 h, which has been previously identified to be a 
sufficient concentration and timeframe to activate autophagic machinery in PC-3 cells 
(Sarbassov et al., 2006).  As shown in Figure 3.3 on the following page, the Cyto-ID® 
Autophagy Detection kit is highly sensitive in visualising changes in rapamycin-
induced autophagic activity.  
 
The pharmacological inhibitor of autophagy, 3-methyladenine (3-MA), was used to 
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establish the role of autophagy in !1-ADR antagonist-induced cytotoxicity in LNCaP 
and PC-3 cells.  3-MA inhibits autophagy by targeting class III PI3K to block the 
formation of PI3P, which is essential for recruitment of Atg proteins and initiation of 
autophagy (Wu et al., 2010a). A concentration of 5 mM has previously been shown to 
inhibit autophagy in prostate cancer cells (Pickard et al., 2015) and was found to 
suppress 100 nM rapamycin-induced autophagy in the present study (data not shown). 
Cells were pre-treated with 3-MA (5 mM) for 30 minutes prior to co-treatment with 3-
MA and doxazosin or prazosin for 24 h. Final concentration was 5 mM of 3-MA and 10 
- 30 µM prazosin and doxazosin. Following treatment, either resazurin reduction 
(described in Chapter 2) or caspase-3 activity (as described previously) assay was 
conducted to determine changes cell survival or apoptotic cell death, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure! 3.3.! CytoGID®! detection! of! rapamycinGinduced! autophagy.! Basal! (A)! and!
rapamycinGinduced!(100!nM,!24!h)!(B)!autophagy!in!PCG3!cells!was!determined!using!
CytoID®! Autophagy! detection! kit! consisting! of! an! autophagic! vesicle! (green)! and!
nuclear!Hoechst!33342! (blue)! stains,! visualised!by! fluorescence!microscopy! (Evos!®!
Cell! Imaging! System,! ThermoGFischer! Scientific).! Arrows! indicate! cells! with!
autophagic!activity.!!
 
!
!
STATISTICAL!ANALYSIS!
Statistical analyses and graphical representation were generated using GraphPad Prism 
(version 6 for Mac OSX). Unless indicated otherwise, all conditions were assayed in 
A B 
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triplicate over three or more independent experiments. The relative IC50 (50% of 
maximal effect) was determined by non-linear regression of dose-response curve for 
each α1-ADR antagonist. For comparisons between control and treated cells, a one-way 
ANOVA with Dunnett’s post hoc test was conducted. Where two or more conditions 
were compared, a two-way ANOVA was conducted with a Tukey-Kramer post-hoc test. 
Statistical significance was defined as P < 0.05.  
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3.4$ RESULTS$
 
Α1GADR!ANTAGONIST!CYTOTOXICITY!
The cytotoxic potential of several α1-ADR antagonists was examined in AR-positive 
LNCaP and AR-negative PC-3 prostate cancer cell lines. Prostate cancer cells were 
treated continuously with alfuzosin, doxazosin, prazosin, silodosin, tamsulosin or 
terazosin for 24 – 72 h. Following treatment, cell survival (survival) was determined 
using a resazurin reduction assay.   
 
Of the α1-ADR antagonists tested, doxazosin and prazosin were found to have the 
greatest cytotoxic effect at all time points and in both cell lines (Figure 3.4). At 
concentrations greater than 10 µM, these drugs significantly reduced cell survival in a 
time-dependent manner, with 72 h exposure completely suppressing PC-3 and LNCaP 
cell survival (P<0.001). In contrast, the highest concentration (100 µM) of terazosin, 
silodosin and alfuzosin, resulted in a modest time-dependent reduction of cell survival, 
with 72 h exposure decreasing PC-3 survival by 42.2%, 25.5%, 28.7% and LNCaP 
survival by 30.0%, 26.7%, 14.0%, respectively (P≤ 0.01 for all drugs, Figure 3.4). In 
contrast, tamsulosin treatment failed to a have a statistically significant effect on cell 
survival at all time points.  
 
To ascertain that the observed findings were in fact due to a reduction in cell survival 
and not to decreased cellular metabolic activity, cellular DNA was quantified using the 
CyQuant® NF cell proliferation assay (Life Technologies) following treatment of PC-3 
cells with prazosin and doxazosin at all time points. As shown in Figure 3.5, resazurin 
reduction was generally consistent with CyQuant® NF findings, except for prazosin, 
where resazurin reduction significantly underestimated PC-3 toxicity following 24 and 
72 h exposure at lower concentrations (1 and 10 µM, and 10 µM, respectively).  
Overall, resazurin reduction was considered an effective assay for the measurement of 
α1-ADR antagonist-induced cytotoxicity and resazurin data was subsequently used to 
determine the relative cytotoxic potencies of these drugs. 
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Figure! 3.4.! Relative! cytotoxic! potency! of! α1GADR! antagonists! in! PCG3! (left! column)!
and! LNCaP! (right! column).! Cell! survival! was! determined! using! the! resazurin!
reduction! assay! as! previously! described.! Data! are! expressed! as! the! percentage! of!
untreated!control!(mean!±SEM,!n#5).!Fix!!
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Figure!3.5.!Comparison!of! resazurin! reduction!and!CyQuant!NF!proliferation!assays!
in! human! prostate! cancer! PCG3! cells! following! treatment! with! prazosin! (left)! or!
doxazosin! (right)! for! 24! (A),! 48! (B)!or! 72!h! (C).!Results! are!expressed!as!percent!of!
untreated!control! (mean!±!SEM,!n=3).!Statistical! significance!was!determined!using!
a! twoGway! ANOVA! with! Tukey’s! post! hoc! test.! *P<0.05! and! ***P<0.001! vs.!
CyQuant®!NF. 
 
 
!
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CYTOTOXIC!POTENCY!OF!Α1GADR!ANTAGONISTS!
The concentration which resulted in a 50% reduction in cell survival (IC50) was used to 
determine relative cytotoxic potency of the investigated α1-ADR antagonists. As shown 
in Table 3.3, prazosin was found to be the most potent, closely followed by doxazosin, 
except at 24 h where doxazosin was insignificantly more potent than prazosin in PC-3 
cells. AR-positive LNCaP cells were more sensitive to doxazosin (48 h, P < 0.05) and 
prazosin (24-72 h, P<0.001) toxicity, compared to AR-negative PC-3 cells. At the time 
points investigated, alfuzosin, silodosin, terazosin and tamsulosin had IC50 values 
greater than the maximal investigated concentration (100 µM), therefore were excluded 
from statistical analysis. Overall, the relative cytotoxic potency in this study was found 
to be: doxazosin = prazosin > terazosin = silodosin = alfuzosin > tamsulosin.  
!
Table!3.3.!Comparison!of!doxazosin!and!prazosin!IC50!values!between!cell!lines!
Mean values (n≥5) with 95% confidence limits are shown for cells treated with drug for 24, 48 or 72h. 
Statistical significance was determined using a two-way ANOVA with Tukey’s post hoc test. *P<0.05, 
**P<0.01 and ***P<0.001 vs. PC-3. ## P<0.01 vs. doxazosin. Non-linear regression of alfuzosin, 
terazosin, silodosin and terazosin dose-response curves returned ambiguous results at all time points, 
and therefore were excluded from statistical analysis. 
! !
 Relative IC50 (95% CI) (µM) 
 24 h 48 h 72 h 
Prazosin    
PC-3 55.3 (47.8-64.1) 26.8 (25.5-28.2) ## 21.3 (19.5-23.3) 
LNCaP 22.0 (18.8-25.8) *** 14.3 (11.6-17.5)*** 13.0 (8.6-19.6)** 
Doxazosin    
PC-3 46.8 (42.5-51.5) 34.1 (32.0-36.4)  23.3 (21.0-25.7) 
LNCaP 35.4 (30.6-41.0) 23.4 (20.3-27.0)* 17.2 (10.9-27.1) 
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ALPHA1GADR!ANTAGONISTSGINDUCED!APOPTOSIS!
Doxazosin is well documented to induce apoptosis of prostate cancer cells (Benning and 
Kyprianou, 2002, Partin et al., 2003); however, less is known about the apoptotic 
potential of equipotent prazosin in these cells. Furthermore, there have been no studies 
directly comparing the apoptotic potential between doxazosin and prazosin, as well as, 
the lesser investigated alfuzosin, terazosin and silodosin in prostate cancer cells. To 
investigate this, the activation of the universal marker of apoptosis, caspase-3, was used 
as an index of apoptotic cell death following continuous 24 h treatment with alfuzosin, 
terazosin (30 µM), doxazosin, prazosin (10-30 µM), tamsulosin (30 µM), or vehicle. For 
this study, the 24 h time-point was chosen, as activation of the apoptotic cascade is 
considered to be an early event in apoptosis, and would likely go undetected at longer 
treatment times.  
 
As shown in Figure 3.6, doxazosin and prazosin treatment resulted in significant 
increases in caspase-3-mediated apoptosis in PC-3 cells (Figure 3.6 A), whereas only 
prazosin was able to enhance LNCaP caspase-3 activity after 24 h exposure (Figure 3.6 
B). Overall, LNCaP cells were more sensitive to the apoptotic effect of doxazosin (30 
µM, 24 h) compared to PC-3 cells. Specifically, 30 µM prazosin resulted in an 
approximately 6-fold increase in LNCaP caspase-3 activity compared to untreated 
control. In contrast, no significant change was observed in caspase-3 activation 
following treatment with alfuzosin, terazosin or tamsulosin (30 µM, p > 0.05) in either 
cell line (Figure 3.6 C and D). 
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Figure!3.6.!CaspaseG3!activity!following!24!h!treatment!of!LNCaP!(A!and!C)!and!PCG3!
(B!and!D)!with!either!prazosin,!doxazosin!at!the!concentrations!shown!(A,!B),!or!30!
µM!alfuzosin,!silodosin,!tamsulosin!or!terazosin!(C!and!D).!!Results!are!expressed!as!
foldGchange! from! control! (mean! ±! SEM,! n! =3).! Statistical! analysis! was! determined!
using!a!oneGway!ANOVA!with!Dunnetts’!post!hoc!test.!**P<0.01!and!***P<0.001!vs.!
control.!
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ALPHA1GADR!ANTAGONISTGINDUCED!AUTOPHAGY!
The contribution of autophagy to the underlying cytotoxic mechanisms of α1-ADR 
antagonist remained to be fully elucidated. To investigate whether α1-ADR antagonists 
are able to induce autophagy, cells were treated with alfuzosin, doxazosin, prazosin, 
silodosin, terazosin and tamsulosin; and live cells were stained with a commercially 
available Cyto-ID® Autophagy Detection kit (Enzo Life Sciences) as described 
previously (Section 3.2). 
 
Basal autophagic vesicle formation (green) was greater in LNCaP than PC-3 cells, as 
shown in Figure 3.7 A. Qualitatively, prazosin and doxazosin were found to increase 
formation of autophagic vesicles in PC-3 and LNCaP cells (Figure 3.7 B). These 
findings were confirmed through quantitative measurement of Cyto-ID® (green) 
fluorescence intensity, which was normalised to fluorescence of the Hoechst 33342 
nuclear counter stain (Figure 3.8)  As shown in Figure 3.8, doxazosin-induced 
autophagy was found to be significantly greater than control in both cell lines (P<0.01 – 
0.001); however, only the highest doxazosin concentration tested (30 µM) was able to 
significantly enhance autophagy within PC-3 cells (10 µM, P=0.068; 30uM P=0.001). 
In contrast to doxazosin, prazosin exposure only possessed autophagic potential in PC-3 
cells, with 30 µM significantly enhancing autophagy by nearly 3-fold (P=0.002). 
However, no appreciable increases in the level of LNCaP autophagy were observed 
following prazosin treatment. 
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Figure'3.7.'Autophagic'activity''of'PC73'and'LNCaP'cells'in'basal'conditions'(A)'or'following'24'h'treatment'with'prazosin'or'doxazosin'(10'
–' 30' µM)' (B)' was' determined' using' a' commercially' available' kit' and' visualised' using' an' Evos' Cell' Imaging' system' (Thermo7Fischer'
Scientific)'as'described'previously'in'this'chapter'(Materials'and'Methods'section).'Autophagic'vesicles'(green)'are'indicated'by'arrows.''
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Figure'3.8.'Prazosin'and'doxazosin'(10'–'30'µM)'induced'autophagy'was'quantified'
by'measuring'CytoEID®'(green)'fluorescence'(excitation:'480'nm;'emission:'530'nm)'
using'a'Modulus'Multimode'plate'reader'(Promega).'CytoEID'fluorescence'was'
normalised'to'the'nuclear'counter'stain'fluorescence'(Hoechst'33342,'excitation:'
350'nm;'emission:'460'nm).'Data'were'represented'as'foldEchange'in'CytoEID®'
fluorescence'from'untreated'control'(mean'±'SEM,'n=4).'Statistical'analysis'was'
determined'using'a'oneEway'ANOVA'with'Dunnett’s'post'hoc'test.'**'P'<'0.01'and'
***'P'<'0.001'vs.'respective'untreated'control.''
 
 
As seen in Figure 3.9 B, no appreciable change in autophagic vesicles compared to 
vehicle control were observed following treatment with alfuzosin, tamsulosin or 
terazosin (30 µM, 24 h) in either LNCaP or PC-3 cells. Interestingly, the non-cytotoxic 
silodosin (30 µM) was observed to increase autophagic vesicles at 24 h. However, since 
silodosin was found to not possess cytotoxic actions on LNCaP cells at the time points 
tested (24 – 72 h), no further investigations of silodosin-induced autophagy were 
pursued. 
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Figure' 3.9.' Autophagic' activity' ' of' PC73' and' LNCaP' cells' in' basal' conditions' (A)' or' following' 24' h' treatment' with' alfuzosin,' silodosin,'
tamsulosin'or' terazosin' (30'µM)' (B)'was'determined'using'a' commercially'available'kit'and'visualised'using'an'Evos'Cell' Imaging' system'
(Thermo7Fischer' Scientific)' as' described' previously' in' this' chapter' (Materials' and' Methods' section).' Autophagic' vesicles' (green)' are'
indicated'by'arrows.''
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THE$CONTRIBUTION$OF$AUTOPHAGY$TO$Α13ADR$ANTAGONIST$INDUCED$
CYTOTOXICITY$
To determine whether doxazosin and prazosin-induced autophagy may be contributing 
to cell survival or to cell death, cells were pretreated for 30 minutes with the autophagy 
inhibitor 3-MA (5 mM) prior to concurrent treatment with doxazosin or prazosin (10 -
30 µM) for 24 h. Following treatment, cell survival and apoptosis was determined by 
resazurin reduction and caspase-3 activity assays.  As seen in Figure 3.10, 5 mM 3-MA 
was capable of suppressing basal autophagic activity (basal activity shown in Figure 
3.11 A), as well as the formation of autophagy-related vesicles in response to prazosin 
and doxazosin.  
 
$
$
Figure$ 3.9.$ Effect$ of$ the$ pharmacological$ autophagy$ inhibitor$ 33MA$ (5mM)$ on$
prazosin3$and$doxazosin3induced$ formation$of$autophagy3related$vesicles$ following$
24$ h$ treatment.$ Inhibition$ of$ prazosin3$ and$ doxazosin3induced$ autophagy$ in$ PC33$
and$LNCaP$cells.$Autophagic$vesicles$(and$nuclei)$were$stained$using$a$commercially$
available$ kit,$ and$ visualised$ using$ an$ Evos®$ Cell$ Imaging$ System$ (Thermo3Fischer$
Scientific)$as$described$previously.$Arrows$indicated$autophagy3related$vesicles.$$
 
 
In the absence of α1-ADR antagonists, pharmacological inhibition of autophagy with 3-
MA treatment significantly reduced LNCaP viability by approximately 41% (± 1.1) 
compared to untreated control (P<0.001) (Figure 3.10 B). In contrast, 3-MA-mediated 
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autophagy inhibition had no effect on PC-3 cell survival. In LNCaP cells, 24 h co-
treatment with either doxazosin or prazosin and 3-MA did not possess an appreciable 
additive effect in all conditions tested.  However, co-treatment with 3-MA and 30 µM 
prazosin in LNCaP cells had a greater effect than other combinations tested (reduced 
cell survival by 20% ±1.7), which corresponded to a significant increase in apoptotic 
caspase-3 activity compared to single-agent-treated controls (P=0.002) (Figure 3.10 D). 
Conversely, inhibition of autophagy by 3-MA was found to partially protect PC-3 cells 
from prazosin-induced toxicity (P=0.004) and significantly suppressed caspase-3 
activity (P<0.001) (Figure 3.10 A and C). Doxazosin treatment in the absence of 
functional autophagy machinery had no statistically significant effect in either cell line.    
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Figure$ 3.10.$ PC33$ and$ LNCaP$ cells$ were$ treated$ with$ prazosin$ or$ doxazosin$ (10330$
µM)$ in$ the$ presence$ or$ absence$ of$ the$ autophagy$ inhibitor$ 33MA$ (5$mM)$ for$ 24$ h.$$
Cell$ survival$ (A)$ was$ determined$ by$ resazurin$ reduction$ and$ normalised$ as$ a$
percentage$ of$ untreated$ control.$ Caspase33$ activity$ (B)$ was$ determined$ using$ a$
commercially$available$kit$and$data$were$expressed$as$fold3change$from$control.$All$
data$ are$ expressed$ as$ the$ mean$ ±$ SEM$ (n=3).$ $ Statistical$ significance$ was$
determined$ using$ a$ two3way$ ANOVA$ with$ Tukey’s$ post$ hoc$ test.$ $ ##P<0.01,$
###P<0.001$vs.$doxazosin$or$prazosin$treated$control.$
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3.5! DISCUSSION!
 
To date, !1-ADR antagonists remain the primary treatment for men experiencing BPH-
associated LUTS, which mitigate the symptoms by blocking !1-ADR-mediated 
prostatic contraction.  Over the years, some of these drugs have been found to exert 
anticancer effects in pre-clinical models (Kyprianou and Benning, 2000, Benning and 
Kyprianou, 2002, Partin et al., 2003, Lin et al., 2007), and importantly, reported to 
reduce the risk of prostate cancer in clinical settings compared to unexposed men 
(Harris et al., 2007). The current study is the first to compare the cytotoxic potency 
various chemically dissimilar (quinazoline vs. non-quinazoline) antagonists in different 
cellular models of prostate cancer cell lines. Additionally, it was previously unknown 
how the cytotoxic efficacy of these antagonists changed with respect to treatment 
duration and AR-receptor status.  The investigated !1-ADR antagonists ranged from the 
non-subtype-selective prazosin, doxazosin and terazosin, which possessed the greatest 
cytotoxicity, to the subtype-selective alfuzosin, tamsulosin and silodosin, which had 
little cytotoxic effect on prostate cancer cells. 
 
AR3STATUS$AND$QUINAZOLINE3DEPENDENT$CYTOTOXICITY$
Prazosin and doxazosin were generally equipotent in all conditions tested, and these 
drugs possessed the greatest potency of all drugs investigated. These findings are 
supported by previous literature (Lin et al., 2007), which also investigated the relative 
cytotoxic potencies of several !1-ADR antagonists including tamsulosin, terazosin, 
doxazosin, prazosin and phentolamine. Consistent with the present findings, prazosin 
was previously found to be the most potent, closely followed by doxazosin in prostate 
cancer PC-3, LNCaP and DU145 cells after 48 h treatment (Lin et al., 2007). The 
overall relative cytotoxic potencies in the present study were found to be: prazosin = 
doxazosin > terazosin = alfuzosin = silodosin > tamsulosin. Overall, there was little 
difference in doxazosin or prazosin cytotoxic potency between prostate cancer cell lines 
with differing AR-status. Only prazosin was found to have significantly greater potency 
in AR-positive LNCaP cells compared to AR-negative PC-3 cells. In contrast, 
doxazosin potency was similar between both prostate cancer cell lines.  
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The cytotoxic potential of the investigated drugs appeared to correspond with previous 
reports of quinazoline-dependence (Benning and Kyprianou, 2002), with the 
quinazoline derivatives prazosin, doxazosin, possessing greater potency than the non-
quinazolines, tamsulosin and silodosin in both cell lines. However, it appears that the 
quinazoline moiety does not ensure cytotoxic effects at the concentrations tested.  The 
cytotoxic effects of 100 µM alfuzosin and terazosin were found to not be significantly 
different than silodosin and tamsulosin in exposures of 24 and 48 h. While the 
quinazoline structure might be important for doxazosin / prazosin cytotoxicity, it must 
be acknowledged that quinazoline-dependent cytotoxicity of prostate cancer cell lines is 
not absolute in the conditions tested here.   
 
AR3STATUS$AND$QUINAZOLINE3DEPENDENT$APOPTOSIS$$
The anti-cancer effect of these cytotoxic antagonists has largely been attributed to the 
induction of apoptotic programmed cell death (Partin et al., 2003, Walden et al., 2004, 
Hui et al., 2008, Garrison and Kyprianou, 2006, Romanska et al., 2010).  However, no 
studies have directly compared the apoptotic potential of these drugs in different 
cellular models of prostate cancer. Consistent with the previous reports of cytotoxic and 
apoptotic quinazoline-dependence (Partin et al., 2003), the present findings 
demonstrated a significant increase in apoptotic caspase-3 activity in both cell lines 
following exposure to doxazosin or prazosin treatment, which occurred in a 
concentration-dependent manner. However, no increase in apoptotic activity could be 
measured following treatment with the lesser-toxic quinazolines alfuzosin and terazosin, 
or the non-quinazolines silodosin or tamsulosin. Similar to the cytotoxic potency data, 
AR-positive LNCaP cells were more sensitive to prazosin exposure and apoptotic 
activity was found to be greater in these cells compared to AR-negative PC-3 cells. In 
contrast to the present findings, terazosin has been reported to elicit apoptosis in 
urogenital cancer cells in vitro, in animal models, as well in tissue specimens from 
clinically treated men (Kyprianou and Benning, 2000, Pan et al., 2003, Tahmatzopoulos 
et al., 2005, Papadopoulos et al., 2013). Discrepancies between the previous findings in 
vitro and the present study are likely attributed to differences in treatment duration or 
concentrations evaluated for apoptotic effect.  However, there is a large gap in the 
apoptotic efficacies of these antagonists between in vitro models and in vivo or in 
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clinical models. In vitro, supra-therapeutic concentrations (<10 µM) are required to 
induce prostate cell apoptosis. However therapeutically relevant doses (nM serum 
concentrations) reportedly increased apoptosis in urogenital tumours of men treated 
with these drugs (Tahmatzopoulos et al., 2005). While the discrepancy between 
apoptotic (and cytotoxic) efficacies are currently unknown, it can be inferred that 
chronic treatment with low concentrations of these antagonists may have a delayed 
apoptotic effect, possibly via antagonist accumulation in the prostate (Korstanje et al., 
2011) or chronic antagonism of endogenous α1-ADR stimulation.  
 
QUINAZOLINE3DEPENDENT$AUTOPHAGIC$CYTOTOXICITY$
In the context of cancer, autophagy is classically associated with maintaining cellular 
homeostasis, thereby acting as a cytoprotective mechanism leading to treatment-
resistance, and subsequent disease progression. By contrast, sustained autophagy can 
have cytotoxic effects in some cancers in a cell-type dependent manner (Pickard et al., 
2015). In the present study, autophagy was found to play opposing roles, contributing to 
LNCaP survival and PC-3 toxicity in response to prazosin exposure. These findings are 
consistent with the cytotoxic data presented in this Chapter, which showed that the 
quinazoline prazosin was the most cytotoxic of the investigated antagonists. 
Quinazoline-based doxazosin, and to a lesser-extent terazosin, were also found to 
trigger autophagic vesicle formation in both cell lines.  However, the quinazoline-
dependence of autophagy induction in prostate cancer cells is not as clear cut as overall 
cytotoxicity and apoptosis. Similar to the cytotoxicity and apoptosis data, the non-toxic 
quinazoline alfuzosin (24 h , 30 µM) was unable to enhance autophagic activity. 
Furthermore, by it was found the non-quinazoline silodosin was able to significantly 
enhance autophagy levels in LNCaP, but not PC-3 cells. Taken together, it is proposed 
that the mechanisms underlying autophagic cell death in the present study are complex 
and may not be quinazoline-dependent. Rather autophagic cell death may be a function 
of cytotoxic potency and AR-status in prostate cancer cells.  
$
$
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AUTOPHAGY$AND$AR3STATUS$
This is the first report of autophagy involvement in !1-ADR antagonist-induced 
cytotoxicity, particularly in prostate cancer cells.  The paradoxical effect of autophagy 
induction in prostate cancer cells was also demonstrated previously (Pickard et al., 
2015) in response to chemotherapeutic agents. The opposing roles are likely to be 
related to AR-status, with AR-signaling in LNCaP cells requiring autophagy for cell 
survival mechanisms.  It was previous demonstrated that prostate cancer AR-signaling 
induced accumulation of intracellular reactive oxygen species, which in turn stimulated 
autophagy and subsequently promoted survival of LNCaP cells (Shi et al., 2013).  
Therefore, in LNCaP cells, antagonist-induced autophagy acts as an adaptive response 
to protect from cell death, and in turn, inhibition of autophagy enhances prazosin and 
doxazosin cytotoxicity and increased apoptosis.  In contrast, the absence of functional 
autophagy machinery partially protected PC-3 cells from prazosin-induced cell death 
via suppression of apoptotic mechanisms. While these findings suggest that autophagy 
contributes to some degree to prazosin-induced PC-3 toxicity, it appears cross-talk 
between autophagic and apoptotic mechanisms exists to regulate !1-ADR antagonist-
mediated cell death.  
 
In conclusion, prazosin and doxazosin were found to be the most potent of the 
investigated antagonists and possessed the greatest apoptotic potential in both AR-
positive and AR-negative LNCaP and PC-3 cells, respectively. This is the first report of 
autophagy involvement in prazosin-induced cytotoxicity. However, autophagy 
contributed differentially in a cell type-dependent manner to promote LNCaP survival 
and PC-3 cell death. Inhibition of autophagy partially protected and suppressed 
apoptotic mechanisms in PC-3 cells exposed to prazosin, giving rise to the possibility of 
cross-talk between these cell death pathways in regulating antagonist-induced cell 
death. Future investigation of longer treatment durations (>72 h) may be required to 
replicate the potential latent cytotoxic actions of alfuzosin, terazosin, silodosin and 
tamsulosin which have been reported in vitro, in vivo or clinically. Additionally, the cell 
signaling pathways regulating doxazosin and prazosin-induced apoptosis or autophagy 
remain to be fully elucidated. Some of these molecular mechanisms are further explored 
in the next chapter (Chapter 4). Further studies evaluating the novel autophagic activity 
of silodosin on LNCaP cells reported here would be of significant interest. While 
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insignificant and unconfirmed, silodosin appeared to have a pro-survival effect on 
LNCaP cells which is consistent with the survival-promoting effect of autophagy in 
AR-positive cells. This effect might have clinical implications for men undergoing 
treatment for prostate cancer.  
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CHAPTER!4:!
!MOLECULAR!MECHANISMS!UNDERLYING!
DOXAZOSIN!AND!PRAZOSIN!CYTOTOXICITY!
 !
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4.1! BACKGROUND!
 
MOLECULAR$MECHANISMS$OF$ALPHA13ADR$ANTAGONIST3INDUCED$CELL$
DEATH$
The molecular mechanisms underlying quinazoline-based α1-ADR antagonists-induced 
cell death are undoubtedly complex and remain to be fully elucidated. However, a 
growing body of evidence suggests that quinazoline-based prazosin, doxazosin and 
terazosin target prostate cancer by triggering apoptosis, anoikis, cell cycle arrest, and 
potentially, autophagic cell death. Together, these mechanisms act to impair tumour 
growth, angiogenesis and metastasis, all of which are important events associated with 
disease progression. Table 4.1 provides a summary of the reported biochemical and 
molecular changes associated with quinazoline-based antagonist-induced cytotoxicity. 
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Table$4.1.$$Overview$of$molecular$mechanisms$contributing$to$α13ADR$antagonist3
induced$cytotoxicity$
Effect Experimental model References 
Apoptosis-associated 
 
  
Activation of TGF-β signaling PC-3 (Partin et al., 2003) 
  Prostate stromal cells (Ilio et al., 2001) 
Activation of IkBα signaling PC-3 (Partin et al., 2003) 
Decrease NFκB mRNA MCF-7 (Hui et al., 2008) 
Upregulation p21WAF-1 PC-3 (Partin et al., 2003) 
Caspase-8 activation PC-3, BPH cells (Garrison and Kyprianou, 2006) 
  786-0, Caki (Sakamoto et al., 2011) 
Increase Fas ligand expression PC3 (Partin et al., 2003) 
Fas-associated death domain PC3, BPH cells (Garrison and Kyprianou, 2006) 
Caspase-3 activation PC-3 (Partin et al., 2003, Walden et al., 2004) 
  HUVEC (Keledjian et al., 2005) 
  HeLa (Gan et al., 2008) 
  786-0, Caki (Sakamoto et al., 2011) 
  H9C2 (Yang et al., 2011b) 
  TRAMP Mice (Chiang et al., 2005) 
Increase Caspase-3 expression Winstar rats (Papadopoulos et al., 2013) 
Cytochrome c release HUVEC (Liao et al., 2011) 
PARP Cleavage TRAMP Mice (Chiang et al., 2005) 
  PC3 (Lin et al., 2007) 
Increase Bax expression PC3, BPH cells (Garrison and Kyprianou, 2006) 
  TRAMP Mice (Chiang et al., 2005) 
Increase Bad expression PC-3 (Lin et al., 2007) 
  HUVEC (Liao et al., 2011) 
Increase Bid expression PC-3 (Lin et al., 2007) 
Increase Bcl-xL expression HUVEC (Liao et al., 2011) 
Decrease Bcl-2 levels TRAMP Mice (Chiang et al., 2005) 
Decrease MCL-1 expression HUVEC (Liao et al., 2011) 
EGFR inhibition MCF-7 (Hui et al., 2008) 
ERK1/2 inhibition MCF-7 (Hui et al., 2008) 
Activation of p38 MAPK H9C2 (Yang et al., 2009) 
Anoikis associated 
 
  
Decrease Akt activity PC-3 (Garrison and Kyprianou, 2006) 
 DU145 (Romanska et al., 2010) 
 TRAMP Mice (Chiang et al., 2005) 
Decrease FAK expression PC-3 (Walden et al., 2004) 
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Effect Experimental model References 
  HUVEC (Keledjian et al., 2005) 
EphA2 receptor activation PC-3 (Petty et al., 2012) 
Decrease integrin expression PC-3, BPH cells (Garrison and Kyprianou, 2006) 
Angiogenesis associated 
 
  
Decrease VEGF mRNA HUVEC (Keledjian et al., 2005) 
Inhibition of glutathione transferase Bovine liver cytosol (Isgor and Isgor, 2012) 
Inhibition of Src kinase Bovine liver cytosol (Isgor and Isgor, 2012) 
Inhibition of PTK activity Bovine liver cytosol (Isgor and Isgor, 2012) 
Increase AP-2α expression HeLa (Gan et al., 2008) 
Autophagy associated 
 
  
Vacuole formation H9C2 (Yang et al., 2011b) 
  PC-3 (Pavithran and Thompson, 2012)  
LC3 conversion H9C2 (Yang et al., 2011b) 
Decrease mTOR activation H9C2 SKOV-3, 
(Yang et al., 2011b) 
(Yang et al., 2009) 
Decrease Akt activity H9C2 SKOV-3 
(Yang et al., 2011b) 
(Yang et al., 2009) 
Lipofuscin accumulation PC 3 (Pavithran and Thompson, 2012)  
Cell cycle associated   
Inhibition of CDK1 PC-3, LnCAP, DU145 (Lin et al., 2007) 
Inhibition of Rb MCF-7 (Hui et al., 2008) 
 Coronary artery SMC (Kintscher et al., 2000a) 
 Bladder SMC (Austin et al., 2004) 
Decrease Cyclin A expression Bladder SMC (Austin et al., 2004) 
 
!
APOPTOSIS!
The reader is referred to Chapter 3 for detailed overview of the apoptotic signaling 
transduction pathway.  Quinazoline-based antagonist-induced prostate cancer apoptosis 
has been reported to primarily involve transforming growth factor beta (TGF-β) and 
Smad signaling, activation of IκBα, and subsequent inhibition of the survival 
transcription factor NfκB (Partin et al., 2003). However, subsequent reports indicate 
apoptotic cell death may occur by additional intrinsic (Lin et al., 2007) and extrinsic 
mechanisms (Partin et al., 2003, Garrison and Kyprianou, 2006) including, 
mitochondrial-dependent activation of the caspase cascade (Lin et al., 2007) and Fas-
associated death domain (FADD) activation (Garrison and Kyprianou, 2006).  
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Doxazosin, and related quinazoline antagonists, may also induce prostate cancer 
apoptosis though inhibition of tyrosine kinase receptors such as EGFR. EGFR is a cell 
surface receptor that is stimulated by a diverse number of ligands to promote cellular 
proliferation and survival by downstream signaling via several pathways including 
MAPK (Yarden, 2001). The mitogen-activated protein kinase (MAPK) family consists 
of JNK, p38, and ERK1/2. These MAPKs transduce extracellular and intracellular 
stimuli to regulate cellular responses such as differentiation, proliferation, or cell death 
(Krishna and Narang, 2008). In particular, ERK1/2 is frequently associated with EGFR 
activation and is known to contribute to androgen-dependent and –independent prostate 
cancer survival mechanisms (Zelivianski et al., 2003, Carey et al., 2007). Interestingly, 
the quinazoline structure is common to cytotoxic antagonists (doxazosin, prazosin and 
terazosin) and the EGFR inhibitors gefitinib (Iressa) and erlotinib (Tarceva) (Figure 
4.1). Similar to these EGFR inhibitors, it is postulated that quinazoline-based α1-ADR 
antagonists may trigger apoptosis by inhibiting aberrant EGFR activity and, 
subsequently, downstream ERK1/2-mediated survival-signaling (Hui et al., 2008). 
 
 
  
 
Gefitinib (Iressa) 
 
Erlotinib (Tarceva) 
Figure$4.1.$Chemical$structures$of$the$EGFR$inhibitors,$gefitinib$and$erlotinib.$These$
drugs$ also$ contain$ a$ quinazoline$ structure$ (red$ box)$ common$ to$ doxazosin,$
prazosin,$alfuzosin$and$terazosin.$
 
ANOIKIS!
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Anoikis is a type of apoptotic cell death in response to detachment from the 
extracellular matrix (ECM) (Frisch and Francis, 1994). Upon loss of ECM contact, 
normal endothelial or epithelial cells undergo rapid intrinsic and extrinsic apoptotic 
signaling resulting in cell death. Cancer cells can become anoikis-resistant and are able 
to freely detach from the primary tumour and migrate, leading to cancer metastases. 
Metastasis is the spread or colonization of cancers cells originating from the primary 
tumour to local or distant sites (Figure 4.2) (Sakamoto and Kyprianou, 2010). The 
development of metastasis is an important, yet devastating event in disease progression 
and is strongly associated with prostate cancer related-death (Bubendorf et al., 2000).  
$
$
Figure$ 4.2.$ Anoikis3resistance$ leads$ to$ cancer$ metastasis.$ Following$ loss$ of$ cell3
ECM$ interaction,$ normal$ non3cancerous$ cells$ undergo$ apoptotic$ cell$ death.$
However,$ cancerous$ cells$ can$ develop$ anoikis3resistance$ or$ an$ anchorage3
independent$ phenotype$ allowing$ these$ cells$ to$ migrate$ and$ develop$ secondary$
tumours.$Figure$adapted$from$Sakamoto$and$Kyprianou,$2010.$
 
 
Anoikis occurs via various mechanisms including loss of integrin-mediated survival 
signaling and activation of intrinsic and extrinsic apoptotic pathways (Figure 4.3). 
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Integrins are transmembrane receptors that play a key role in detecting cell-ECM 
interactions. Detachment of the cell, and thus integrins, from the ECM results in 
dephosphorylation (inactivation) of important survival factors such as focal adhesion 
kinase (FAK), P13K, Akt, MAPK, and ERK (Sakamoto and Kyprianou, 2010).  Of 
particular interest, quinazoline-based antagonists have been shown to induce anoikis-
mediated cell death in prostate cancer (Keledjian and Kyprianou, 2003) and vascular 
endothelial cells (Keledjian et al., 2005) thereby reducing cancer metastasis. As 
summarised in Table 4.1, quinazoline-based α1-ADR antagonist-mediated anoikis has 
been evidenced previously by anoikis-associated morphological changes (Walden et al., 
2004), inactivation (dephosphorylation) of FAK / Akt survival signaling (Keledjian and 
Kyprianou, 2003, Walden et al., 2004, Garrison and Kyprianou, 2006, Romanska et al., 
2010, Sakamoto et al., 2011), and downregulation of integrin expression (Garrison and 
Kyprianou, 2006). Additionally, inhibition of survival signaling was also paired with 
increased in extrinsic (Garrison and Kyprianou, 2006) and intrinsic apoptotic pathways 
(Keledjian and Kyprianou, 2003).  
 
More recently, Petty and colleges (2012) identified doxazosin as a novel agonist for 
EphA2 receptors. In this study, direct doxazosin-EphA2 receptor interactions resulted in 
anoikis-like events, including cell rounding, detachment and apoptosis.  In some 
cancers, Eph receptors acquire ligand-independent activity, possibly mediated through 
aberrant AKT activity (Miao et al., 2009), and in turn, promote metastatic-like 
behaviors, including resistance to anoikis, and increased cellular proliferation (Chen et 
al., 2014). This tumourigenic propensity to proliferate/metastasize can be reversed 
through ligand-dependent stimulation leading to suppression of downstream pro-
survival signaling, including FAK and integrins, to restore tumour suppressor actions 
and anoikis mechanisms (Miao et al., 2000, Pasquale, 2005, Petty et al., 2012). 
Interestingly, these ligand-dependent tumour-suppressor actions are consistent with 
previously documented anoikis-related effects of these drugs, suggesting that some 
quinazoline-based α1-ADR antagonists may activate EphA2 and restore tumour 
suppressor functions in prostate cancer cells. Nevertheless, it is currently unknown if 
the chemically similar quinazoline, prazosin has EphA2 agonist potential.  
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Figure$ 4.3.$ Cell$ signaling$ and$ apoptotic$ pathways$ following$ non3cancerous$ cell$
detachment$ from$ the$extracellular$membrane.$ Following$detachment,$ the$extrinsic$
apoptotic$pathway$is$activated$initiated$by$the$Fas$receptor$(A),$ leading$to$effector$
caspase$ activation.$ Integrin3mediated$ contact$with$ the$ ECM$ promotes$ inactivation$
of$ survival$ signaling$ pathways.$ Loss$ of$ cell3ECM$ interaction$ results$ in$
dephosphorylation$ (inactivation)$ of$ PI3K$ /$ Akt$ thereby$ sensitising$ the$ cell$ to$
apoptosis$ (B).$ Additionally,$ intrinsic$ apoptosis$ mechanisms$ have$ also$ been$ shown$
to$ be$ involved$ in$ anoikis$ cell$ death$ (C)$ Figure$ adapted$ from$ Sakamoto$ and$
Kyprianou,$2010.$
!
AUTOPHAGY!
The reader is referred to Chapter 3 for background information on autophagy. Little is 
currently known with regards to the molecular mechanisms underlying doxazosin, 
prazosin induced autophagy, particularly in prostate cancer cells. In one study using 
rodent cardiomyocytes, prazosin was found to decrease expression of mTORC1 and its 
substrate, p70S6K, which corresponded with an expressional decrease and increase in 
the upstream mTORC1 modulators AKT and AMPK, respectively (Yang 2011).  Paired 
with these findings, this study demonstrated the formation of autophagy-related vesicles 
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in response to prazosin treatment.  However, pharmacological autophagy inhibition 
could not confer significant cytoprotection. On the contrary, inhibition of autophagic 
mechanisms resulted in enhanced caspase activity. From this, the authors 
controversially concluded that prazosin induced autophagic cell death despite failing to 
demonstrate a causal role between autophagy and cytotoxicity. In this study, the 
involvement of autophagy in prazosin toxicity remains unclear. The absence of 
cytoprotection following autophagy inhibition suggests that autophagy either plays a 
protective role from prazosin-toxicity or cross-talks with apoptotic mechanisms to 
increase apoptosis to compensate for the absence of autophagic-mediated cell death.  
Similar findings were reported in a separate study investigating the effects of doxazosin 
on human endothelial cells, indicating the doxazosin also modulates mTORC1 activity, 
possibly by reducing AKT activity (Park et al., 2014a). However, this study did not 
show a direct causal link between mTORC1 inhibition and the induction of apoptosis. 
Taken together, it can be inferred that these drugs have autophagy-modulating effects 
through their indirect actions on mTORC1. At the present time, it remains to be 
elucidated whether prazosin/doxazosin also have autophagy modulating effects in 
prostate cancer cell lines. Furthermore, it remains to be seen if autophagy actively 
contributes to the cytotoxic potential of these drugs.  
 
CELL!CYCLE!ARREST!
In eukaryotic cells the cell cycle consists of interphase and mitosis (Figure 13). 
Interphase is comprised of growth (G1, G2) and DNA replication (S) phases in 
preparation for mitosis (M phase). M phase is divided into four distinct phases: 
prophase, metaphase, anaphase, and telophase. Prophase and metaphase are 
characterised by condensation of chromosomes and alignment of duplicate 
chromosomes on in the center of the cell, respectively. The mitotic spindle-mediated 
separation of chromosome pairs to opposite poles of the cell occurs during anaphase. 
Telophase is the final stage of mitosis where the nuclear envelope reassembles and 
chromosomes de-condense (Santella et al., 2005). The progression of the cell cycle is 
regulated by cyclin-dependent kinases (CDKs). Complete activation of CDKs requires 
both cyclin-binding and phosphorylation by cyclin-activating kinase. Inhibition of CDK 
can occur via dephosphorylation of activation sites, phosphorylation of inhibitory 
 103 
subunits, binding of cyclin-dependent kinase inhibitors, or disassociation of cyclins 
(Morgan, 1995).  
 
Few have investigated the effects of α1-ADRs antagonists on cell cycle progression; 
however, it appears to be drug- and cell type-dependent. One study by Lin et al. 
demonstrated that prazosin triggered G2 check point arrest in prostate cancer lines, 
which was possibly mediated by inactivation of the cell cycle promoter CDK1 (Lin et 
al., 2007). In contrast, prazosin-mediated cell cycle arrest could not be replicated in 
human endothelial vascular cells (Liao et al., 2011). In breast cancer cells, doxazosin 
caused an increase in G0/G1 phase cells paired with a dose-dependent decrease in the 
number of cells in S phase (Hui et al., 2008). Similar findings were also evidenced in 
human coronary (Kintscher et al., 2000a) and bladder (Austin et al., 2004) smooth 
muscle cells, implicating inactivation of the tumour suppressor protein retinoblastoma 
(Rb) (Kintscher et al., 2000a, Austin et al., 2004, Hui et al., 2008) and decreased Cyclin 
A expression (Austin et al., 2004). Further investigation is required to fully elucidate the 
dose and treatment duration effects of quinazoline-based α1-ADR antagonists on 
prostate cancer cell cycle. 
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Figure$4.4.$Regulation$of$cell$cycle$progression.$The$cell$cycle$consists$of$interphase$
(G1,$S,$and$G2$phases)$and$mitosis$(M$phase).$Each$step$in$the$cell$cycle$is$primarily$
regulated$by$CDK3cyclin$ interactions$ (Santella$et$al.,$2005).$ Image$provide$courtesy$
of$Abcam.$Image$copyright$©$2016$Abcam.$$
!
ANGIOGENESIS!
Angiogenesis, or development of blood vessels, is a hallmark of malignant tumours. 
Like normal, non-malignant tissues in the human body, tumours require sufficient blood 
supply to grow beyond a critical size (Carmeliet and Jain, 2000). Tumours are able to 
recruit blood vessels by release of pro-angiogenesis regulators such as vascular 
endothelial growth factor (VEGF) (Carmeliet and Jain, 2000). Briefly, free VEGF binds 
to its receptor (VEGFR) on the membrane of vascular endothelial cells which triggers a 
complex signaling cascade promoting vascular endothelial proliferation, survival, and 
development of blood vessels (Karamysheva, 2008). Angiogenesis is a common 
therapeutic target for many human cancers, including advanced stage prostate cancer 
(Shojaei, 2012).  Suppression of angiogenesis is commonly achieved through VEGF-
neutralizing or VEGFR inhibiting agents such as bevacizumab (Shojaei, 2012). Despite 
promising in vitro and in vivo pre-clinical trials (Melnyk et al., 1999), single agent anti-
angiogenic therapies have demonstrated unsatisfactory oncological and survival effects 
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in men with prostate cancer (Figg et al., 2001b, Reese et al., 2001). These findings 
prompted investigation of anti-angiogenetic agents in combination with docetaxel for 
men with advanced prostate cancer (Figg et al., 2001a, Ning et al., 2010), including 
those who had failed docetaxel therapy previously (Di Lorenzo et al., 2008). Phase II 
clinical trials of docetaxel plus anti-angiogenics improved progression free and overall 
survival (Figg et al., 2001a, Di Lorenzo et al., 2008, Ning et al., 2010). Unfortunately, a 
phase III clinical trial demonstrated no survival benefit with the addition of 
bevacizumab to docetaxel and was also associated with greater incidence of adverse 
events (Kelly et al., 2012). While these results may be discouraging, the use of anti-
angiogenic agents in combination with docetaxel remains a viable option for late stage 
prostate cancer and should be investigated further.  
 
Interestingly, the quinazoline-based drugs doxazosin and terazosin are known to impair 
tumour angiogenesis. Early findings demonstrated reduced tumour vascularity in 
prostate specimens of men exposed to terazosin for BPH or hypertension compared to 
men who received no treatment (Keledjian et al., 2001). Similar anti-angiogenic 
activities were also found in men with bladder cancer (Tahmatzopoulos et al., 2005).  In 
vitro and in vivo studies suggest that quinazoline-based antagonists suppress tumour 
angiogenesis by downregulating VEGF transcription and expression levels (Pan et al., 
2003). Similarly, doxazosin was found to inhibit VEGF-mediated human vascular 
endothelial cell invasion, migration and endothelial tube formation (Keledjian et al., 
2005). Together these findings suggest a two-fold effect, targeting tumour angiogenic 
signals and vascular endothelial response. Therefore, these drugs may prove effective as 
anti-cancer therapies.  
 !
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SUMMARY!
 
The underlying cell signaling mechanisms contributing to the anti-cancer effects of α1-
ADR antagonists are undoubtedly complex. Fully understanding the mechanism of 
action of the cytotoxic antagonist is important for exploitation of their anti-cancer 
potential to either prevent prostate cancer or delay disease progression.  Furthermore, 
the exploration of the molecular mechanisms may also provide insight to the observed 
enhanced anti-cancer potency of these antagonists in vivo or clinically at therapeutic 
concentrations, compared to the low cytotoxic potency observed in vitro.  
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4.2! ! AIMS!!
 
The overall aim of this study was to further elucidate the molecular mechanisms 
underlying the cytotoxic actions of doxazosin and prazosin in prostate cancer cells.  
 
The specific aims include: 
 
1.! To determine the change in expression or activation of tumour suppressor- or 
promotor-related proteins in response to doxazosin and prazosin exposure. 
2.! To determine changes in activation status of various receptor tyrosine kinases 
and related signalling nodes following treatment with doxazosin and prazosin. 
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4.3!! MATERIALS!AND!METHODS 
DRUGS$AND$REAGENTS$
Drugs and reagents used throughout this chapter are listed below in Table 4.2.  Stock 
solutions were made up either in sterile dH20 or DMSO and stored according to the 
manufacturer’s instructions. 
 
Table$ 4.2.$ Drugs$ and$ chemicals$ including$ details$ of$ stock$ solutions,$ storage$
conditions$
$
Drug / Chemical Stock solution Storage Supplier Cat. No. 
Bovine serum 
albumin 
N/A N/A Sigma-Adrich A7030  
Bradford’s 
Reagent 
N/A N/A Sigma-Adrich  B6916 
Lithocholic Acid 
100mM, 
DMSO 
30 days, 20ºC Sigma-Adrich  L6250 
Protease 
Inhibitor cocktail 
10X, solution 
in sterile dH20 
14 days, 4ºC Sigma-Adrich  P2714 
PMSF 
100 mM, 
DMSO 
Made fresh 
daily 
Sigma-Adrich  P7626 
 
ASSAYS$AND$KITS$
The following assays and kits were used thoughout this chapter (Table 4.3). All kits 
were stored as per the manufacture’s instructions and were used well within the expiry 
date.  
 
$ $
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Table$4.3.$Details$of$assays$and$kits$used$
 
Assay / Kit Source Cat. No. 
Human Cell Stress Array R&D Systems ARY018 
PathScan® RTK Signaling Antibody Array 
Kit (Chemiluminescent Readout) 
Cell Signaling 
Technologies 
7982 
Human Phospho-EphA2 DuoSet IC ELISA R&D Systems DYC4056 
$
TREATMENT$OF$CELLS$
Human LNCaP and PC-3 prostate cancer cells were seeded at sub-confluent densities 
(Table 4.4) and allowed to attach for 24 or 48 h, respectively.  Cells were treated with 
tamsulosin, prazosin, doxazosin (30 – 100 µM) or vehicle for 1 – 2 h, or overnight for 
24 h. As previously demonstrated in Chapter 3, doxazosin and prazosin concentration of 
30 µM was found to induce apoptosis and/ or autophagy in a cell-type dependent 
manner.  
 
$
$ $
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Table$ 4.4.$ Experimental$ treatment$ times$ and$ typical$ seeding$ conditions$ for$ PC33$
and$LNCaP$cell$lines.$$
 
GENERATION$OF$CELLULAR$LYSATE$
Following treatment, cells were immediately placed on ice and cells were dislodged by 
scraping in ice-cold PBS. Cells were collected by centrifugation at 1500 RPM for 5 
minutes at 4ºC. Assay-specific lysis buffer supplemented with 1X protease cocktail 
inhibitor and PMSF (1mM) was added to cells and incubated for 15 – 30 minutes, 
depending on assay-specific manufacture instructions. Unless specified, lysates were 
clarified by centrifugation at 14,000g for 10 minutes and stored at -80ºC until use. 
 
BRADFORD’S$ASSAY$
Bradford’s Assay was conducted as per the manufacturer’s instructions, with some 
modifications. Briefly, clarified lysates were diluted in distilled and deionized H20 by 
1:10 – 1:20 depending on expected protein concentration and to prevent incompatibility 
of the lysis buffer and Bradford’s reagent. BSA protein standards (0.0612 – 1 mg/ml) 
were made up in distilled / deionized H20, with 1:2 serial diluations.  Standards or 
samples (10 µL) of lysates were added to wells of a 96-well plate in triplicate. A zero 
standard and lysis buffer control was included in all experiments. Bradford’s reagent 
Experiment 
Treatment 
time 
Tissue 
Culture 
Vessel 
Seeding Density 
(cells/cm2) 
PC-3 LNCaP 
Human Cell Stress Array 24 h T-75 Flask 1.9x104 3.0x104 
Human RTK Array 24 h T-75 Flask 1.9x104 3.0x104 
Phospho-EphA2 ELISA 2 h T-75 Flask 3.7x104 N/A 
Lithocholic Acid 
Treatment 
1, 2 and 24 h 
96-well and 
24-well plate 
3.2x104 N/A 
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(200 µL) was added to wells containing standards or samples, and incubated for 5 
minutes at room temperature.  Absorbance was read at 595 nm using a Modulus 
Microplate plate reader (Promega). Blank absorbance values (dH20/lysis buffer) were 
subtracted from absorbance values of samples/standards.  Unknown sample protein 
content was interpolated from the linear standard curve equation (as seen in Figure 4.4) 
and adjusted for dilution factor.  
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Figure$ 4.4.$ An$ example$ of$ a$ linear$ regression$ of$ known$ BSA$ protein$ standards$
plotted$ against$ respective$ Bradford’s$ absorbance$ values$ (read$ at$ 595$ nm)$ from$
which$protein$concentration$of$generated$lysates$was$determined$by$interpolation.$
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HUMAN$CELL$STRESS$ARRAY$
Cells were treated with prazosin, doxazosin, tamsulosin (30 µM) or vehicle for 24 h. 
After treatment, cells were lysed as described previously (Generation of cellular lysate).  
 
The relative expression of cell stress related-proteins following 24 h doxazosin, 
prazosin or tamsulosin treatment was determined using a Human Cell Stress Array kit 
(R&D Systems, Minneapolis, USA) according to the manufacturer’s instructions. 
Briefly, following blocking, membranes were incubated with samples containing 350 
µg of protein overnight at 4°C on a platform rocker. Membranes were then washed and 
incubated with HRP-linked secondary antibody (1:2000) for 1 h at room temperature. 
Protein expression was visualised by chemiluminescence using a ChemiDoc SSD 
Camera (BioRad), and semi-quantified using ImageJ (Version 1.49 for Mac OS X) 
image analysis software.  
 
 
 
Figure$4.5.$Map$of$cell$stress3related$protein$targets$(R&D$Systems)$as$described$ in$
Table$4.5.$$
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Table$ 4.5.$ Evaluated$ cell$ stress3related$ proteins$ and$ alternate$ nomenclature$ using$
the$commercially$available$human$cell$stress$protein$array$(R&D$Systems).$
 
 * Target (Alt. Nomenclature) 
Phosphorylation 
Site 
1 ADAMTS1   
2 Bcl-2   
3 Carbonic Anahydrase IX (CA9)   
4 Cited-2   
5 COX-2   
6 Cytochrome C   
7 Dkk-4   
8 FABP-1 (L-FABP)   
9 HIF-1!   
10 HIF-2! (EPAS1)   
11 Phospho-HSP27 Ser78 / Ser82 
12 HSP60   
13 HSP70   
14 IDO (Indoleamine 2, 3-dioxygenase)   
15 Phospho-JNK Pan   
16 NFĸB1   
17 p21/CIP1 (CDNK1A)   
18 p27 (Kip1)   
19 Phospho-p38α Thr180 / Tyr182 
20 Phospho-p53 Ser46 
21 PON1   
22 PON2   
23 PON3   
24 Thioredoxin-1   
25 SIRT2 (Sirtuin 2)   
26 SOD2 (Mn-SOD)   
*Numbers correspond to location on array membrane as shown in Figure 4.5. 
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HUMAN$PHOSPHO3RECEPTOR$TYROSINE$KINASE$SIGNALING$ARRAY$
Cells were treated with 30 µM prazosin, doxazosin, tamsulosin (treatment control) or 
DMSO vehicle control (0.06%) for 24 h. After treatment, cells were lysed as described 
previously (Generation of cellular lysate).  
 
The relative expression of phosphorylated (activated) receptor tyrosine kinases 
following 24 h treatment with doxazosin, prazosin, or tamsulosin treatment was 
determined using a PathScan® RTK Signaling Antibody Array Kit (Cell Signaling 
Technologies) according to the manufacturer’s instructions. Following blocking of the 
membranes for 15 minutes, samples containing 80 µg of protein were loaded onto the 
membrane and incubated for 2 h at room temperature on an orbital shaker. The 
membrane was washed before and after addition of the detection antibody cocktail (1 h) 
and HRP-linked streptavidin (30 minutes). Phosphoprotein expression was visualized 
by chemiluminescence using a ChemiDoc SSD Camera (BioRad), and semi-quantified 
using ImageJ (Version 1.49 for Mac OS X) image analysis software.  
 
  
 
$
Figure$4.6.$Map$of$RTK$and$related$signaling$node$of$the$Human$RTK$signaling$array$
(Cell$Signaling$Technology)$listed$in$Table$4.6.$$
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Table$4.6.$Human$RTK$signaling$array$targets$
 
 #* 
Target Family Phosphorylation Site 
1 EGFR/ErbB1 EGFR pan-Tyr 
2 HER2/ErbB2 EGFR pan-Tyr 
3 HER3/ErbB3 EGFR pan-Tyr 
4 FGFR1 FGFR pan-Tyr 
5 FGFR3 FGFR pan-Tyr 
6 FGFR4 FGFR pan-Tyr 
7 InsR Insulin R pan-Tyr 
8 IGF-IR Insulin R pan-Tyr 
9 TrkA/NTRK1 NGFR pan-Tyr 
10 TrkB/NTRK2 NGFR pan-Tyr 
11 Met/HGFR HGFR pan-Tyr 
12 Ron/MST1R HGFR pan-Tyr 
13 Ret Ret pan-Tyr 
14 ALK LTK pan-Tyr 
15 PDGFR PDGFR pan-Tyr 
16 c-Kit/SCFR PDGFR pan-Tyr 
17 FLT3/Flk2 PDGFR pan-Tyr 
18 M-CSFR/CSF-1R PDGFR pan-Tyr 
19 EphA1 EphR pan-Tyr 
20 EphA2 EphR pan-Tyr 
21 EphA3 EphR pan-Tyr 
22 EphB1 EphR pan-Tyr 
23 EphB3 EphR pan-Tyr 
24 EphB4 EphR pan-Tyr 
25 Tyro3/Dtk Axl pan-Tyr 
26 Axl Axl pan-Tyr 
27 Tie2/TEK Tie pan-Tyr 
28 VEGFR2/KDR VEGFR pan-Tyr 
29 Akt/PKB/Rac Akt Thr308 
30 Akt/PKB/Rac Akt Ser473 
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 #* 
Target Family Phosphorylation Site 
31 ERK 1/2 (p44/42 MAPK) MAPK Thr202/Tyr204 
32 S6 Ribosomal Protein RSK Ser235/236 
33 C-Able Abl pan-Tyr 
34 IRS-1 IRS pan-Tyr 
35 Zap-70 Zap-70 pan-Tyr 
36 Src Src pan-Tyr 
37 Lck Src pan-Tyr 
38 Stat1 Stat Tyr701 
39 Stat3 Stat Tyr705 
*Numbers correspond to location on array membrane as shown in Figure 4.5. 
 
 
PHOSPHO3EPHA2$ELISA$
Human prostate cancer PC-3 cells were seeded at sub-confluent densities as detailed in 
Table 4.4.  Cells were treated with 100 µM doxazosin or prazosin for 1 – 2 h.  
Immediately following treatment, cells were lysed as previously described (generation 
of cellular lysate). Prior to use, protein content of each sample was determined using 
Bradford’s Assay.  
 
Phosphorylated (activated) EphA2 was determined using a human phospho-EphA2 
DuoSet IC ELISA kit (R&D Systems) according to the manufacture’s instructions, with 
some modifications. The wells of a high-binding 96-well strip plate (Corning, Sigma 
Cat. No. CLS3590) were coated with capture antibody (8 µg/mL) overnight at room 
temperature. Wells were washed (0.05% Tween® 20 in PBS) before and after blocking 
with buffer containing 1% BSA. Lysates (200 µg of protein) were added to wells and 
incubated for 2 h at room temperature. Wells were again washed before and after 
addition of streptavidin-HRP (1:250) for 20 minutes at room temperature, followed by 
addition of substrate solution for 30 minutes (1:1 mixture of H2O2 and 
tetramethylbenzidine, Cat. No. DY999, R&D Systems).  The colourimetric reaction was 
stopped by addition of the stop solution (2 N H2SO4, Cat. No. DY994, R&D Systems). 
Absorbance (450 nm) was read using a Modulus Multimode plate reader (Promega). 
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Samples were diluted in lysis buffer to ensure quantifiable phosphorylated EphA2 
absorbance values fell within the linear portions of the standard curve. The amount of 
phosphorylated EphA2 in samples was determined by interpolation from known 
standard curve as shown in Figure 4.7. Fresh phospho-EphA2 standards provided in the 
kit were used for each independent experiment to generate a matched standard curve. 
 
 
 
  
Figure$ 4.7.$ Example$ non3linear$ sigmoidal$ regression$ of$ known$ concentrations$ of$
phosphorylated$ EphA2$ plotted$ against$ absorbance$ (read$ at$ 490$ nm)$ from$ which$
sample$concentrations$were$interpolated$from$the$linear$portion$of$the$curve.$
 
$
INHIBITION$OF$EPHA2$ACTIVATION$
Human prostate cancer PC-3 cells were seeded at sub-confluent densities as detailed in 
Table 4.4.  Cells were pre-treated with lithocholic acid (10-100 µM) for 30 minutes, 
prior to co-treatment with doxazosin or prazosin (10-100 µM) for 1, 2, or 24 h. 
Lithocholic acid (LCA) is a bile acid that has previously been shown to inhibit EphA2 
receptor-ligand interactions and subsequent activation in PC-3 cells (Giorgio et al., 
2011). Single agent and vehicle treatment controls were included in all experiments. 
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Cell viability was determined using resazurin reduction as previously described 
(Chapter 2, General Methods). Images were taken using an EVOS® Cell Imaging 
System (Thermo-Fisher Scientific) 
 
STATISTICAL$ANALYSIS$
As mentioned previously, arrays were semi-quantified using ImageJ (Version 1.49 for 
Mac OS X) image analysis software. Array data were normalised to positive control 
spots for comparisons between membranes. Membrane positive controls consisted of 
anti-species antibodies that captured the detection antibodies. Unless indicated 
otherwise, all investigated conditions were assayed in duplicate over three or more 
independent experiments. Due to the preliminary nature of the array-based experiments, 
no expression or phosphorylation controls of evaluated targets were included. Where 
appropriate, results were expressed as mean ± standard error of the mean. Statistical 
significance was determined using a one- or two-way ANOVA with either Tukey’s or 
Dunnett’s post hoc test as appropriate. The statistical tests used are specified in the 
following Results section.  
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4.4! RESULTS!
 
HUMAN$CELL$STRESS3RELATED$PROTEINS$
To further the understanding of how prazosin and doxazosin induce cell death, 
expressional changes in twenty-six cell stress-related proteins following 24 h treatment 
with these drugs (30 µM) in AR-positive LNCaP and AR-negative PC-3 cells were 
investigated using a commercially available array, and were semi-quantified using 
ImageJ analysis software (Figure 4.8).  The experimental conditions correspond to 
concentration and treatment duration previously determined to induce apoptosis and/or 
autophagy in PC-3 and LNCaP cells. As detailed in Table 4.7, the stress-related 
proteins have been grouped together based on their documented activity as either 
tumours promoters or suppressors (Figures 4.9 & 4.10, respectively). 
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Figure$ 4.8.$ Representative$ images$ of$ cell$ stress$ arrays$ (n=3)$ following$ 24$ h$
treatment$with$either$ tamsulosin,$doxazosin,$prazosin$ (30$µM)$or$vehicle$ control.$
Refer$ to$ Methods$ section$ for$ map$ of$ protein$ targets.$ Pixel$ density$ (signal$
intensity)$ of$ each$ spot$ was$ determined$ using$ ImageJ$ analysis$ software$ and$
normalised$to$positive$control$for$standardization$between$membranes.$
$ $
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Table$ 4.7.$ Cell$ stress3related$ proteins$ investigated$ grouped$ into$ either$ promoters$
or$inhibitors$of$tumourigenesis.$$$
Tumour promotors 
Target 
Change)(P>0.05,)n=4)) Function / Activity 
BCL-2 ⎯ Anti-apoptotic (Yang et al., 2003) 
CA9 ⎯ pH homeostasis, tumour microenvironment acidosis (Benej et al., 2014) 
COX-2 ⎯ Inflammatory protein, pro-survival actions (Kirschenbaum et al., 2001) 
FABP-1 ⎯ Uptake of fatty acids (Inoue et al., 2014) 
HIF-1α ↓ Adaptive response to hypoxia (Masoud and Li, 2015) 
HIF-2α ⎯ Adaptive response to hypoxia (Masoud and Li, 2015) 
IDO ⎯ Immunomodulary (Kallberg et al., 2010) 
HSP27 ⎯ Chaperone protein; pro-survival signaling (Lianos et al., 2015) 
HSP60 ⎯ Mitochondrial chaperone; regulates permeability (Lianos et al., 2015) 
HSP70 ⎯ Chaperone protein (Lianos et al., 2015) 
NFκB ⎯ Transcription factor with pro-survival activity 
PON1 ⎯ Cellular antioxidant (Devarajan et al., 2014) 
PON2 ⎯ Cellular antioxidant (Devarajan et al., 2014) 
PON3 ⎯ Cellular antioxidant (Devarajan et al., 2014) 
SOD2 ⎯ Antioxidant (Hempel et al., 2011) 
Thioredoxin-1 ⎯ Redox signaling; antioxidant (Watanabe et al., 2010) 
Tumour suppressors 
Target 
Change)(P>0.05,)n=4) Function / Activity 
ADAMTS1 ↑↓ Anti-angiogenic  (Gustavsson et al., 2009) 
Cytochrome-C ⎯ Pro-apoptosis (Mohammad et al., 2015) 
Cited-2 ↓ Negative regulator of HIF-1 transcription (Koritzinsky et al., 2005) 
Dkk-4 ⎯ Inhibitor of cell invasion (Baehs et al., 2009) 
Phospho-JNK ⎯ Cell death signal transduction (Tournier, 2013) 
p21 ⎯ Inhibitor of cell cycle progression (Dutto et al., 2015)                                                                                                                                                                                                                                                                                                              
p27 ↑ Inhibitor of cell cycle progression (Lee and Kim, 2009) 
Phospho-p38α ↑ Apoptosis signal transduction (Cai et al., 2006) 
Phospho-p53 ⎯ Pro-apoptosis (Mishra et al., 2015) 
SIRT2 ⎯  Regulation of cell cycle (Inoue et al., 2007) 
TUMOUR!PROMOTERS!
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Hypoxia3inducible$factor$1$alpha$(HIF31α)$
In response to doxazosin or prazosin treatment, the expression of only one 
tumourigenesis-related protein, HIF1α, was found to be statistically different to control 
in LNCaP cells (Figure 4.9). Briefly, the hypoxia-sensing signaling molecule, HIF-1α, 
is stabilised in the absence of oxygen as an adaptive mechanism (Fraga et al., 2015) and 
is known to be overly expressed in cancers to enhance tumour growth, and in prostate 
cancer, promotes transition to castrate-resistant disease (Ranasinghe et al., 2013). The 
role of HIF-1α in tumourigenesis is discussed further in Chapter 5. Consistent with 
previous findings (Ranasinghe et al., 2013), the degree of HIF-1α expression was 
associated with metastatic potential, with the aggressive PC-3 cells possessing nearly 
10-times higher levels of HIF-1α, compared to the more docile LNCaP cells. However, 
only LNCaP HIF1α was altered by 24 h antagonist treatment, with doxazosin 
possessing the greatest suppressive effect.  Doxazosin (30 µM) treatment significantly 
reduced levels of HIF-1α (P<0.001) by more than 50% in LNCaP cells, but the effect 
was not significantly different from that of prazosin (P>0.05).  In contrast, prazosin did 
not have a statistically significant effect on HIF-1α compared to control.  As expected, 
the non-toxic tamsulosin (30 µM, 24 h) had no appreciable effect on the investigated 
tumour promoting proteins in either cell line at the concentration and time point 
investigated. While it was previously reported that doxazosin treatment suppressed 
NFκB levels in breast cancer cells (Hui et al., 2008), the present study suggests that 
neither doxazosin nor prazosin affect NFκB in prostate cancer cells following 24 hour 
treatment (Figure 4.9).  
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Figure' 4.9.' Changes' in' expression' or' phosphorylation' of' cell' stress8related' proteins' with' tumour' promotor' functions' following' 24' h'
treatment'with' prazosin,' doxazosin,' tamsulosin' (30' μM)' or' vehicle' control' in' LNCaP' (A)' and' PC83' (B)' cells.' Results'were' semiquantified'
using'ImageJ'image'analysis' software'and'were'normalised'to'positive'control.'Data'are'represented'as'the'mean'±'SEM'(n=3).'Statistical'
significance'was'determined'using'two8way'ANOVA'with'Tukey’s'post'hoc'test.'*P<0.05,'**P<0.01'and'**P<0.001'vs.'untreated'control.'
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TUMOUR&SUPPRESSORS&
Prazosin and doxazosin treatment was found to reduce the expressional or 
phosphorylation levels of ADAMTS1, cited-2, p27 and p38α, which occurred in a cell 
type- and drug-dependent manner (Figure 4.10). Refer to Table 4.7 for a summary of 
antagonist-induced changes in tumour suppressor proteins.  
!
A!disintegrin!and!metalloproteinase!with!thrombospondin!motifs!1!(ADAMTS1)!
The anti-angiogenic factor ADAMTS1 is a proteinase member of the notch signaling 
cascade and has previously been reported to be down regulated in human prostate 
cancers (Gustavsson et al., 2009). In line with its tumour-suppressive actions, basal 
levels of ADAMTS1 were approximately 8-times higher in the less metastatic LNCaP 
than the aggressive PC-3 cells (Figure 4.10 A & B).  In PC-3 cells, both doxazosin and 
prazosin were able to increase ADAMTS1 expression (P<0.001 and P=0.056, 
respectively) (Figure 4.10 B). However, doxazosin was found to have an insignificantly 
greater effect than prazosin, increasing ADAMTS1 expression by 144% ± 85.9 versus 
84% ± 59.2 (P=0.06), respectively. Doxazosin, but not prazosin, suppressed ADAMTS1 
in PC-3 cells, which was greater than that of the effect of tamsulosin (non-cytotoxic 
treatment control) (P=0.001). This indicates ADAMTS1 may participate in antagonist-
mediated PC-3 cytotoxicity. No significant changes were observed in LNCaP 
ADAMTS1 expression. However, doxazosin and prazosin appeared to have a slight 
inhibitory effect on ADAMTS1 (Figure 4.10 A). While statistically insignificant, 
doxazosin treatment had a greater inhibitory effect on ADAMTS1 compared to 
doxazosin or tamsulosin treatment, suppressing ADAMTS1 expression by 24% (± 13) 
in LNCaP cells. 
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Figure! 4.10.! Changes! in! expression! or! phosphorylation! of! cell! stressDrelated!
proteins!with!tumour!suppressor! functions! following!24!h!treatment!with!prazosin,!
doxazosin,! tamsulosin! (30! μM)! or! vehicle! control! in! LNCaP! (A)! and! PCD3! (B)! cells.!
Results! were! semiquantified! using! ImageJ! image! analysis! software! and! were!
normalised!to!signal!intensity!of!positive!control.!Data!are!represented!as!the!mean!
±! SEM! (n=3).! Statistical! significance! was! determined! using! twoDway! ANOVA! with!
Tukey’s!post!hoc!test.!*P<0.05,!**P<0.01!and!**P<0.001!vs.!untreated!control.!
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CitedD2!
Cited-2 (Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal 
domain 2) acts as a tumour suppressor via negative regulation of HIF-1α activity 
(Koritzinsky et al., 2005).  Basal expression of Cited-2 were similar in between AR-
negative PC-3 and AR-positive LNCaP cell lines.  Treatment with doxazosin, prazosin 
or tamsulosin decreased Cited-2 expression by less than 50% in both cell lines, however 
statistical significance was only present amongst prazosin and doxazosin treated LNCaP 
cells (P<0.001 and P<0.01, respectively) (Figure 4.10).  A similar, but not significant 
reduction of Cited-2 was observed in PC-3 cells in response to doxazosin and prazosin 
treatment (Figure 4.10 B). Tamsulosin treatment had a significantly greater effect on 
Cited-2 expression than doxazosin and prazosin in PC-3 cells, whereas the effect of 
tamsulosin was not significantly different than doxazosin and prazosin in LNCaP cells. 
While unexpected, the decrease in the tumour suppressor cited-2 expression is unlikely 
to contribute to antagonist cytotoxicity and will be further discussed later in this 
chapter.  
!
p27!
Basal levels of the cell cycle inhibitor p27 were similar between PC-3 and LNCaP cells 
(Figure 4.10), and were significantly altered following treatment with doxazosin and 
prazosin in LNCaP cells. Consistent with previous findings (Xu et al., 2003b, Kintscher 
et al., 2000b), p27 expression was enhanced by approximately 1.5-fold and >2.5-fold 
within LNCaP cells treated with prazosin and doxazosin, respectively, compared to 
untreated control (Figure 4.10 A). Doxazosin appeared to be more effective than 
prazosin at up-regulating p27 regulation, however the difference between doxazosin and 
prazosin were not significant (P=0.102). Importantly, both cytotoxic drugs displayed a 
greater effect on p27 than tamsulosin, raising the possibility of p27 involvement in 
doxazosin and/or prazosin toxicity. In contrast to LNCaP cells, there were no 
observable expressional changes in p27 in PC-3 cells (Figure 4.3 B).  
 
 !
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p38α!
The mitogen-activated protein kinase (MAPK) p38α is known to participate in either 
cell survival or death signaling, which occurs in a stimuli- and cell type-dependent 
fashion.  However, it is usually considered to have tumour suppressive effects by 
preventing malignant transformation (Igea and Nebreda, 2015). In PC-3 and LNCaP 
cells, activation of p38α was significantly enhanced in response to prazosin (P<0.01 and 
P<0.001, respectively), while doxazosin a caused a similar but insignificant 
enhancement of p38α phosphorylation in PC-3 and LNCaP cells (P=0.149 and P=0.575, 
respectively, vs. control) (Figure 4.10). This effect was greatest in PC-3 cells with 
prazosin enhancing p38α activity by 150%, in contrast to approximately 100%-increase 
amongst LNCaP cells.  Furthermore, the effect of the cytotoxic antagonists doxazosin 
and prazosin on p38α activation were nearly 1.5 and 2-times greater, respectively, than 
tamsulosin in both cell lines, strongly suggesting involvement of p38α in underlying 
cytotoxic mechanisms of these drugs. 
 
Similar to its lack of effect on levels of tumour-promoting proteins, tamsulosin (30 µM, 
24 h) was found to have no effect on any of the tumour suppressor-related proteins 
evaluated in all tested conditions (Figure 4.10).  In contrast to previous reports, no 
changes were observed in p21 (Partin et al., 2003), p53 (Shaw et al., 2004, Yang et al., 
2011a, Park et al., 2014b) or cytochrome c release (Liao et al., 2011) in response to 
doxazosin or prazosin in either LNCaP or PC-3 cells. In contrast to LNCaP cells which 
express wild-type p53, a lack of change of p53 phosphorylation in PC-3 cells is 
expected as these cells do not express functional p53 protein (van Bokhoven et al., 
2003). In PC-3 cells, the detection of phospho-p53 in likely to be an experimental 
artifact due to non-specific binding or limitations in the semi-quantification 
methodology. 
 
 
  
 129 
RECEPTOR!TYROSINE!KINASES!AND!RELATED!SIGNALING!NODES!
Next, whether prazosin or doxazosin (30 µM, 24 h) was able to alter the activation of 
receptor tyrosine kinases (RTKs) and related signaling proteins was investigated using a 
commercially available array (Figure 4.11).  Pixel density (also referred to as signal 
intensity) was semi-quantified using ImageJ analysis software.  The evaluated targets 
were grouped according to their role as a RTKs or a signaling node (Figures 4.12 & 
4.13). Changes in activation (phosphorylation) following treatment with the 
investigated α1-ADR antagonists are summarised in Table 4.2 on the following page.  
Phosphorylation levels of ALK, Axl, EphA1, EphB1, EphB3, FLT3/Flk2, Met, 
Ron/MST1R, Ret, PDGFR, TrkA/NTRK1, TrkB/NTRK and Tyro3/Dtk were 
undetectable in all tested conditions and therefore were excluded from analyses and 
figures. 
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Figure! 4.11.! Representative! images! of! RTK! arrays! following! 24! h! treatment! with!
either! tamsulosin,! doxazosin,! prazosin! (30! µM)! or! vehicle! control! (n=4).! Refer! to!
Methods! section! for!map!of!protein! targets.!Pixel!density! (signal! intensity)!of!each!
spot!was!determined!using!ImageJ!analysis!software.  
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Table!4.2.!Investigated!receptor!tyrosine!kinases!and!related!signaling!nodes!
RTK or 
Signaling 
Node 
Family 
Change* 
(P<0.05, 
n=3) 
Function Reference 
c-Abl Abl ⎯ Cell division, adhesion, differentiation, response to 
stress 
(Zhao et al., 
2014) 
Akt-Ser473 Akt ↑ Survival signaling (Lee et al., 
2015) Akt-Thr308 Akt ↑ Survival signaling 
Axl Axl X Stimulates cell proliferation, involved in epithelial-to-
mesenchymal transition 
(Paccez et al., 
2014) 
 
Tyro3/Dtk Axl X Cell survival and migration 
EGFR/ErbB1 EGFR ⎯ Survival signaling (Yarden, 2001) 
 
 
HER2/ErbB2 EGFR ⎯ Survival signaling 
HER3/ErbB3 EGFR ⎯ Survival signaling 
EphA1 EphR X Cell adhesion, proliferation, rounding and detachment 
(Lisle et al., 
2013) 
 
 
 
 
 
EphA2 EphR ⎯ Cell adhesion, proliferation, rounding and detachment 
EphA3 EphR ⎯ Cell adhesion, proliferation, rounding and detachment 
EphB1 EphR X Cell adhesion, proliferation, rounding and detachment 
EphB3 EphR X Cell adhesion, proliferation, rounding and detachment 
EphB4 EphR ⎯ Cell adhesion, proliferation, rounding and detachment 
FGFR1 FGFR ⎯ Cell proliferation, migration, differentiation (Touat et al., 2015) 
FGFR3 FGFR ⎯ Cell proliferation, migration, differentiation  
FGFR4 FGFR ⎯ Cell proliferation, migration, differentiation  
Met/HGFR HGFR X Cell proliferation, treatment resistance (Gelsomino et al., 2014) 
Ron/MST1R HGFR X Pro-metastatic activity (Yao et al., 2013) 
IGF-IR Insulin R ⎯ Glucose homeostasis (Wu and Yu, 2014) 
 InsR Insulin R ⎯ Glucose homeostasis 
IRS-1 IRS ⎯ Glucose homeostasis (Shaw, 2011) 
ALK LTK X Survival signaling (Ou and Shirai, 2016) 
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RTK or 
Signaling 
Node 
Family 
Change* 
(P<0.05, 
n=3) 
Function Reference 
ERK 1/2  MAPK ⎯ Cell adhesion, proliferation, rounding and detachment (Carey et al., 2007) 
TrkA/NTRK1 NGFR X Cell survival  
TrkB/NTRK2 NGFR X Cell survival, differentiation (Thiele et al., 2009) 
c-Kit/SCFR PDGFR ⎯ Pro-migration and invasion signals (Liang et al., 2013) 
FLT3/Flk2 PDGFR X Survival signaling (Kayser and Levis, 2014) 
M-CSFR PDGFR ⎯ Differentiation, invasion, angiogenesis, metastasis, 
treatment resistance 
(Chockalingam 
and Ghosh, 
2014) 
PDGFR PDGFR X Survival signaling (Ehnman and Ostman, 2014) 
Ret Ret X Cell proliferation (Plaza-Menacho et al., 2014) 
S6 Ribosomal 
Protein RSK ↓ 
Substrate of p70S6K, 
protein synthesis 
(Fenton and 
Gout, 2011) 
Lck Src ⎯ Cell proliferation, angiogenesis, invasion (Varkaris et al., 
2014) 
 Src Src ↑↓ Cell proliferation, angiogenesis, invasion 
Stat1 Stat ⎯ Anti-proliferative, pro-apoptotic (Thota et al., 2014) 
Stat3 Stat ⎯ Cell survival  and proliferation (Lavecchia et al., 2011) 
Tie2/TEK Tie ⎯ Pro-angiogenesis activity (Barton et al., 2014) 
VEGFR2/KDR VEGFR ⎯ Pro-angiogenesis activity (Park et al., 2014a) 
Zap-70 Zap-70 ⎯ Survival signaling (Wong and Abubakar, 2008) 
Changes in phosphorylation (activation) were indicated as increase (↑), decrease (↓), 
not changed (⎯) or undetectable (X). 
 
Statistically significant changes were observed in only three of the thirty-nine total 
RTKs and related signaling nodes evaluated in LNCaP and PC-3. These included: S6 
ribosomal protein, Src, and Akt, which were all signaling-related proteins and not RTKs 
(Figure 4.5). None of the investigated drugs had any significant effect on the 
investigated RTKs (Figure 4.12)  
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Figure! 4.12.! Change! in! phosphorylation! of! RTKDrelated! signaling! nodes! in! PCD3! (A)!
and!LNCaP!(B)!cells! following!treatment!with!tamsulosin,!prazosin!or!doxazosin! (30!
µM,! 24! h).! Data! are! represented! as! the!mean! ±! SEM! (n=4).! Statistical! significance!
was! determined! using! a! twoDway! ANOVA!with! Tukey’s! post! hoc! test.! *! P<0.05,! **!
P<0.01!and!***!P<0.001!vs.!untreated!control.!
Ak
t-S
er4
73
Ak
t-T
hr
30
8
c-A
bl
Er
k1
/2
IR
S-
1
Lc
k
S6
 R
p Sr
c
St
at1
St
at3
Za
p-7
0
0
1000
2000
3000
4000
5000
6000
8000
10000
Si
gn
al
 In
te
ns
ity
Control
Tamsulosin
Prazosin
Doxazosin
**
*
**
*
**
*
Ak
t-S
er4
73
Ak
t-T
hr
30
8
c-A
bl
Er
k1
/2
IR
S-
1
Lc
k
S6
 R
p Sr
c
St
at1
St
at3
Za
p-7
0
0
2000
4000
6000
Si
gn
al
 In
te
ns
ity
*
**
**
** **
**
PC-3
LNCaP
A
B
 134 
   
c-K
it
EG
FR
Ep
hA
2
Ep
hB
4
FG
FR
1
FG
FR
3
FG
FR
4
He
r3
IG
F-I
R
Ins
R
M-
CS
FR Tie
2
0
200
400
600
800
1000
Si
gn
al
 In
te
ns
ity
Control
Doxazosin
Prazosin
Tamsulosin
c-K
it
EG
FR
Ep
hA
1
Ep
hA
2
Ep
hA
3
Ep
hB
4
FG
FR
1
FG
FR
3
FG
FR
4
HE
R2 He
r3
IG
F-I
R
Ins
R
M-
CS
FR Tie
2
TR
KA
/N
TR
K1
VE
GF
R
0
200
400
600
800
1000
Si
gn
al
 In
te
ns
ity
A
B
PC-3
LNCaP
Figure'4.13.'Changes' in' phosphorylation'of'RTKs' in' PC;3' (A)'and'LNCaP' (B)' cells' following' treatment'with' tamsulosin,' prazosin'or'doxazosin'
(30'µM,'24'h).'Results'were'semi;quantified'using'ImageJ'image'analysis'software'and'were'normalised'to'signal'intensity'of'positive'control.'
Data' are' represented' as' the'mean' ±' SEM' (n=4).' Statistical' significance'was' determined' using' two;way' ANOVA'with' Tukey’s' post' hoc' test.'
*P<0.05,'**P<0.01'and'**P<0.001'vs.'untreated'control.'
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SIGNALING'NODES'
!
Akt!(Ser473!/!Thr308)!
Akt, also known as protein kinase B, is well documented to have two activation sites, 
serine 473 (Ser473) and threonine 308 (Thr308), and phosphorylation of both sites are 
required for full enzymatic activity (Alessi et al., 1997, Stephens et al., 1998, Chang et 
al., 2015). In basal conditions, Akt phosphorylation levels were similar between both 
cell lines. However, basal Akt appeared to exist partially phosphorylated at Ser473 site, 
with little phosphorylation at Thr308 (Figure 4.12). There were no significant changes 
in Akt activation in PC-3 cells following treatment with any of the antagonists (Figure 
4.12 A). However, prazosin and tamsulosin were found to partially enhance PC-3 Akt 
activity via Thr308 phosphorylation, whereas doxazosin possessed a modest inhibitory 
effect on Thr308 activation. In contrast, all drugs enhanced LNCaP Akt activation, by 
increasing phosphorylation of both Ser473 and Thr308 (Figure 4.12 B) in a drug-
dependent manner, with only doxazosin and prazosin exhibiting significance (P<0.001). 
While prazosin was able to increase phosphorylation of Ser473 by 100% and Thr308 by 
approximately 475% (P<0.001 and P=0.136 versus control, respectively), only 
doxazosin was able to significantly increase full activation of Akt (P<0.001 and 
P=0.025 for Ser473 and Thr308 versus control, respectively) (Figure 4.12 B). However, 
modulation of Akt activity by doxazosin or prazosin was not significantly different than 
the non-toxic tamsulosin, except for doxazosin on Thr308 in LNCaP cells (P=0.007) 
(Figure 4.12 B). 
 
S6!ribosomal!protein!
The most notable change was the doxazosin and prazosin-mediated suppression of S6 
ribosomal protein activation in both cell lines.  Briefly, S6 ribosomal protein belongs to 
the ribosomal s6 kinase (RSK) family and is activated primarily by p70-RSK. 
Activation of S6 ribosomal protein promotes protein synthesis and cell proliferation 
(Fenton and Gout, 2011). In basal conditions, both cell lines had relatively high levels 
of S6 ribosomal protein activity, which were approximately 1.5-times greater in PC-3 
cells than LNCaP. Exposure to prazosin and doxazosin significantly decreased ( > 50% 
of control) ribosomal S6 protein kinase in both cell lines compared to untreated control 
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(P<0.01 for both cell lines and antagonists) (Figure 4.5).  The drug which possessed the 
greatest effect was cell type-dependent, with prazosin possessing a larger effect in PC-3 
cells (P=0.041 vs. doxazosin) and doxazosin amongst LNCaP cells (P=0.075 vs. 
prazosin (Figure 4.12 A & B, respectively). Tamsulosin had a minimal effect on S6 
ribosomal protein activity (< 25% in both cell lines, and the suppressive effect of 
prazosin and doxazosin were found to be significantly greater compared to the non-
toxic tamsulosin (P<0.001 between tamsulosin and prazosin or doxazosin for both cell 
lines), indicating potential involvement of the p70S6K/ S6 ribosomal protein signaling 
cascade in antagonist-induced cytotoxicity. 
 
Src!
Cellular Src kinase (c-Src, and referred to as Src), is a non-receptor tyrosine kinase 
which possesses a plethora of tumourigenic actions such as cell survival, proliferation, 
invasion and angiogenesis (Varkaris et al., 2014). The phosphorylation status of Src was 
nearly twice as great in the metastatic PC-3 cells, compared the more docile LNCaP 
cells (Figure 4.12). Modest, yet significant changes were observed in the 
phosphorylation status of the proto-oncogene Src in both cell lines, which occurred in a 
drug-dependent manner.  Consistent with the cytotoxic actions, both prazosin and 
doxazosin treatment slightly suppressed Src phosphorylation in PC-3 cells (< 10%, 
P>0.05 for both drugs), Figure 4.12 A).  In contrast, both doxazosin and prazosin 
increased Src phosphorylation in LNCaP cells, but only doxazosin had a significant pro-
activation effect (P=0.007) (Figure 4.12 B). Interestingly, tamsulosin had no effect on 
the phosphorylation status of other RTK and related signaling kinases, except for Src 
where treatment with the non-toxic agent significantly increased Src activation by 
nearly 20% in PC-3 cells (P<0.002). 
 
In contrast to previous literature, no significant changes were observed in vascular 
endothelial growth factor receptor 2 (VEGFR2) activity (Park et al., 2014a) or EphA2 
(or related Eph receptors) (Petty et al., 2012) after 24 h treatment. Conversely, 
epidermal growth factor receptor (EGFR) and the downstream signaling effector 
ERK1/2 appear to be insignificantly enhanced in response to doxazosin and prazosin, 
which opposes previous reports of the inhibitory effects of antagonist treatment on these 
targets (Hui et al., 2008).   
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INVOLVEMENT!OF!EPHA2!IN!ANTAGONISTIINDUCED!CYTOTOXICITY!
In the present study, 24 h treatment with doxazosin or prazosin did not alter 
phosphorylation status of EphA2 (Figure 4.13). However, a study by Petty and 
colleagues (2012) demonstrated transient EphA2 phosphorylation (activation)-
dependent cytotoxicity of prostate cancer cells in response to acute 60-minute doxazosin 
treatment. While the authors did not report doxazosin-mediated EphA2 activation 
timecourse in PC-3 cells, significant EphA2 activation was observed within five 
minutes and peaked after 30 minutes of doxazosin exposure in human breast cancer 
MDA-231-A cells. These findings prompted further investigation of EphA2 
involvement in quinazoline-based cytotoxicity; particularly whether acute prazosin 
treatment is able to also enhance activation of EphA2 receptors.  
 
To investigate whether doxazosin, prazosin or tamsulosin are able to alter the 
phosphorylation status of EphA2, PC-3 cells were treated with these drugs for 1 – 2 h. 
Subsequent EphA2 activation was determined by ELISA method using a commercially 
available kit. Only PC-3 cells were investigated for EphA2 activity, as they have 
previously been shown to express high levels of EphA2, whereas LNCaP cells 
reportedly do not (Walker-Daniels et al., 1999).  Consistent with findings of Petty et al. 
(2012), doxazosin was found to induce significant transient phosphorylation of EphA2 
at 1 h, which was completely abolished at 2 h (Figure 4.14). In contrast, prazosin 
treatment resulted in a slight but not significant increase in EphA2 phosphorylation, 
whereas EphA2 activity was undetectable in tamsulosin treated PC-3 cells (data not 
shown).  
 
Stimulation of EphA2 receptors are known to trigger cell rounding and detachment that 
was previously demonstrated in response to doxazosin treatment (Giorgio et al., 2011, 
Petty et al., 2012). Consistent with prior and present findings, doxazosin induced cell 
rounding affected more than 50% of cells at 1 h, and nearly all cells displayed a rounded 
morphology at 2 h, presumably via EphA2 activation (Figure 4.16). Unlike doxazosin, 
prazosin was unable to stimulate cell rounding at the time points investigated. 
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!
Figure!4.14.!!Change!in!phosphorylation!(activation)!of!EphA2!in!PCI3!cells!following!
1! –! 2! h! treatment! with! prazosin,! doxazosin! (100! µM)! or! vehicle! control.! EphA2!
phosphorylation! status! was! determined! using! a! PhosphoIEphA2! ELISA! kit! (R&D!
Systems).!PhosphoIEphA2!levels!were!normalised!to!loaded!protein,!and!results!are!
expressed!as!mean!±!SEM! (n=3).! Statistical! significance!was!determined!using! twoI
way! ANOVA!with! Tukey’s! post! hoc! test.! ***! P<0.001! vs,! control;! and! ###! P<0.001!
vs.!1!h!doxazosin!treatment.!
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Figure!4.16.!Time!lapse!of!PCI3!cell!rounding!following!1I!2!h!exposure!to!doxazosin!
and! prazosin! (100! µM).! All! images! are! representative! of! three! independent!
experiments!and!were!captured!using!a!Evos®!Cell! Imaging!System!(ThermoIFischer!
Scientific)!at!100X!magnification.!
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Next, whether inhibition of transient EphA2 activation may protect cells from 
doxazosin or prazosin-induced cytotoxicity was investigated. EphA2 phosphorylation 
was inhibited pharmacologically using lithocholic acid.  Lithocholic acid (LCA) was 
previously identified to hinder EphA2 activation in prostate cancer cells (IC50 value of 
48 µM) with no effect on cell survival (Giorgio et al., 2011).  Consistent with previous 
findings (Giorgio et al., 2011), at concentrations ≤ 100 µM, LCA had no cytotoxic 
effect on PC-3 survival following 24 h treatment (Figure 4.17 A). In contrast, the 
highest dose of LCA investigated (300 µM), significantly reduced cell survival by 
26.4% (P<0.01), and thus, was subsequently excluded from further testing.  In these 
experimental conditions, doxazosin and prazosin suppressed cell viability by 18 (±5.5) 
and 34 (±5.7)%, respectively (P<0.05-0.01) (Figure 4.17 B). The combination of 
antagonist and LCA was only able to partially protect PC-3 cells from doxazosin-
induced cytotoxicity (Figure 4.17 C) and cell rounding (Figure 4.18) after 24 h 
treatment.  In contrast, LCA (10-100 µM) had no appreciable effect on cell survival 
(Figure 4.17 D) or cell rounding when combined with prazosin (data not shown).  
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!
Figure! ! 4.17.! Human! prostate! cancer! PCI3! cells! were! treated! for! 24! h! with! singleI
agent! lithocholic! acid! (LCA,! 0I300! µM)! (A),! doxazosin,! prazosin! (30! µM)! (B),! or!
combination! treatment! with! LCA! (0I100! µM)! and! either! doxazosin! (C)! or! prazosin!
(D)! (30! µM! for! both).! ! A! resazurin! reduction! assay! was! used! as! an! index! of! cell!
survival.! Results! are! expressed! as! a! percentage! (mean! ±! SEM,! n≥3)! of! untreated!
control! (A,B)! or! of! doxazosin! or! prazosin! treated! control! (C! and! D,! respectively).!
Statistical! significance!was! determined! using! oneIway! ANOVA!with! Dunnett’s! post!
hoc!test.!**!P<0.01!vs.!untreated!control.!
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Figure! 4.18.! Protection! from!doxazosinIinduced! (30!μM)! cell! rounding!of! PCI3! cells!
by!LCA!(100!μM)!following!24!h!coItreatment.!Live!cell! images!were!captured!using!
an!Evos®!Cell!Imaging!System!at!100X!magnification.!!
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4.5$ DISCUSSION 
 
In Chapter 3, which investigated the relative cytotoxic potencies and cell death 
mechanisms, it was demonstrated that prazosin and doxazosin possess apoptotic 
potential in prostate cancer cell lines. In addition, these drugs are able to increase 
autophagy in PC-3 and LnCAP cells with paradoxical outcomes; contributing to 
antagonist-induced cytotoxicity or survival mechanisms, respectively. However, the cell 
signaling pathways underlying antagonist-induced apoptosis or autophagy remained to 
be fully elucidated.  The overall aim of this study was to investigate the molecular 
mechanisms underlying doxazosin and prazosin cytotoxicity. The findings of the 
present study provided evidence for the involvement of mTOR signaling, p27 cell cycle 
inhibition, and p38α MAPK activity in mediating antagonist-induced cytotoxicity. 
Additionally, EphA2 activity was further confirmed in the present study as an 
underlying mechanism of doxazosin-induced toxicity, but did not appear to contribute 
to prazosin toxicity. 
 
MTOR!SIGNALING 
The mTOR family comprises the well-characterised complex 1 (mTORC1) and the 
lesser known complex 2 (mTORC2). While mTORC2 is undoubtedly important, the 
focus of this text will be to examine the involvement of mTORC1 in doxazosin- and 
prazosin-induced cell death. As previously reviewed in Chapter 3, autophagy is 
negatively regulated by mTORC1. In addition to the classical autophagy inhibition 
cascade via Ulk complex, mTORC1 acts on 4E-BP1, serum/glucocorticoid regulated 
protein kinase 1 (SGK1) and p70S6 kinase (p70S6K) (Hong et al., 2008, Laplante and 
Sabatini, 2009, Mori et al., 2014). Of particular interest, p70S6 kinase promotes the 
activation of a plethora of regulators of cell survival, including S6 ribosomal protein 
(rpS6) (Laplante and Sabatini, 2009). Doxazosin- and prazosin-induced autophagic 
response of both PC-3 and LNCaP cell lines (Chapter 3) is further confirmed by the 
significant inhibition of S6 ribosomal (rbS6) protein, a downstream target of mTORC1. 
Therefore, it can be inferred that these drugs suppress the activity of mTORC1, thereby 
resulting in downregulation of the mTORC1 substrates including p70S6K, and in turn, 
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inhibit rbS6 activity. In support of the present findings, the down-regulation of 
mTORC1/p70S6K signaling axis was previously shown in rodent cardiomyocytes 
treated with prazosin (Yang et al., 2011a). However, the precise molecular mechanism 
of mTORC1 inhibition by these drugs, and thus induction of autophagy, remains 
unclear.   
 
Activation of the signaling kinase, Akt, inhibits autophagy via indirect activation of 
mTORC1. Likewise, the induction of autophagy is classically associated with 
suppression of Akt phosphorylation (Laplante and Sabatini, 2009). The present findings 
demonstrated otherwise, showing a paralleled increase in Akt phosphorylation (current 
chapter) and increase in autophagy activity (Chapter 3). While the present findings 
appear to be inconsistent, it suggests that prazosin/doxazosin-mediated mTORC1 
inhibition, and subsequently induction of autophagy, occurs downstream or 
independently of Akt-mediated regulation of mTORC1. Prior literature is consistent 
with these findings, demonstrating that the induction of autophagy was associated with 
either inhibition or activation of Akt which was cell type specific (Sarbassov et al., 
2006) In this study, Akt phosphorylation remained unchanged in PC-3 cells, suggesting 
prazosin- and doxazosin-induced autophagy also occurs independently of Akt in PC-3 
cells.  
 
Several Akt-dependent mechanisms are known to regulate mTOR activity, including the 
Ras/MEK/ERK signaling cascade, phospholipase D/phosphatidic acid signaling, and of 
particular interest, the energy-sensing AMPK. A previous study demonstrating 
prazosin-induced autophagic cytotoxicity in rodent cardiac cells, reported increased 
activation of AMPK, which correlated with decreased mTORC1 and p70S6K activation 
(Yang et al., 2011a). AMPK is regulated by two primary mechanisms, LKB1 or 
calcium/calmodulin-dependent protein kinase beta (CaMKKβ) (Mihaylova and Shaw, 
2011, Gormand et al., 2011). In response to energy depletion or genotoxic stress, LKB1 
acts on AMPK to modulate the activity of many targets, including the inhibition of 
mTORC1, and in turn, induction of autophagy. In contrast, AMPK is also responsive to 
increases in intracellular calcium through actions of CaMKKβ (Kishi et al., 2000), and 
has the potential to promote AMPK-dependent inhibition of mTORC1. However, direct 
evidence of this has yet to be reported in the literature. The LKB1/AMPK pathway is 
known to crosstalk with the mTORC1 signaling pathway at several points (Mihaylova 
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and Shaw, 2011), including the activation of tuberous sclerosis protein (TSC)1/2 and 
phosphorylation of raptor (Gwinn et al., 2008, Lee et al., 2010a) contributing to 
mTORC1 inhibition and induction of autophagy. Taken together with the previous 
(Chapter 3) and present findings, it is proposed that doxazosin and prazosin-induced 
autophagy occurs via the AMPK/mTORC1 signaling axis in PC-3 and LNCaP prostate 
cancer cells. However, precisely how these drugs induce AMPK activation is unclear. 
Early reports suggest these drugs do not affect intracellular ATP levels (Gordon et al., 
1991), which suggest AMPK becomes activated by mechanisms other than energy 
depletion. As mentioned previously, genotoxic stress and DNA damage also promote 
activation of AMPK signaling activity. Interestingly, prazosin (≥10 µM) was previously 
associated with increased DNA double strand breaks following acute 1 h exposure (Lin 
et al., 2007). Likewise, doxazosin was found to directly interact with DNA to down-
regulate genes associated with DNA repair after 24 h drug exposure (Arencibia et al., 
2005). Taken together, this suggests that AMPK may be activated as a consequence of 
doxazosin/prazosin-mediated DNA interactions and damage stress. 
 
While autophagy appears to be an important mediator of antagonist-induced PC-3 
cytotoxicity, it is clear from findings in Chapter 3 that autophagy does not contribute to 
toxicity in LNCaP cells, and instead is primarily regulated by apoptotic mechanisms. 
Furthermore, it is unknown whether autophagy alone (in PC-3 cells), or the autophagy-
independent effects of mTORC1 inhibition, such as suppression of p70S6K, underlie 
doxazosin and prazosin toxicity. In previous, but separate, studies it was found that 
prazosin treatment resulted in reduction of mTORC1 and p70S6K activity (Yang et al., 
2011a), and direct or indirect inhibition of p70S6K had anti-proliferative effects in 
cancer cell lines (Doscas et al., 2014, Kyou Kwon et al., 2014). Overall, the cytotoxic 
effects of p70S6K inhibition are likely mediated by the loss of cell growth and survival 
signaling, including but not limited to loss of p70S6K-mediated cell motility and 
chemotaxis, suppression of EEF2 and rbS6 mediated translation and restoration of BAD 
(pro-apoptotic protein) activity (Ip et al., 2011, Zhang et al., 2013). In addition, p70S6K 
and 4EBP1 jointly promote the protein synthesis of the tumourigenesis-related protein, 
HIF-1α, in an oxygen-independent manner.  Although supported by previous findings 
(Keledjian and Kyprianou, 2003, Park et al., 2014a), the modest reduction in  HIF-1α 
levels in the present study is unlikely to underlie doxazosin/prazosin-induced toxicity 
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by itself, but provides further support for the doxazosin/prazosin-mediated suppression 
of mTORC1 signaling cascade.  
 
P27!SIGNALING!PATHWAY!
In general, p27 activity is regulated by site-specific phosphorylation resulting in 
degradation, inhibition of nuclear translocation, or inhibition of cell cycle progression 
(Lee and Kim, 2009). Appropriately phosphorylated-p27 inhibits the cell cycle, through 
inhibition of cyclin (D, E):CDK(2, 4, 5) complex preventing hyper-phosphorylation and 
inactivation of the cell cycle inhibitor, retinoblastoma protein (Rb). In the presence of 
doxazosin and prazosin, levels of the cell cycle inhibitor, p27 (KIP1) were found to be 
enhanced in LNCaP cells.  These findings are supported by previous literature showing 
increases in p27(KIP1) expression and corresponding G1/S cell cycle arrest following 
doxazosin and terazosin treatment (Kintscher et al., 2000b, Xu et al., 2003b). Likewise, 
these drugs have also been shown to prevent inhibition of the p27-regulated cell cycle 
inhibitor Rb in various cell lines (Kintscher et al., 2000b, Austin et al., 2004).  
 
In further support, p27 is also known to be negatively regulated indirectly by mTORC1. 
The downstream substrate of mTORC1, SGK1, has been previously reported to 
promote instability and suppress nuclear translocation of p27 (Hong et al., 2008), 
permitting progression of the cell cycle. In the absence of mTORC1 signaling, as in the 
proposed model of doxazosin/prazosin-induced cytotoxicity, loss of SGK1 activity 
would allow p27 to persist, leading to cell cycle arrest. Interestingly, AMPK signaling 
may also impact levels of p27, however with potentially unconventional outcomes. The 
actions of AMPK have been reported to follow the classical pathway by increasing p27, 
decreasing Rb and in turn induce cell cycle arrest and toxicity (Ben Sahra et al., 2008).  
In contrast, AMPK reportedly promotes cytosolic accumulation of p27, via 
phosphorylation-site-dependent (Thr198) inhibition of nuclear translocation, promoting 
cell cycle progression, inhibiting apoptosis and parallel induction of autophagy (Short et 
al., 2008, Liang et al., 2007). However, it is unknown whether p27 is able to directly 
activate autophagy mechanisms via interaction with autophagy-related proteins or if it 
occurs passively through the AMPK/mTORC1/Ulk1 autophagy signaling axis.  
!
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P38!MAPK!SIGNALING!PATHWAY 
The p38 MAPK protein family consists of four isoforms including the well documented 
alpha and beta, and the lesser known gamma and sigma. A plethora of stimuli result in 
p38 MAPK activation, including growth factors, cellular stress, pro-inflammatory 
cytokines, oxidative stress and DNA damage (Igea and Nebreda, 2015). In neoplasms, 
p38α is specifically known to act as either a tumour-promoter or –suppressor, which is 
likely to be dependent on stimuli and cell type (Igea and Nebreda, 2015). In the context 
of apoptosis, p38 MAPK alters activity of anti-apoptotic and pro-apoptotic Bcl-2 family 
to tip the scale towards cell death, as well as congruently promoting the downregulation 
of survival pathways (Cai et al., 2006).  Specifically, p38α activity was found to 
promote prostate cancer cell apoptosis to various cytotoxic agents (Gao et al., 2014, 
Honisch et al., 2014) by facilitating the caspase activation cascade (Al-Azayzih et al., 
2012). Likewise, doxazosin and prazosin were able to increase p38α phosphorylation to 
some degree in both prostate cancer cell lines. However, only prazosin treatment 
yielded a statistically significant increase p38! in both cell lines. Taken together with 
previous reports of quinazoline induced p38 MAPK-dependent cytotoxicity (Yang et 
al., 2009), it can be inferred that phosphorylation and activation of p38α isoform 
underlies prazosin, and potentially, doxazosin-induced apoptosis. One proposed 
mechanism underlying increased activation of p38!  is by doxazosin/prazosin-induced 
DNA damage. It is known that these drugs either indirectly or directly result in DNA 
damage (Arencibia et al., 2005, Lin et al., 2007) and interestingly, the DNA damage 
response element Gadd45a and activator of p38! (Jehle et al., 2012, Salerno et al., 
2012), was previously shown to be deregulated following treatment with doxazosin in 
LNCaP cells (Arencibia et al., 2005).  
 
 
EPHA2IMEDIATED!ANOIKIS!
Mechanisms regulating anoikis, or detachment-induced apoptotic cell death (see current 
chapter Introduction for review), are commonly suppressed in many cancers, including 
prostate cancer, leading to increased metastatic potential. Doxazosin, but not prazosin, 
has been reported to restore anoikis-mediated cell death mechanisms, and has been 
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evidenced primarily through the suppression of focal adhesion kinase (FAK) (Walden et 
al., 2004, Sakamoto and Kyprianou, 2010, Sakamoto et al., 2011).  In a study conducted 
by Petty and colleagues (2012), it was previously demonstrated that doxazosin was a 
small molecule agonist for the EphA2 receptor, which was found to be a significant 
mediator of prazosin-induced anoikis-mediated apoptotic cell death. Consistent with 
these previous findings, short doxazosin treatment resulted in a significant increase in 
EphA2 activity and subsequent cell rounding and detachment, which are known 
hallmarks of EphA2-mediated anoikis. Likewise, inhibition of EphA2 activity partially 
protected cells from doxaozin-induced cytotoxicity. Despite a similar quinazoline-based 
structure, the current findings suggest that prazosin toxicity occurs independently of 
EphA2. The difference between these drugs is likely attributed to minor, yet important, 
conformational differences between doxazosin and prazosin chemical structure. 
Surprisingly, interactions between the EphA2 receptor and doxazosin are likely to 
involve the methoxy groups as well as the benzodioxin and carbonyl groups (Petty et 
al., 2012) (Figure 4.19), and not the quinazoline structure as originally proposed 
(Benning and Kyprianou, 2002). In addition to prostate cancer, doxazosin-induced 
EphA2-mediated cytotoxicity and apoptosis, is also known to occur in cardiomyocytes 
(Jehle et al., 2012).  
 
!
Figure! 4.19.! Chemical! structure! of! doxazosin! highlighting! methoxy! (orange),!
carbonyl!(purple)!and!benzodioxin!groups!(blue).!
!
 !
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CITEDI2,!ADAMTS1!AND!SRC!
In addition to doxazosin and/or prazosin responsive targets previously discussed, Cited-
2, ADAMTS1 and Src were found to be altered following treatment with these drugs. 
While this is the first report of significant expressional changes in these target proteins 
in response to cytotoxic drugs investigated, the biological implications of these findings 
remain to be experimentally elucidated.  
 
CITED-2'
Cited-2 (Cbp/p300-interacting transactivator 2) acts to modify gene transcription via 
interactions with transcription factors as opposed to binding DNA directly. Activation 
of Cited-2 is regulated by various cytokines and growth factors such as interleukins, 
interferon-gamma, TGF-α/EGFR, PDGF and insulin, while TGF-beta inhibits Cited-2 
activity (Chou et al., 2006, Chou and Yang, 2006, Chou et al., 2012), As its name 
suggests, activated Cited-2 binds p300/CBP, as well as several other transcription 
factors including Smad7, TFAP2, Lhx2 and HIF-1α to modify their transcriptional 
activity (Chou et al., 2012, Chou and Yang, 2006).  The present study found 
doxazosin/prazosin suppressed Cited-2 expression in AR-positive LNCaP but not 
significantly in AR-negative PC-3 cells. In support of these findings, the negative 
regulator of Cited-2, TGF-", was previously reported to be involved in doxazosin-
mediated toxicity (Partin et al., 2003), providing a potential mechanism contributing to 
the observed inhibition of Cited-2 expression by doxazosin and prazosin. TGF-β is 
known to primarily function as a tumour suppressor via induction of apoptotic 
mechanisms; however pro-oncogenic roles of TGF-β have also been reported (Horbelt 
et al., 2012). While cytotoxic doxazosin/prazosin-induced TGF-β/Smad signaling and 
consequent suppression of Cited-2 is likely to promote apoptosis, it cannot be 
ascertained for certain from the current literature as TGF-β-dependence has not yet been 
established. It is acknowledged that tamsulosin had the most consistent suppression of 
Cited-2 expression. At this time,  
 
 '
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ADAMTS1 
ADAMTS1 is a member of the ADAMTS family of proteases, which is known to have 
opposing roles in regulating tumour vascularisation; acting to promote or inhibit 
angiogenesis mechanisms (Sun et al., 2015b).  In general, whether ADAMTS1 has pro- 
or anti-angiogenic effects is understood to be influenced by the tumour 
microenvironment, proteolytic cleavage of thrombospondin (TSP)1 and/or TSP2, and 
interactions with VEGFR. Briefly, the presence or absence of heparin in the tumour 
microenvironment dictates whether ADAMTS1 exists as the full-length or truncated 
form, respectively, mediated by blocking ADAMTS1 cleavage site. Full length 
ADAMTS1 is reported to have pro-angiogenic actions, which has been suggested to 
involve heparin-dependent ADAMTS1-VEGFR interaction. Additionally, ADAMTS1-
VEGFR may also have anti-proliferative effects, by inhibiting ERK1/2 survival 
signaling. In contrast, shortened ADAMTS1 has anti-angiogenic effects, particularly 
through interactions with the well-known angiogenesis inhibitors TSP 1/2. While these 
molecules are able to regulated angiogenesis, truncated ADAMTS1 binds and cleaves 
TSPs, resulting in the release of the highly potent and soluble anti-angiogenic molecule, 
3TSR from the extracellular matrix (Bak and Weerapana, 2015).  
 
Both human prostate tissues and cancer cell lines have been shown to differentially 
express members of the ADAMTS family. In particular, levels of ADAMTS1 are 
known to be inversely correlated with tumourigenic phenotype in prostate cancer.  This 
relationship has been demonstrated in both clinical and laboratory settings.  
Specifically, it has been reported that levels of ADAMTS1 are decreased within prostate 
tumours compared to non-malignant epithelial cells (Gustavsson et al., 2009). 
Furthermore, the same study identified lower expression of ADAMTS1 in castrate-
resistant disease compared to hormone-sensitive tumours.  These clinical findings are 
supported by previous studies demonstrating that established in vivo  prostate cancer 
cell tumours contain lower expressional levels of ADAMTS compared to primary BPH 
cells isolated from resected human prostates and in vitro prostate cancer cell lines 
(LNCaP, and PC-3) (Cross et al., 2005). While the precise contribution of ADAMTS to 
tumourigenesis has yet to be clearly defined, one study elucidated that ADAMTS 
regulates the morphology of tumour vasculature leading to reduced tumour growth and 
establishment (Gustavsson et al., 2010).  Together, these prior findings are consistent 
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with the present study that identified lower basal levels of ADAMTS1 in the highly 
metastatic and castrate-resistant (AR-negative) PC-3 cell compared to the modestly 
tumorigenic AR-positive LNCaP cells. Interestingly, doxazosin and prazosin were 
found to have differential and cell type-dependent effects on ADAMTS1 expression. 
ADAMTS1 expression was enhanced in PC-3 cells, which is line with previous reports 
of decreased metastatic and angiogenic potential of prostate cancer cells treated with 
these drugs (Chiang et al., 2005, Park et al., 2014a). In contrast, conflicting findings 
were found in LNCaP cells where these cytotoxic drugs decreased expression of 
ADAMTS1. While the relationship is unclear, one study reported that suppression of 
ADAMTS1 in these cells was associated with smaller blood vessel and decreased 
tumour establishment (Gustavsson et al., 2010). In further support of these apparently 
conflicting findings, LNCaP prostate cancer cells challenged with TGF-β displayed 
decreased expression of ADAMTS1; whereas TGF-β had no effect on PC-3 ADAMTS1 
levels (Cross et al., 2005). The authors proposed that TGF-β enhanced expression of the 
negative regulator of ADAMTS1, tissue inhibitor of metalloproteinase (TIMP) 3. 
TIMP3 has recently been reported to have important implications in tumourigenesis in 
an animal model, where loss of TIMP3 resulted in increased tumour growth and micro-
vessel density (Adissu et al., 2015).  As previously mentioned, doxazosin was found to 
increase TGF-β expression in prostate cancer cell lines (Partin et al., 2003), and 
although currently unknown, it is assumed prazosin may possess a similar effect on 
TGF-β. It can be inferred that in the present study doxazosin/prazosin-mediated TGF-β 
expression indirectly downregulates ADAMTS1 by upregulating TIMP3 in LNCaP 
cells. While these drugs appear to have a tumour-promoting effect on ADAMTS1 in 
LNCaP cells, the plethora of apoptotic mechanisms induced by doxazosin/prazosin is 
likely to override this effect. However, the downregulation of ADAMTS1 in these cells 
may also be associated with decreased tumour establishment (Gustavsson et al., 2010) 
and remains to be fully elucidated.  
 
In summary, the combination of current findings in PC-3 cells and previous literature 
suggest that doxazosin/prazosin increase ADAMTS1 by an unknown mechanism, and 
subsequently contribute to reduced tumourigenesis through ADAMTS1-mediated anti-
angiogenesis effects. Conversely, these drugs reduced ADAMTS expression in LNCaP 
cells, which is proposed to occur via TNGβ-mediated upregulation TIMP3.   
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SRC'
Src is a non-receptor tyrosine kinase that belongs to the Src family of kinases (SFK) 
along with Fyn, Lyn, Yes, Blk, Lck, Hck, Fgr and Yrk (Varkaris et al., 2014). The 
transition to a cancerous phenotype is often associated with increased activity of the 
SFKs, as they often sit downstream of aberrantly hyperactive RTKs that possess pro-
oncogenic activity, thereby promoting survival, proliferation and metastasis (Varkaris et 
al., 2014).  An abundant number of SFK activators have been identified, which include, 
but are not limited to; growth factor receptors (such as PDGF, EGFR, FGFR, IGFR and 
HGFR), β-adrenergic receptor, integrin/FAK, beta catenin, RANKL, ILR and the 
androgen receptor (Varkaris et al., 2014). It can be reasoned that the modest, yet 
insignificant, increase in the phosphorylation status of growth factor receptors such as 
EGFR and FGFRs following treatment with doxazosin and prazosin may facilitate 
elevated Src phosphorylation. However, this may only be true for LNCaP cells where 
increases in growth factor receptors and Src phosphorylation were greatest.  Enhanced 
activity of EGFR and FGFR are known to participate in pro-oncogenic signaling, 
leading to increased prostate cancer survival (Yarden, 2001, Feng et al., 2012, 
Ojemuyiwa et al., 2014). However, due to the lack of statistically significant effects of 
doxazosin/prazosin on these growth factor receptors, further investigation is required to 
evaluate the relationship between Src and EGFR/FGFR in prostate cancer cells.  
  
The absence of appreciable doxazosin- or prazosin-mediated suppression of EGFR, 
ERK1/2, NFKB or VEGFR phosphorylation observed here (Hui et al., 2008, Park et al., 
2014a), may be due in part to transient activation or expression of these kinases in 
response to cytotoxic doxazosin/prazosin. For example, in previous studies doxazosin-
mediated suppression of EGFR and ERK1/2 was assayed following an acute thirty-
minute treatment, whereas the present study evaluated the sustained effects (24 h) of 
these drugs on various protein and RTK targets. Likewise, doxazosin-mediated EphA2 
phosphorylation was found to be unchanged at 24 h (array data), which was later 
demonstrated to be maximally phosphorylated following 1 h treatment (ELISA data) 
and is consistent with previous reports of transient EphA2 activity (Petty et al., 2012). 
While many of proteins targets act early in the cytotoxic signalling, such as EGFR, are 
likely to display similar transient activation. However, it was the intention of this study 
to evaluate the molecular mechanisms underlying the more therapeutically relevant 
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treatment durations (24 h), as opposed to acute (< 24 h) antagonist treatment of prostate 
cancer cells. Likewise, in a preliminary study it was found that acute treatment with 
doxazosin or prazosin (1 h, 100 µM) is only modestly cytotoxic following 24 h drug-
free recovery, suggesting that transient suppression or activation of cell death signal 
transduction pathways by doxazosin/prazosin does not fully regulate the cytotoxic 
actions of these drugs.  It is acknowledged that the present findings are indeed a 
snapshot of protein expression and phosphorylation changes in response to 24 h 
exposure to doxazosin, prazosin or tamsulosin. It would be of significant interest to 
investigate identified protein targets in time-lapse experiments.  
!
! !
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SUMMARY!
 
The present study expands the current knowledge of molecular mechanisms 
contributing to the doxazosin and prazosin-induced autophagic and apoptotic 
mechanisms in AR-positive and AR-negative prostate cancer cells. These findings 
suggest inhibition of mTOR signaling (independent of Akt), and subsequent activation 
and that inhibition of the p70S6K/rbS6 axes, may play an important role in doxazosin 
and/or prazosin cytotoxicity following 24 h exposure. Additionally, the current findings 
are consistent with previous findings indicating that EphA2 activity mediates anoikis 
response to doxazosin, which appears to be drug-specific, with prazosin having no 
effect on EphA2 phosphorylation in acute or 24 h treatment settings. In addition, 
signaling mechanisms involving p38α MAPK and p27 also appear to contribute to 
doxazosin and prazosin-induced prostate cancer cell death.  However, the contribution 
of these protein targets to doxazosin/prazosin-mediated cell death requires further 
investigation. Moreover, this is the first report of doxazosin and prazosin induced 
expressional/phosphorylational changes in ADAMTS1, Cited-2 and Src.  However, 
their role in mediating cell survival or death in response to these drugs remain to be 
fully explored.   
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5.1$ $ INTRODUCTION$
RADIATION!THERAPY!
As discussed in Chapter 1, radiotherapy is a standard treatment used to treat local or 
locally advanced prostate cancer by delivering lethal doses of ionising-radiation to the 
tumour. In most cases, the cytotoxic effect of irradiation is primarily attributed to its 
ability to indirectly induce DNA damage via oxygen-dependent production of free 
radicals (Figure 5.1). Second to this, when absorbed by DNA, irradiation causes direct 
DNA damage. In both cases, the damaged DNA will trigger cell death in the affected 
cell. A third cytotoxic mechanism of radiotherapy known as the radiation-induced 
bystander effect (RIBE) also exists. While the precise mechanism is still under 
investigation, it is currently defined as the phenomenon where irradiated cells indirectly 
induce various biological effects, such as abnormal chromosomal modification, 
formation of ROS and apoptosis of nearby un-irradiated cells (Hatzi et al., 2015). 
Interestingly, there is recent evidence that a pro-survival or “rescue” bystander effect 
exists, where un-irradiated cells may provide a survival benefit or “rescue” irradiated 
cells by pro-survival intercellular signalling. Similarly, mechanisms contributing to this 
rescue-bystander effect are not fully elucidated (Lam et al., 2015). 
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!
!
Figure!5.1.!The!indirect!and!direct!cytotoxic!actions!of!irradiation!(Hall,!2006).  
!
RADIORESISTANCE!
Approximately one-third of patients will experience biochemical recurrence following 
definitive radiotherapy (Zumsteg et al., 2015), with approximately 30% of these patients 
developing clinical metastasis (Pound et al., 1999). In many cases, radiotherapy 
treatment failure is attributed to either innate or acquired tumour radioresistance by 
many mechanisms (Chang et al., 2014). However, tumour hypoxia is one of the most 
important drivers of radioresistance, and therefore, will be the primary focus of this 
literature review.   
!
TUMOUR!HYPOXIA!
Hypoxia is generally defined as oxygen levels below typical physiological levels (20-70 
mm Hg), ranging from 5-15 to 25- 30 mmHg (Rademakers et al., 2008); however a 
specific hypoxic threshold remains to be defined. Tumour hypoxia is a common feature 
of many tumors and occurs as a direct result of abnormal or insufficient vasculature as a 
consequence of rapid tumour proliferation.  However, hypoxia is not only a by-product, 
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but also aggressively drives tumourigenesis and malignancy. Therefore, hypoxia may be 
the “Achilles heel” of many cancers and targeting hypoxia may be an effective 
treatment strategy.  
 
Varying degrees of hypoxia exist from low, moderate to high levels, which are 
distributed heterogeneously throughout the tumour. Regional differences are commonly 
attributed to two types of hypoxia, chronic or acute/cycling hypoxia.  Chronic hypoxia 
is stable and its existence is highly predictable, occurring just outside the limits of 
oxygen diffusion (approximately 70 µm, or 10 cells) from local blood supply (Figure 
5.2).  Cancer cells residing >100 µm from blood vessels are in a state of anoxia, or total 
lack of oxygen, and subsequently undergo necrotic cell death.  In contrast, the 
manifestation of acute or cycling tumour hypoxia is unpredictable, but is thought to be 
influence by several factors including imbalanced angiogenesis and changes in blood 
flow, possibly via blood vessel occlusion (Harada, 2011).  
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Figure! 5.2.! Relationship! between! blood! vessels! and! tumour! hypoxia.! Illustration!
indicating! locations!of! acute! and! chronic! regions!of! hypoxia! (Harada,! 2011).! Figure!
reprinted!with!permission!from!copyright!holder.!
'
CLINICAL'SIGNIFICANCE'OF'TUMOUR'HYPOXIA'
While extreme hypoxia and anoxia (< 1 mmHg) is disadvantageous to tumour growth, 
low and moderate levels of hypoxia contribute to disease progression and treatment 
failure via two intertwined mechanisms. Firstly, hypoxia promotes tumourigenesis and 
angiogenesis, and secondly, by reducing anticancer treatment efficacy (Jans et al., 2010, 
Milosevic et al., 2012, Ranasinghe et al., 2013). Of particular importance, the 
microenvironment of cyclical (acute) hypoxic regions is believed to further promote 
tumourigenesis, by exacerbating pro-proliferation inflammation (Tellier et al., 2015) 
and enhancing factors contributing to cancer cell survival, invasion and metastasis (Dai 
et al., 2011). Additionally, acute hypoxia was found to have a greater effect on the 
metastatic potential of tumour cells, compared to chronic hypoxia (Rofstad et al., 2007).  
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Tumour hypoxia is well documented to be a prognostic marker for poor survival in 
many cancers including cervical, neck and neck, pancreatic and prostate cancer (Dhani 
et al., 2015). In the case of prostate cancer, localised disease can be treated successfully 
by surgery or radiotherapy. However, nearly 25 - 30% of men will experience 
recurrence. Tumour hypoxia is likely to be responsible for a significant portion of 
prostate cancer treatment failures. One study uncovered a greater risk for biochemical 
relapse in men with greater levels of tumour hypoxia at diagnosis (Milosevic et al., 
2012). 
'
HYPOXIA-INDUCIBLE'FACTOR'1ALPHA'
The cell response to hypoxia is predominantly regulated by the transcription factor, 
hypoxia inducible factor 1 alpha (HIF-1α). HIF-1 consists of two subunits, alpha and 
beta. Unlike the stable beta subunit, the alpha subunit is negatively regulated by the 
presence of molecular oxygen, and plays a critical role in the transcriptional activity of 
HIF-1α (discussed below).  
 
 !
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OxygenIdependent!regulation!of!HIFI1α!
In normoxic conditions, oxygen promotes the destabilization of HIF-1α by the 
enzymatic hydroxylation of key residues by HIF-specific prolyl-hydroxylases (PHD). In 
turn, this triggers von Hippel-Lindau (pVHL) complex-mediated ubiquination and 
downstream proteosomal degradation (Huang et al., 1998) (Figure 5.3). Additionally, 
transcriptional activity of HIF-1α is negatively regulated by factor inhibiting HIF1-α 
(FIH-1). In normoxic conditions, FIH-1 inhibits HIF-1α by oxygen-dependent 
hydroxylation of key co-factor binding sites, preventing HIF-1α from binding DNA and 
subsequently inhibiting gene transcription (Chen et al., 2015, Masoud and Li, 2015). In 
hypoxic environments HIF-1α is not recognized by pVHL complex, escaping pVHL-
mediated sequestration, allowing HIF1α to accumulate in the cytoplasm. Stabilised HIF-
1α dimerises with HIF-1β and translocates to the nucleus where the HIF-1α and -1β 
binding pair interacts with various cofactors to trigger expression of its gene targets to 
promote cell survival, migration, homeostasis, angiogenesis and anaerobic metabolism 
(Dewhirst et al., 2008).  
 
Of these targets, the angiogenic vascular endothelial growth factor (VEGF) is arguably 
the most documented.  Hypoxia and angiogenesis are believed to participate in a 
positive feedback loop, where hypoxia induced HIF-1α activity promotes VEGF-
mediated angiogenesis, resulting in further tumour proliferation, hypoxia, and 
angiogenesis.  Likewise, hypoxia is considered the “angiogenic switch” enabling the 
transition of low-grade tumours to a more aggressive phenotype (Harada, 2011).  
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Figure!5.3.!OxygenIdependent!regulation!of!HIFI1α!(Maes!et!al.,!2012).!Figure!
reprinted!with!permission!from!copyright!holder.!
!
!
HypoxiaIindependent!regulation!of!HIF1α!
Hypoxia-independent regulation of HIF-1α activity and subsequently HIF-1α-mediated 
tumourigenesis has also been described (Bilton and Booker, 2003). Various cytokines 
and growth factors including, insulin, insulin-like growth factor (IGF), EGF, platelet 
derived growth factor (PDGF), TGF-1β, tumour necrosis factor alpha (TNFα), and 
interleukin-1 beta (IL-1β) have all been shown to increase expressional levels of HIF-
1α, primarily by stimulation of the PI3K/Akt/mTOR pathway (Feldser et al., 1999, 
Richard et al., 2000, Zhong et al., 2000, Zundel et al., 2000)  
 
Aberrant receptor activation, either by ligand-dependent or independent mechanisms 
and downstream signaling also promotes the expression and transcriptional activity of 
HIF-1α. The signal transduction pathways involved in HIF-1α regulation include 
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Ras/MEK/MAPK and PI3K/Akt/mTOR cascades (Treins et al., 2002).  Furthermore, 
activation of these pathways may co-operate with hypoxia-mediated HIF-1α 
stabilisation to enhance accumulation and activation of HIF-1α (Minet et al., 2000).  
 
In prostate cancer, the androgen receptor has been implicated as a regulator of HIF-1α 
activation. Furthermore, correlational evidence suggests that AR-signaling may also 
regulate VEGF-mediated tumourigenesis via HIF1-dependent mechanisms (Boddy et 
al., 2005).  
 
 
 
!
Figure!5.4.!ReceptorImediated!activation!of!HIFI1α.!Figure!from!Bilton!and!Brooker,!
(2003),!with!slight!modification.!Original!figure!reprinted!with!permission!from!
copyright!holder.!
 '
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CLINICAL'SIGNIFICANCE'OF'HIF-1Α'EXPRESSION'
In prostate cancer, HIF-1α level is positively correlated with Gleason score, suggesting 
expression of HIF-1α may enhance disease aggression, metastasis (Makarewicz et al., 
2011), and in turn, poor prognostic outcomes. Additionally, HIF-1α and related 
regulatory proteins may predict treatment failure in men opting to receive radical 
prostatectomy or ADT (Jans et al., 2010). In men undergoing ADT, inhibition of HIF-
1α significantly improved disease free survival by four years, and reduced incidence of 
developing castrate-resistant prostate cancer by 71%  (Ranasinghe et al., 2013).  
However, it is unknown whether HIF-1α levels in these studies is driven by tumour 
hypoxia, occur by hypoxia-independent mechanisms, or whether both hypoxia-
dependent and independent activation of HIF-1α act to promote disease progression. 
'
HYPOXIAIMEDIATED!RADIORESISTANCE!
Hypoxia-mediated tumour radioresistance is a significant problem affecting the 
oncological and survival outcomes patients diagnosed with cancer (Milosevic et al., 
2012). Ionizing radiation relies on the “oxygen enhancement effect” where well-
oxygenated areas of tumours are far more radiosensitive than hypoxic areas. This effect 
is believed to occur through two independent pathways. Chemically, oxygen contributes 
to irradiation-induced accumulation of free radicals, which in turn causes irreversible 
damage to the DNA and ultimately cell death. In contrast, irradiation is less effective in 
the absence of oxygen, resulting in fewer free radicals, and in turn, less DNA damage. 
Furthermore, as previously discussed, a hypoxic environment alters cellular signaling 
pathways by increasing intracellular HIF-1α, thereby promoting adaptation and 
survival. As a consequence, hypoxic cancer cells are often able to repair incidental 
DNA damage allowing the cells to continue to proliferate. While radiotherapy is 
understood to promote the re-oxygenation of tumours and consequently reduce HIF-1α 
activity, over the long term HIF-1α remains active promoting tumour angiogenesis, 
proliferation, and metastasis.  
 '
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RADIOSENSITISERS'
To date, several radiosensitising techniques and drugs have been studied with only a 
handful reaching clinical trials. Strategies such as delivering oxygen to the hypoxic 
tumour, hypoxia-selective agents (including oxygen mimics and bio-reductive 
prodrugs), VEGFR and HIF-1α inhibitors, gene therapies, and enhanced radiotherapy 
delivery techniques are currently being investigated (Harada, 2011).   
!
Enhanced!oxygen!delivery!
In theory, the most direct method to overcoming hypoxia-mediated radioresistance is by 
increasing oxygen to the tumour. Some of these methods include hyperbaric oxygen 
therapy, combination of carbogen and nicotinamide, and hemoglobin modification (as 
reviewed by (Yoshimura et al., 2013).  Unfortunately, the aforementioned therapies 
have shown mixed results in clinical trials and have not yet been translated into modern 
radiotherapy regimens (Fletcher et al., 1977, Haffty et al., 1999, Janssens et al., 2012). 
 
HypoxiaIselective!cytotoxics!
Bio-reductive drugs undergo biotransformation by oxidoreductase, which yields a 
highly toxic metabolite. Since this process is inhibited and reversed by the presence of 
oxygen, the cytotoxic effects are unmasked in hypoxic regions, leaving normoxic cells 
unharmed. Currently, there are five classes of bio-reductive drugs, nitro(hetero)cyclic 
(nitroimidazole-derivatives) compounds, aromatic N-oxides, quinones and metal 
complexes. To date, several bioreductive drugs including the misonidazole and 
nimorazole (oxygen-mimics) PR-104, TH-302, EO9 and tirapazamine have been or are 
currently being trialed either as single agents or in combination with other anti-cancer 
therapies (Guise et al., 2014). While bio-reductive prodrugs and radiotherapy seem to be 
complementary therapies, none of the above agents, except for tirapazamine, have been 
clinically investigated in combination with radiotherapy to overcome hypoxia-mediated 
radioresistance. The outcomes of a phase III clinical trial evaluating tirapazamine in 
combination with cisplatin and irradiation for regionally confined cervical cancer were 
recently published. Unfortunately, the addition of tirapazamine did not improve 
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oncological outcomes, compared to cisplatin and irradiation combination therapy 
(DiSilvestro et al., 2014). 
 
Angiogenesis!inhibitors!
Anti-angiogenetic agents such as the VEGFR inhibitor sunitinib and the anti-VEGF 
antibody bevacizumab were shown to have a synergistic effect when combined with 
irradiation in cultured cells and in vivo (Dings et al., 2007, Hoang et al., 2012) 
Specifically, it was found that xenograft ovarian, melanoma and breast cancer tumours 
in mice displayed a more normalised vascularity when irradiation was combined with 
VEGFR inhibitors compared to irradiation alone (Dings et al., 2007). However, there 
exists a caveat. Inhibition of angiogenetic signaling may increase tumour hypoxia over 
the long term (Ou et al., 2009).  This suggests that the radiosensitising effects of 
angiogenesis inhibitors may be schedule dependent and optimisation of the anti- 
angiogenic agent and irradiation timing may be imperative for clinical success (Ou et 
al., 2009, Dings et al., 2007).   
 
HIFI1α!inhibitors!
As previously reviewed, HIF-1α levels, whether existing dependent or independent of 
hypoxia, are directly correlated to disease aggression and metastatic potential, as well as 
risk for treatment failure (Dai et al., 2011, Milosevic et al., 2012). Furthermore, 
compounding the direct radioresistant effects of hypoxia, HIF-1α enhances 
radioresistance through survival and adaptive signaling mechanisms (Hennessey et al., 
2013). Therefore, it can be inferred that targeting HIF-1α activity may provide 
significant oncological and survival benefit. The currently available HIF-1α inhibitors 
target each step from transcription of HIF-1α mRNA, to direct inhibition of HIF-1α 
expression, to suppression of HIF-1α-mediate gene transcription. 
 
Few of the HIF-1α inhibitors, such as rapamycin (sirolimus), everolimus (previously, 
RAD001), topotecan and YC-1 have progressed to clinical trial as part of a combination 
radiation therapy regimen. However, pre-clinical studies investigating the 
radiosensitising effects of these agents are promising.   
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One of the most well investigated agents, rapamycin, is an inducer of autophagy by 
direct inhibition of mTOR, and also acts to inhibit of HIF-1α expression indirectly via 
suppression of the mTOR signaling cascade. Rapamycin was found to possess anti-
angiogenic effects, presumably through suppression of HIF-1α / VEGF signaling and, in 
turn, enhanced radiosensitivity in vitro (Dai et al., 2013, Seront et al., 2013). In a 
separate study, treatment with rapamycin prior to radiotherapy was shown to enhance 
efficacy by normalising tumour vasculature, promoting perfusion, and radiosensitising 
rhabdomyosarcoma in rodents (Myers et al., 2012).  Rapamycin and similar analogues, 
such as everolimus, are no stranger to clinical settings, being approved for prophylaxis 
of organ rejection after transplant and treatment of some cancers (Australian 
Therapeutic Goods Administration, 2013). However, knowledge of their efficacy to 
overcome hypoxia- or HIF-1α-mediated radioresistance in humans is limited. A recent 
phase I/II clinical trial evaluated the use of rapamycin in combination with radiotherapy 
for rectal cancer.  Overall the investigators reported positive findings, boasting a safe 
and biologically active profile (Buijsen et al., 2015).  
 
Another well investigated agent, topotecan, is a chemotherapeutic with HIF-1α targeting 
effects (Choi et al., 2009). In advanced solid tumours, treatment with topotecan was 
highly effective in suppressing both HIF-1α and VEGF expression (Kummar et al., 
2011) and has also been shown to be effective when combined with radiotherapy for 
several cancers (Ge et al., 2013, Sun et al., 2015a, Wei et al., 2015). However, whether 
the improved treatment efficacy is due to topotecan-induced HIF-1α modulation or via 
broad inhibition of DNA topoisomerases (type I) remains to be elucidated. 
 
The multi-target HIF-1α inhibitor YC-1 inhibits both translation and stabilisation of 
HIF-1α (Li et al., 2008b), however, has yet to progress to clinical trials. Strong pre-
clinical data supports the anti-cancer activity of YC-1 mono-therapy (Carroll et al., 
2013), as well as in combination with irradiation as a hypoxic radiosensitising agent 
(Harada et al., 2009, Moon et al., 2009). However, one study indicates that the use of 
HIF-1α inhibitor such as YC-1 to overcome hypoxia radioresistance may be schedule-
dependent (Harada et al., 2009). As previously mentioned, HIF-1 α is strongly 
associated with angiogenesis. Therefore, inhibition of HIF-1 α would hypothetically 
suppress blood vessel formation, reduce perfusion, and in turn, further exacerbate 
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tumour hypoxia. In the context of radiotherapy, this could be detrimental to treatment 
efficacy. In accordance, one study demonstrated that treatment with YC-1 prior to 
irradiation, effectively inhibited hypoxia-induced HIF-1 α accumulation but promoted 
enhanced tumour hypoxia via suppression of micro-vessel density in the hours leading 
up to irradiation, yielding poor radiobiological outcomes. In contrast, irradiation 
followed by YC-1 treatment inhibited post-irradiation surge in HIF-1α activity resulting 
in significant radiosensitising effects (Harada et al., 2009).  This paradoxical effect of 
HIF-1α modulation by YC-1 in radiotherapy settings will require further investigations 
before the full magnitude of its potential can be realised.  
 
 !
 170 
DOXAZOSIN,!PRAZOZIN!AND!RADIATION!THERAPY!
In addition to hypertension and BPH, α1-adrenoceptor antagonists are frequently used 
in radiotherapy either prophylactically or concomitantly to combat the treatment-
associated LUTS (Zelefsky et al., 1999).  However, the effect of these drugs on solid 
tumours in combination with radiotherapy is largely unknown. The findings presented 
in Chapter 4 suggest that doxazosin and prazosin inhibit mTORC1 as evidenced by the 
inhibition of the downstream signaling effector rbS6. While at this time only an 
inference can be made, this suggests that prazosin and doxazosin may have similar 
actions on HIF-1α expression as the mTOR inhibitors rapamycin (sirolimus) and 
everolimus. A search of the literature resulted in a single report investigating the 
potential radiosensitising actions of doxazosin and terazosin in castrate-resistant (AR-
negative) PC-3 prostate cancer cells. While the investigators reported no synergistic 
activity after concomitant treatment with doxazosin or terazosin plus irradiation (3 Gy), 
irradiation was found to have schedule-dependent radiosensitising actions when 
combined with doxazosin or terazosin (Cuellar et al., 2002).  However, the investigators 
only examined immediate effect (24 h), leaving a gap in knowledge regarding long term 
effects of radiotherapy in the presence of these drugs. Likewise, the effect of these 
drugs in hypoxic conditions mimicking the biology of solid tumours is entirely 
unknown.  
 
!
!
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!
!
Figure! 5.6.! mTOR! signaling! cascade! leading! to! phosphorylation! of! S6! and! HIFI1α!
expression! (Semenza,! 2003).! Figure! reprinted! with! permission! from! copyright!
holder.!
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 172 
SUMMARY!
 
It is clear from review of the current literature that tumour hypoxia is a significant 
problem, which contributes to treatment failure, disease progression and poor prognosis, 
particularly in prostate cancer. Specifically, solid tumour hypoxia poses a significant 
hurdle for radiotherapy-based treatments, as the low levels of oxygen hinder treatment 
efficacy. Compounding the issue, hypoxia-mediated HIF-1α signaling promotes tumour 
proliferation, adaptation and angiogenesis, further enhancing radio-resistance.  
 
Not many of the previously investigated radiosensitising agents have reached clinical 
practice due to poor treatment-based side effects or insignificant oncological 
improvement. Therefore, there is a need for additional radiosensitising agents to 
overcome innate hypoxia-mediated radioresistance. Doxazosin or prazosin may make 
potential candidates to improve radiotherapy efficacy as they possess novel anti-cancer 
effects and are already used clinically for mitigation of radiotherapy-induced LUTS in 
men treated for prostate cancer.  
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5.2$ $ AIMS$$
The overall aim of this study was to investigate the potential radiosensitising actions of 
the α1-adrenoceptor antagonist prazosin on hypoxic and normoxic AR-positive LNCaP 
and AR-negative PC-3 prostate cancer cell lines and the mechanisms underlying this.    
 
The specific aims of this study were to: 
1.' Determine the relative radiosensitivities of LNCaP and PC-3 cells under 
normoxic and hypoxic conditions.  
2.' Evaluate the effect of prazosin on radiosensitivity of LNCaP and PC-3 cells 
under normoxic and hypoxic conditions. 
3.' Determine if prazosin effects on radiosentivity on LNCaP and PC-3 cells were 
mediated by ROS production, induction of HIF-1α or apoptotic or autophagic 
pathways. 
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5.3$ METHODS 
 
DRUG!TREATMENT!
PC-3 and LNCaP cells were seeded in glass petri dishes or glass 96-well plates at sub-
confluent densities (see Table 5.1) to allow for uninhibited growth for the duration of 
treatment.  Following appropriate incubation for cell adhesion (PC-3 24 h and LNCaP 
48 h), PC-3 and LNCaP cells were treated with prazosin (10-100 µM), tamsulosin (100 
µM) or vehicle control for 2.5 h at room temperature in a normoxic or hypoxic 
environment and in the presence or absence of irradiation. The acute room temperature 
incubation of cell cultures did not appear to have any adverse effects. However, all 
treatment conditions were incubated at room temperature to control for any impact on 
experimental outcomes. Although no additional buffers were added to the treatment 
culture medium, changes in pH of culture medium during treatment incubation were 
controlled for in all independent experiments.  Refer to Figure 5.7 for treatment 
timeline.  
 
Table! 5.1.! Typical! subIconfluent! seeding! densities! of! PCI3! and! LNCaP! cells! used!
throughout!this!chapter.!
 
 
 
 
 
 
 
 
Assay 
Assay time 
point 
Cell Line 
PC-3 LNCaP 
Resazurin reduction 
3-5 days-post 
irradiation 
6.25x103/cm2 6.25x103/cm2 
DCF Immediate 3.125x104/cm2 3.125x104/cm2 
HIF-1α"ELISA Immediate 3.125x104/cm2 3.125x104/cm2 
Caspase-3 Activity 
24 h-post 
irradiation 
3.125x104/cm2 3.125x104/cm2 
CytoID Autophagy 
Detection 
25 h-post 
irradiation 
3.125x104/cm2 3.125x104/cm2 
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Figure'5.7.'Timeline'of'LNCaP'and'PC73'treatment'for'each'experimental'condition'(unirradiated'normoxia,'unirradiated'hypoxia,'irradiated'normoxia'
and'irradiated'hypoxia).'
 176 
GENERATION)OF)HYPOXIA)
For investigations involving hypoxia, cells were treated and degassed in glass vessels as 
opposed to plastic. Prior literature suggests plastics can act as an oxygen reservoir 
releasing oxygen into anoxic aqueous culture medium (Davies and Baker, 1970) and 
potentially confound any hypoxia-mediated effects.  As shown in Figure 5.8, the 
protective effect of hypoxia may be partially lost amongst cells cultured, gassed and 
irradiated in plastic vessels as opposed to glass vessels.  
 
Hypoxia (< 0.2% oxygen in culture medium) was generated as previously described 
(Anoopkumar-Dukie et al., 2005b).  Briefly, cells seeded in glass vessels were placed in 
environment-controlled chambers (Billups Rothenberg, Cat. No. MIC-101) and gassed 
with 95% Nitrogen 5% CO2 gas mixture at a flow rate of 10 L/min for 8 minutes, 
followed by 2 L/min for 30 minutes. Chambers were sealed and cells were maintained 
at room temperature in a hypoxic environment for an additional 2 h. Normoxic cells 
were also maintained at room temperature for the duration of hypoxia (2 h and 38 
minutes). Refer to Figure 5.7 for treatment timeline.  
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)
)
Figure) 5.8.) Effect) of) plastic) (polycarbonate)) or) glass) culture) vessels) on) PCF3) cell)
proliferation) 3) days) following) irradiation) (IRR)) in) normoxic) or) hypoxic) conditions.))
Resazurin) reduction) assay) was) used) as) a) measure) of) cell) proliferation.) Data) are)
expressed)as)mean)percentage)of) untreated)normoxic) control) (n=1) for)plastic) and)n=2)
for)glass)petri)dishes).)
)
IRRADIATION))
Using a linear particle accelerator (Clinac iX Series, Varian) a radiation dose of 6.2Gy 
(6MV) at a dose rate of 2Gy per minute was delivered in one fraction to hypoxic or 
normoxic cells in environment controlled chambers (see Figure 5.9 A & B). The 
treatment field was opened to 40 cm2 and the environment-controlled chamber 
containing cells was positioned atop of a piece of acrylic with a thickness of 1 cm.  
Cells received radiation approximately 1.5 h following initiation of drug (or vehicle 
control) treatment. Refer to Figure 5.7 for treatment timeline. 
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RESAZURIN)REDUCTION)PROLIFERATION)ASSAY)
The resazurin reduction assay has previously been shown to be a viable alternative to 
the colony formation assay for determining cell viability after irradiation (Anoopkumar-
Dukie et al., 2005a).  Following acute 2.5 h treatment, cells were washed with 
phosphate buffered saline (PBS), and fresh drug-free complete culture medium was 
added above the cells and incubated for 3 to 5 days.  For 5-day incubation, culture 
medium was renewed at 72 h post irradiation. After the intended incubation period, the 
resazurin reduction proliferation assay was conducted as previously described (Chapter 
2). Changes in culture medium pH were controlled for in all experiments.  Likewise, 
data were represented as a percent of respective untreated normoxic or hypoxic control.  
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Figure)5.9.) Irradiation) (6.2)Gy,)6)MV))of)prostate)cancer)PCF3)and)LNCaP)cells)using)
a) linear) particle) accelerator) (Clinac) iX) Series,) Varian).) Photograph) [A]) and)
illustration) [B]) of) positioning) of) environment) controlled) chamber) with) respect) to)
gantry.))
 
A"
B"
100"cm" 40"cm
2"
1"cm"
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2,7FDICHLORODIHYDROFLUORECEIN)DIACETATE)ASSAY)
The presence of intracellular reactive oxygen species (ROS) and subsequent oxidative 
stress is commonly measured using fluorescent probes such as 2,7-
dichlorodihydrofluorescein diacetate (DCFH-DA). In its reduced form, DCFH-DA is a 
non-fluorescent and cell permeable product, which undergoes hydrolysis by 
intracellular esterases or hydroxide ion to form the byproduct, 2,7-
dichlorodihydrofluorescein (DCFH). Further oxidation, presumably via the presence of 
intracellular ROS, results in the formation of 2,7-dichlorofluorescein (DCF) (Figure 
5.10).  Oxidation of DCFH to fluorescent DCF is known to be non-specific to the type 
of ROS or reactive nitrogen species present, with reports of DCFH reacting with H202, 
superoxide, and hydroxide, ONOO- to generate DCF (Figure 5.10) (Chignell and Sik, 
2003). Representative images of intracellular DCF fluorescence is shown in Figure 
5.11. 
 
The use of DCFH-DA for measuring oxidative stress in response to irradiated cells has 
previously been reported by various techniques (Anoopkumar-Dukie et al., 2005b), but 
primarily by use of a fluorescent plate reader (excitation: 498 nm; emission: 522 nm). 
Cells were seeded at a density of 1.0x104 trypan blue-excluding cells per well and 
allowed to attach for 24 or 48 h (PC-3 and LNCaP, respectively). On the day of 
irradiation, cells were pre-loaded with 25 µM DCF-DA in fresh un-supplemented 
phenol red-free culture medium for 60 minutes prior to treatment. Cells were then 
washed once with PBS and treated with prazosin (100 µM, 2.5 h) in un-supplemented 
culture medium as previously described.  Prazosin-treated, DCF-DA-preloaded cells 
were incubated in the presence or absence of oxygen and irradiation (see “Generation of 
Hypoxia” and “Irradiation” sections).   As DCF is known to suffer from photoreduction 
(Chignell and Sik, 2003), cells were protected from direct light at all times during the 
experiment. To ensure oxidised DCF was not lost to washing, ROS formation was 
measured in treatment medium immediately following 2.5 h exposure using a Modulus 
Multimode fluorescent plate reader (Promega, excitation: 490 nm; emission: 530 nm). 
DCF fluorescence values were normalised to resazurin reduction obtained from parallel 
cell cultures. Appropriate cell-free controls were included to control for undesirable 
effects of prazosin on DCF fluorescence.  
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)
Figure) 5.10.) Conversion) of) nonFfluorescent) DCFHFDA) to) the) highly) fluorescent) DCF)
byFproduct)(Gomes)et)al.,)2005).)Figure)reprinted)with)permission)from)copyright)holder. 
 
 
 
 
 
 
 
 
Figure)5.11.)Representative)images)(n=2))of)intracellular)DCF)fluorescence)in)PCF3)
cells)in)basal)conditions)(A))or)2)hFpost)irradiation)treatment)(B).)
 )
A B 
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DETECTION)OF)HIFF1Α)EXPRESSION))
Immediately following drug treatment (± environmental oxygen and/or irradiation), 
total HIF-1α protein content was determined using a Human Total HIF-1α DuoSet IC 
sandwich-ELISA (R&D Systems, Minneapolis, USA) according to the manufacturer’s 
instructions.  
 
Cells were lysed using lysis buffer supplemented with 1 mM PMSF, 1X protease 
inhibitor cocktail, and 1X phosphatase inhibitor cocktail (Cayman Chemical).  Sample 
protein concentration was determined using Bradford Reagent as previously described 
(Chapter 4).  Wells of a high-bind 96-well plate were incubated over night with 4 
µg/mL of kit provided capture antibody.  Following incubation, wells were blocked 
with PBS containing 5% BSA and 0.05% tween-20 for 1 h.  Sample lysates (200 µg of 
protein) were added to each well and incubated for 2 h at room temperature. Wells were 
washed before and after incubation with detection antibody (1:2000, 2 h) and HRP-
linked antibody (1:500, 20 minutes) at room temperature.  Substrate solution was added 
to wells for 20 min, and the reaction was stopped using sulfuric acid. Absorbance was 
read at 450 nm and HIF-1! concentrations were interpolated from a standard curve 
(Figure 5.12). A standard curve was generated with each independent experiment.  
)
Figure) 5.12.) A) representative) nonFlinear) (sigmoidal)) regression) of) known)
concentrations) of) HIFF1α) plotted) against) absorbance) (at) 490) nm)) from) which) the)
HIFF1α)concentration)in)collected)samples)was)determined.)
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CASPASEF3)ACTIVITY)ASSAY)
Caspase-3 activation was used as an index of apoptotic cell death. Twenty-four hours 
following acute prazosin/tamsulosin treatment (± irradiation and atmospheric oxygen), 
caspase-3 activity was determined using the caspase-3 activity fluorescence kit 
(Cayman Chemicals) as previously described in Chapter 3.  
 
CYTOID®)AUTOPHAGY)DETECTION)ASSAY)
Twenty-four hours following acute prazosin/tamsulosin treatment (± irradiation and 
atmospheric oxygen), change in autophagic activity was measured using a CytoID® 
autophagy detection kit (Enzo Sciences) as previously described in Chapter 3. 
Frequency of cells undergoing autophagy was determined using ImageJ analysis by 
representing number of autophagic cells as a percent of total number of counted cells.  
For each condition, a minimum sample of 100 cells was counted in all three 
independent experiments. 
 
STATISTICAL)ANALYSIS)
Data were analysed using a one- or two-way ANOVA as appropriate. Statistical 
significance was determined using either Dunnett’s or Tukey’s post hoc test. Details of 
the specific tests used are indicated throughout the Results section.  
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5.4$ RESULTS 
IRRADIATION)TIMEFDEPENDENT)CYTOTOXICITY)
Irradiation of PC-3 and LNCaP prostate cancer cells was found to induce time 
dependent cytotoxicity, with 5 days resulting in approximately 75% and 70% reduction 
in cell survival compared to untreated control (Figure 5.13).  As shown in Figure 5.13, 
irradiation had the greatest effect 5 days-post irradiation and as such, further 
investigations of cell proliferation assays were carried out at the 5-day post irradiation 
time point.   
 
 
Figure) 5.13.) Cell) proliferation) of) PCF3) (A)) or) LNCaP) (B)) 1,) 3) or) 5) daysFpost)
irradiation.)Resazurin)reduction)was)used)as)an) index)of)cell)proliferation)and)data)
are) expressed) as) the) mean) percentage) of) unirradiated) normoxic) control) (±) SEM,)
n≥3).) Statistical) significance)was)determined)using) a)oneFway)ANOVA)with) Tukey’s)
post) hoc) test) for) comparisons) between) control) and) treated) groups.) **) P<0.01) and)
***P<0.001) vs) unirradiated) control.) For) comparisons) between) 3F) and) 5Fdays) post)
irradiation,) #) P<0.05) and) ###) P<0.001) and) 1Fday) vs.) 5Fday) post,) ^^) P<0.01) and) ^^^)
P<0.001.)
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HYPOXIAFMEDIATED)RADIORESISTANCE))
To investigate the effect of hypoxia on the radiosensitivities of PC-3 and LNCaP cells, 
prostate cancer cells were irradiated in normoxic or acute hypoxic conditions (2.5 h). 
Cells were incubated for 5 days following irradiation and cell survival was determined 
by resazurin reduction. As shown in Figure 5.14, acute hypoxia (2.5 h) was able to 
significantly protect both PC-3 and LNCaP cells from irradiation-induced cell death 
(P<0.001 and P<0.05, respectively).  Furthermore, hypoxia had a significantly greater 
effect in PC-3 cells than LNCaP cells (Figure 5.15), increasing cell survival by 3.5- and 
2.2-fold, respectively (P<0.05 for comparison between PC-3 and LNCaP).  
)
)
Figure)5.14.))Survival)of)castrateFresistant)PCF3)and)castrateFsensitive)LNCaP)cells)5F
days)post)irradiation)(6.2)Gy,)6MV))in)the)presence)or)absence)of)acute)hypoxia)(2.5)
h).)Resazurin) reduction)was)used)as) a)measure)of) cell) survival.)Data)are)expressed)
as)percent)of) untreated) control) and)are) represented)as)mean) control) ±) SEM) (n=5).))
Statistical) significance)was) determined) using) a) twoFway) ANOVA)with) Tukey’s) post)
hoc.)*)P<0.05)and)***)P<0.001)vs.)respective)untreated)control.)
) )
No
rm
ox
ia
Hy
po
xia
No
rm
ox
ia 
+ I
RR
Hy
po
xia
 + 
IR
R
0
50
100
150
C
el
l S
ur
vi
va
l
(%
 o
f u
nt
re
at
ed
 c
on
tro
l)
PC-3
**
*
^^
No
rm
ox
ia
Hy
po
xia
No
rm
ox
ia 
+ I
RR
Hy
po
xia
 + 
IR
R
0
50
100
150
LNCaP
***
^^^
***
BA"
 186 
)
Figure) 5.15.) HypoxiaFmediated) increase) in) PCF3) and) LNCaP) survival) five) days)
following) irradiation.) ) Cell) survival) was) determined) by) reseazurin) reduction.) Data)
are)represented)as)foldFincrease)in)irradiated)cell)survival) in)the)absence)of)oxygen)
(mean)±)SEM)[n=5]).)Statistical)significance)was)determined)using)a)student’s)tFtest.)
For)comparison)of)PCF3)vs.)LNCaP)cells,)P=0.0146.)
 
RADIOSENSITISATION)BY)PRAZOSIN)
To investigate whether prazosin possesses radiosensitising potential, PC-3 and LNCaP 
cells were treated acutely (2.5 h) in a hypoxic or normoxic environment in the presence 
or absence of irradiation. Five days after irradiation, cell survival was determined by 
resazurin reduction. In a normoxic environment, acute prazosin treatment (2.5 h, 10 – 
100 µM) had no appreciable effect on PC-3 cell survival after five-day drug-free 
incubation (13% reduction at 100 µM), P>0.05) (Figure 5.16 A). In contrast, LNCaP 
cells appeared to be more sensitive to the short treatment with prazosin, with 30 and 100 
µM significantly reducing cell survival by approximately 35% and 46%, respectively, 
compared to untreated normoxic control (Figure 5.16 B).  In hypoxia treated cells, the 
highest concentration of prazosin (100 µM) significantly reduced survival in both cell 
lines compared to control (48.2%, P<0.001; and 42.2% P<0.001, respectively) (Figure 
5.16 A & B). 
 
In irradiated conditions, prazosin (30-100 µM) was found to significantly enhance 
hypoxic PC-3 and LNCaP cytotoxicity, reducing the survival fraction to that of 
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normoxic irradiated cells (Figure 5.17). In contrast, prazosin showed a statistically 
significant effect on normoxic irradiated prostate cancer cell survival compared to the 
untreated control (Figure 5.17 [white bar]; P>0.05 for all). As shown in Figure 5.17 
(black bar), prazosin concentration-dependently reduced irradiated cell survival in 
hypoxic conditions. Importantly, the highest concentrations of prazosin (30 – 100 µM, 
PC-3 [P<0.001] and 100 µM LNCaP [P<0.01]) abolished hypoxia-mediated 
radioresistance. The sum of these findings indicate that prazosin selectively 
radiosensitises hypoxic prostate cancer cells to irradiation.   
 
 
)
Figure) 5.16.) Effect) of) acute) prazosin) treatment) (0F100) µM,) 2.5h)) on) unirradiated)
normoxic) or) hypoxic) PCF3) (A)) and) LNCaP) (B)) cells) following) fiveFday) drugFfree)
recovery.) ) Resazurin) reduction) was) used) as) an) index) of) cell) survival.) Results) are)
expressed)as)a)percent)of)untreated)normoxic)control)and)are)expressed)as)mean)±)
SEM) (n=5).) Statistical) significance) was) determined) using) a) twoFway) ANOVA) with)
Tukey’s)post)hoc)test.)***)P<0.001)vs.)respective)normoxic)or)hypoxic)control.)
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)
Figure) 5.17.) Effect) of) acute) prazosin) treatment) (0F100) µM)) on) irradiated) (6.2) Gy,)
6MV)) normoxic) or) hypoxic) PCF3) (A)) or) LNCaP) (B)) cells) following) fiveFday) drug) free)
recovery.) Resazurin) reduction) was) used) as) an) index) of) cell) survival.) Results) are)
expressed) as) percent) change) from) respective) unirradiated) controls) (mean) ±) SEM,)
n≥5).) Statistical) significance)was)determined)using)a) twoFway)ANOVA)with)Tukey’s)
post)hoc) test.)**)P<0.01)and)***)P<0.001)vs.) respective)untreated)control.)#P<0.05)
and)###)P<0.001)vs.)normoxia.)
)
INVOLVEMENT)OF)ALPHA1FADR)ANTAGONISM)IN)PRAZOSIN)
RADIOSENSITISATION)
To elucidate whether this prazosin-mediated radiosensitisation occurred via α1-
adrenoceptor-dependent mechanisms, PC-3 and LNCaP cells were treated acutely with 
tamsulosin (100 µM) in a normoxic or hypoxic environment in the presence or absence 
of irradiation (6.2 Gy, 6 MV), and cell survival was determined after five days. In 
contrast to prazosin, tamsulosin was unable to enhance the irradiation-mediated 
cytotoxicity in the normoxic or hypoxic treated PC-3 or LNCaP cells (Figure 5.18 A & 
B, respectively) 
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Figure) 5.18.) ) PCF3) and) LNCaP) survival) 5) days) following) a) combination) of) acute)
tamsulosin) (100) µM,) 2.5) h)) and) irradiation) (IRR)) in) normoxic) or) hypoxic)
environment.) Cell) survival) was) determined) by) resazurin) reduction) assay.) Data) are)
represented)as)a)percentage)of)untreated)normoxic)control)(±)SEM,)n=3).)Statistical)
significance)was)determined)by)twoFway)ANOVA,)but)no)statistical)differences)were)
found)between)untreated)controls)and)tamsulosin)treated)cells.))
  
OXIDATIVE)STRESS)
Tumour hypoxia reduces the oxygen-dependent cytotoxic effect of radiotherapy, 
thereby promoting radioresistance. Since prazosin was able to restore radiosensitivity to 
hypoxic prostate cancer cells, it was postulated that prazosin may enhance free-radical 
production as a mechanism underlying this novel effect. To investigate this, the 
formation of intracellular ROS was measured using the DCF assay immediately 
following prazosin treatment (30-100 µM, 2.5 h) in the presence or absence of 
irradiation and environmental oxygen.  In cell-free control experiments, prazosin did not 
affect DCF fluorescence (data not shown). As shown in Figure 5.19 A & C, prazosin 
was found to have a modest pro-oxidant effect that occurred in a concentration-
dependent manner. At the highest concentration investigated (100 µM), prazosin alone 
increased ROS formation by 86% (± 43.5) and 38% (± 3.5) in PC-3 and LNCaP cells, 
respectively. Furthermore, this pro-oxidant effect was not altered by a hypoxic 
environment. As expected, irradiation increased intracellular ROS formation in both cell 
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lines, which was attenuated by hypoxic conditions (comparison between Figure 5.19 A 
& B, C vs. D).  The combination of prazosin (100 µM) and irradiation further enhanced 
free-radical production in both normoxic and hypoxic conditions compared to 
unirradiated controls. However, after adjusting for the effects of prazosin alone on ROS 
formation in irradiated cells, it appears that the increase in ROS is merely an additive 
effect of irradiation and prazosin as opposed to a synergistic one (Figure 5.20 on the 
following page).  
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)
Figure)5.19.)Relative) intracellular)ROS) formation) in)normoxic)or)hypoxic)PCF3) (A,B))
and) LNCaP) (C,D)) cells) following) treatment) with) prazosin) (0F100uM,) 2.5) h)) in) the)
absence)(FIRR;)A,C))or)presence)(+IRR,)B,D))of)irradiation)(6.2Gy,)6MV).)Relative)DCF)
fluorescence) was) used) as) an) index) of) ROS) production.) Data) are) expressed) as)
percentage) of) unirradiated) (FIRR)) untreated) normoxia) or) hypoxia) controls) (mean)
±SEM,) n=3).) Statistical) significance) was) determined) using) twoFway) ANOVA) with)
Tukey’s) post) hoc) test.) *P<0.05,) **P<0.01) and) ***P<0.001) vs.) respective) untreated)
control.)#)P<0.05)vs.)normoxia.)
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Figure) 5.20.) Increase) in)ROS) formation) in) PCF3) (A)) and) LNCaP) (B)) cells) represented)
as) a) percentage) of) respective) unirradiated) hypoxia) or) normoxia) treated) controls)
(mean) ±) SEM).) Statistical) significance)was) determined) using) twoFway) ANOVA)with)
Tukey’s) post) hoc) test.) No) statistical) differences)were) found) between) controls) and)
treated)cells.)
)
EFFECT)OF)PRAZOSIN)ON)HIFF1ALPHA)
To further uncover potential mechanisms of hypoxia-selective radiosensitisation, the 
effect of prazosin on HIF-1α expression or stabilisation was investigated. Total HIF-1! 
expression was quantified using an ELISA (R&D Systems) immediately following 
acute prazosin treatment in the presence or absence of irradiation and atmospheric 
oxygen. Basal expression of HIF-1α was found to be greatest in PC-3 cells, with more 
than 3-fold greater HIF-1α protein content than LNCaP cells (326 pg/mL vs.105 pg/mL, 
respectively). Acute hypoxia increased HIF-1α expression resulting in a 3.4- and 4.5-
fold increase in PC-3 and LNCaP cells, respectively (Figure 5.21).  Interestingly, 
treatment with prazosin (100 µM, 2.5 h) suppressed total HIF-1α expression across all 
treatment groups in both prostate cancer cell lines. In some instances, such as the 
normoxic irradiated and prazosin treated LNCaP cells, the expression of HIF-1α in 
samples were below the threshold of the ELISA kit sensitivity (< 125 pg/mL) and 
therefore were unquantifiable (Figure 5.21 B). In PC-3 cells, prazosin (100 µM) was 
able to reduce HIF-1α expression by approximately 2.3-fold in hypoxic unirradiated and 
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irradiated cells (Figure 5.21 A). Although unquantifiable, a similar trend was observed 
amongst LNCaP hypoxic un-irradiated and irradiated cells (Figure 5.21 B). 
 
 
Figure)5.21.)Total)HIFF1α)expression)immediately)following)acute)prazosin)(100)µM))
treatment) of) hypoxic) or) normoxic) PCF3) (A)) and) LNCaP) (B)) cells) in) the) presence) or)
absence) of) irradiation.) Changes) in) HIFF1α) expression) were) determined) using) a)
commercially) available) ELISA) kit.) Data) are) expressed) as) picogram) of) HIFF1α) per)
milligram) of) total) protein) (mean±) SEM,) n=3).) Statistical) significance) was)
determined) using) a) twoFway) ANOVA) with) Tukey’s) post) hoc) test.) *) P<0.05) and)
***P<0.001) vs.) untreated) normoxia.) For) comparisons) of) control) vs.) prazosin,) ##)
P<0.01)and)###)P<0.001.)+)P<0.05)vs.)irradiated)normoxia.)
 
CELL)DEATH)MECHANISMS)OF)PRAZOSINFINDUCED)RADIOSENSITISATION)
APOPTOSIS'
Changes in the universal apoptotic marker caspase-3 were determined 24 h post- 
irradiation and acute prazosin/tamsulosin treatment of PC-3 and LNCaP normoxic or 
hypoxic cells and subsequently normalised to resazurin reduction. As shown in Figure 
5.22 on the following page, a similar trend in cell survival was present in 24 h recovery 
as 5-day recovery; however, hypoxia significantly reduced PC-3 cell survival at the 5-
day time point (Figure 5.22 A). Consistent with previous findings, prazosin showed 
hypoxia selective effects by significantly reducing PC-3 cell survival in the presence or 
 194 
absence of irradiation (Figure 5.22 A & B). In contrast, LNCaP cells were less sensitive 
to the hypoxia-selective effect, with an appreciable response to prazosin (100 µM) in 
irradiated hypoxic cells (P=0.09) (Figure 5.22 C & D).    
 
)
Figure) 5.22.) Cell) survival) of) normoxic) or) hypoxic) PCF3) (A,B)) and) LNCaP) (C,D)) 24) h)
following) acute) prazosin) treatment) (0) –100) µM,) 2.5) h)) in) the) absence) (A,C)) or)
presence) of) irradiation) (B,D).) Resazurin) reduction) assay) was) using) as) an) index) of)
cell) survival) and) data) are) represented) as) percent) of) untreated) normoxic) control)
(mean) ±) SEM,) n=3).) Statistical) significance)was) determined) using) twoFway) ANOVA)
with)Tukey’s)post)hoc)test.)*P<0.5,)**P<0.01)and)***P<0.001)vs.)respective)control.)
#P<0.05)and)###)P<0.001)vs.)normoxia.)))
 
In both un-irradiated and irradiated prostate cancer cells, enhanced caspase-3 activity 
was only appreciable in prazosin-treated hypoxic cells (Figure 5.23 A, B & C) except 
for unirradiated LNCaP cells, where prazosin (30-100 µM) had no effect on caspase-3 
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activity in normoxic or hypoxic conditions (Figure 5.23 C). The irradiation of hypoxic 
prazosin treated cells modestly, yet significantly, increased caspase-3 activity in both 
PC-3 (P<0.05 for prazosin 30 and 100 µM) and LNCaP cells (P<0.001 for prazosin 100 
µM).  LNCaP cells demonstrated the greatest increase in apoptosis, with 100 µM 
prazosin treatment resulting in an approximately 4-fold increase in caspase-3 activation 
compared to unirradiated normoxic control (Figure 5.23 D). In contrast to hypoxia 
conditions, irradiation or the combination of irradiation and prazosin (30-100 µM) did 
not increase normoxia cell apoptosis in either cell line at the investigated time point (24 
h). These findings further confirm the hypoxia-selective radiosensitisation effect of 
prazosin in prostate cancer cells.   
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)
Figure) 5.23.) CaspaseF3) activity) in) normoxic) or) hypoxic) PCF3) (A,B)) and) LNCaP) (C,D))
cells)was)determined)24)h)following)acute)prazosin)treatment)(2.5)h,)0)–)100)μM))in)
the) absence) (A,C)) or) presence) (B,D)) of) irradiation.) Data) were) normalised) to)
resazurin) reduction) and) are) expressed) as) the) foldFchange) in) caspaseF3) activation)
from)unirradiated)normoxic)control)(mean)±)SEM,)n)=)3).)Statistical)significance)was)
determined) using) twoFway) ANOVA) with) Tukey’s) post) hoc) test.) ***P<0.001) vs.)
respective)control.)###)P<0.001)vs.)normoxia.))
 '
-IRR
0 30 100
0
1
2
3
4
5
Prazosin (µM)
Fo
ld
-c
ha
ng
e 
in
 c
as
pa
se
-3
 a
ct
iv
ity
(N
or
m
al
is
ed
 to
 re
sa
zu
rin
 re
du
ct
io
n)
**
*
#
##
##
#
+IRR
0 30 100
0
1
2
3
4
5
Prazosin (µM)
Normoxia
Hypoxia
*
**
*
##
##
#
-IRR
0 30 100
0
1
2
3
4
5
Prazosin (µM)
Fo
ld
-c
ha
ng
e 
in
 c
as
pa
se
-3
 a
ct
iv
ity
(N
or
m
al
is
ed
 to
 re
sa
zu
rin
 re
du
ct
io
n) +IRR
0 30 100
0
1
2
3
4
5
Prazosin (µM)
**
*
##
#
A B
C D
PC
-3
LN
C
aP
 197 
AUTOPHAGY'
It was previously shown in Chapter 3 that 24 h prazosin exposure is capable of inducing 
autophagy in LNCaP and PC-3 cell lines; with opposing roles by contributing to cell 
survival or death, respectively. However, whether acute prazosin treatment is capable of 
inducing sustained autophagy, and if autophagy may contribute to hypoxia-mediated 
radiosensitisation actions of prazosin was previously unknown.  To investigate this, 
autophagic activity was determined using the CytoID® autophagy detection kit 24 h 
post-irradiation and acute prazosin treatment (0-100 µM, 2.5 h) in hypoxic or normoxic 
prostate cancer cells. Increase in number of autophagy cells was quantified (Figure 
5.24) using image analysis software from fluorescence microscopy images (Figures 
5.25 & 5.26). Measureable changes in levels of autophagy were only observed in PC-3 
cells (Figures 5.24 A & 5.25), whereas LNCaP cells had high levels of autophagy in all 
conditions tested (Figures 5.24 B & 5.26). In PC-3 cells, hypoxia alone did not 
significantly affect autophagic activity in PC-3 cells, whereas irradiation treatment had 
the opposite effect, enhancing autophagy by approximately 4.5-fold (P=0.0579) (Figure 
5.24 A & 5.25). The combination of irradiation and hypoxia had no effect on 
autophagic activity compared to normoxic conditions.  Strikingly, prazosin treatment 
(100 µM) increased autophagy by 4- and nearly 10-fold increase in normoxic (P=0.48) 
and hypoxic PC-3 cells (P<0.04), respectively.  A similar trend in prazosin-mediated 
increase in autophagy was seen amongst the irradiated normoxia and hypoxia groups, 
although to a lesser extent. Only 30 µM prazosin treatment significantly increased 
autophagy in normoxia irradiated PC-3 cells; however, prazosin (100 µM) was found to 
nearly double autophagy in irradiated hypoxic conditions (P>0.05). By contrast, 
autophagy in PC-3 irradiated in presence of 30µM prazosin was significantly reduced 
by hypoxia. 
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Figure) 5.24.) Autophagic) activity) following) acute) prazosin) treatment) (2.5) h,) 0F100)
µM)) in) the) presence) or) absence) of) irradiation) (IRR)) amongst) hypoxic) or) normoxic)
PCF3)(A))and)LNCaP)(B))cells.)Autophagy)was)determined)using)a)CytoID®)Autophagy)
Detection)Kit) (Enzo) Life) Sciences).)Data) are) expressed)as)percentage)of) autophagic)
cells) (mean)±)SEM,)n=3).)Data)were)analysed)using)a) twoFway)ANOVA)with)Tukey’s)
post)hoc)test.)*P<0.05)vs.)untreated)hypoxia;)#)P<0.05)vs.)prazosinFtreated)(30)µM))
normoxia;)and)^^)P<0.01)vs.)prazosinFtreated)(30µM))irradiated)normoxia)cells.))
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Figure) 5.25.) Representative) fluorescent) images) of) PCF3) cells) using) CytoID®)
Autophagy) Detection) Kit) 24) h) following) acute) prazosin) (0F100) µM)) and) irradiation)
treatment) of) normoxic) or) hypoxic) cells.) Images) were) captured) at) 100x)
magnification) using) an) Evos®) Cell) Imaging) System.) Arrows) indicate) areas) with)
autophagic) activity) (Blue) [DAPI]) represents) nuclei) and) green) [FITC]) represents)
autophagyFrelated)vesicles).)
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Figure) 5.26.) Representative) fluorescent) images) of) LNCaP) cells) using) CytoID®)
Autophagy) Detection) Kit) 24) h) following) acute) prazosin) (0F100) µM)) and) irradiation)
treatment) of) normoxic) or) hypoxic) cells.) Images) were) captured) at) 100x)
magnification) using) an) Evos®) Cell) Imaging) System.) Arrows) indicate) areas) with)
autophagic) activity) (Blue) [DAPI]) represents) nuclei) and) green) [FITC]) represents)
autophagyFrelated)vesicles).)
 
30 µM 100 µM0 µM
C
on
tro
l'
H
yp
ox
ia
'
Irr
ad
ia
te
d'
Irr
ad
ia
te
d'
+'
H
yp
ox
ia
'
 201 
5.5$$ DISCUSSION$
 
The overall aim of this chapter was to determine whether prazosin treatment would 
enhance the cytotoxic effects of irradiation in normoxic or hypoxic conditions on AR-
negative PC-3 or AR-positive LNCaP cells. While hypoxia was found to confer 
radioresistance, acute prazosin treatment caused hypoxia-selective sensitisation of both 
PC-3 and LNCaP cells to irradiation as measured after five days of drug free recovery. 
This effect was largely attributed to mechanisms other than antagonism of α1-ADRs 
and is likely to be mediated by prazosin-induced ROS formation and/or HIF-1α 
suppression; contributing to either autophagy and/or apoptosis in a cell type-dependent 
manner. Consistent with findings presented in Chapter 3, apoptosis appeared to 
primarily regulate prazosin hypoxic-radiosensitisation of LNCaP cells, whereas 
interplay between autophagy and apoptosis was likely to mediate PC-3 cytotoxicity. 
Lastly, the radiosensitising actions of prazosin appear to be consistent with previous 
reports of quinazoline-dependent cytotoxicity (discussed in Chapter 3). While it was 
found that the non-quinazoline tamsulosin was not cytotoxic in the presence or absence 
of irradiation and oxygen, further investigation is required to ascertain the importance of 
the quinazoline structure in the radiosensitisation of prostate cancer cells.   
 
The formation of ROS is an important indirect mechanism underlying irradiation 
induced-DNA damage and subsequently cancer cell death. Low levels of molecular 
oxygen, as in the inner portions of solid tumours, act to circumvent the killing capacity 
of irradiation, and contribute to radioresistance of cancer cells (Harada, 2011).  The 
oxygen-dependent effects of irradiation were confirmed in present study, with hypoxic 
conditions significantly hindering the cytotoxic effect of irradiation and the formation of 
intracellular ROS. Surprisingly, acute prazosin treatment was found to increase ROS in 
an oxygen-independent fashion in the presence or absence of irradiation. This is the first 
report of prazosin-mediated intracellular ROS production, and is proposed to contribute 
to some degree to the hypoxia-selective radiosensitising effect of prazosin through 
induction of oxidative stress and subsequent cell death by autophagy-mediated or 
apoptotic mechanisms.  Briefly, oxidative stress is a state in which the accumulation of 
intracellular ROS overwhelms the cell’s innate anti-oxidant mechanisms, which leads to 
a plethora of cell type- and stimuli-dependent responses including adaptation, growth-
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arrest, apoptosis or necrosis (Milkovic et al., 2014, Paschos et al., 2013). 
Physiologically sustainable levels of intracellular ROS participate in redox-signalling 
cascades and are known to contribute to the pathogenesis of many diseases, including 
prostate cancer (Kumar et al., 2008). On the other hand, high levels of intracellular ROS 
are typically toxic, resulting in DNA damage and modification of the structure and 
functional activity of proteins and lipids (Han and Chen, 2013, Milkovic et al., 2014, 
Bak and Weerapana, 2015). However, the mechanism by which prazosin generates ROS 
production is unclear. As previously mentioned in Chapter 4, one proposed mechanism 
of doxazosin/prazosin toxicity may be via direct interactions with DNA causing 
genotoxic-stress (Arencibia et al., 2005, Lin et al., 2007).  DNA damage itself is known 
to promote the accumulation of intracellular ROS in consequence, and acts to regulate 
cellular senescence or death (Nair et al., 2015). Taken together, prazosin is likely to 
induce DNA damage by direct-interactions or indirectly through endogenous ROS 
accumulation.  In combination with the direct-DNA damaging actions of irradiation, 
this may potentiate sensitivity of prostate cancer cells to irradiation in hypoxic 
environments.   
 
In support of the present findings, sources of endogenous or exogenous ROS are known 
to drive autophagy and/or apoptosis in prostate cancer cells by various stimuli-
dependent mechanisms (Chung et al., 2013, Kim et al., 2013, Gundala et al., 2014, Shin 
et al., 2013, Zhou et al., 2015). Of particular interest, the literature reveals that these 
ROS-responsive mechanisms appear to cross-talk, converging on regulation of HIF-1α. 
Aside from inhibiting irradiation-induced free radical DNA damage, tumour hypoxia 
enhances HIF-1α levels to promote survival and adaptation, leading to further 
radioresistance. Consistent with previous findings (Dai et al., 2011) in these prostate 
cancer cell lines, acute hypoxia was found to promote accumulation of HIF-1α, cell 
proliferation and radioresistance; all of which were reduced in the presence of prazosin 
presumably via ROS-generating actions.  In androgen-responsive prostate cancer cells, 
ROS-mediated apoptosis was recently reported to occur via the AKT/pVHL signalling 
pathway (Chetram et al., 2013). The authors concluded that ROS increased AKT 
activity through catalytic inhibition of PTEN (negative regulator of AKT), resulting in 
direct activation of pVHL and concomitant decrease in HIF-1α and apoptosis. 
Furthermore, this effect was demonstrated to be dependent on pVHL activity since 
genetic knockdown rescued HIF-1α and protected prostate cancer cells from apoptosis. 
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However, whether this pVHL-mediated apoptotic effect was dependant on changes in 
HIF-1α levels or other target substrates is unknown. Interestingly, these prior findings 
were mirrored throughout this thesis, where the ROS-inducing-prazosin increased AKT 
activation in androgen-responsive LNCaP cells, but not AR-negative PC-3 cells, and 
apoptotic cell death. While AKT activity is associated with down-regulation of 
autophagy, ROS also act to promote autophagy through activation of AMPK and 
subsequent inhibition of mTOR by depletion of energy stores or via the DNA-damage 
response molecule, ataxia telangiectasia mutated (ATM) (Choi et al., 2001, Alexander 
et al., 2010a, Alexander et al., 2010b, Kongara and Karantza, 2012). In its active state, 
mTOR promotes hypoxia-independent increase of HIF-1α protein translation in a 
separate signalling cascade to autophagy inhibition. Therefore, inhibition of mTOR by 
ROS/AMPK activity would effectively suppress HIF-1α accumulation and survival 
signalling. It was previously demonstrated in the literature and in Chapter 4 of this 
thesis, that prazosin and doxazosin inhibit mTOR signalling and subsequent HIF-1α 
expression in normoxic conditions (Park et al., 2014a, Yang et al., 2011a). In support of 
the proposed mTOR-dependent hypoxia radiosensitisation by prazosin, a novel inhibitor 
of PI3K/mTOR/p70S6K signalling was revealed to potentiate irradiation induced 
cytotoxicity of normoxic or hypoxic prostate cancer PC-3 cells in vitro and xenograft 
tumours in vivo (Potiron et al., 2013).  Furthermore, the hypoxia-selective 
radiosensitising actions of prazosin in PC-3 cells were found to have markers of both 
autophagy and apoptosis, which may be a characteristic of functionally mutant p53 
status. A similar effect was reported in the AR-independent and p53 mutant or null 
prostate cancer cell lines DU145 and PC-3, respectively, where docosahexaenoic acid 
(omega-3 polyunsaturated fatty acid) stimulated mitochondrial ROS production, 
mTOR-inhibition and subsequent autophagy and apoptosis induction (Shin et al., 2013). 
While further investigation is necessary to ascertain the precise molecular mechanisms 
underlying the hypoxia-selective radiosensitisation effect of prazosin, the following 
pathway is proposed. Prazosin-mediated ROS formation may act to inhibit translation of 
HIF-1α by ROS-dependent activation of AMPK and downregulation of the 
mTOR/p70S6K/S6 mRNA translation signalling axis. In a parallel and possibly cell 
type-dependent mechanism, prazosin-induced ROS may also promote the activation of 
AKT, resulting in pVHL-mediated degradation of existing HIF-1α, further contributing 
to the reduction of intracellular HIF-1α.  
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While the present study does not provide a complete evaluation of the radiosensitising 
effect and underlying mechanisms of prazosin, it provides a platform for further 
investigation. Of particular interest is whether other commonly used α1-adrenoceptor 
antagonists, such as alfuzosin, terazosin and doxazosin possess a similar hypoxia-
selective radiosensitising effect.  It was previously reported that simultaneous 
irradiation and doxazosin or terazosin exposure did not radiosensitise prostate cancer 
cells 24 h after irradiation (Cuellar et al., 2002).  However, the authors report a 
schedule-dependent effect suggesting that doxazosin or terazosin prior to or after 
irradiation may enhance irradiation-induced cytotoxicity. These conflicting findings 
may be attributed to differences in irradiation dosing (3 Gy vs. 6.2).  However, the lack 
of appreciable radiosensitisation is expected, since radiosensisation by prazosin was 
found to be both hypoxia-and time-dependent. Preliminary experimentation suggests 
doxazosin may have similar hypoxia-selective effects (Figure 5.27), which may 
translate into radiosensitising actions upon further testing.  
 
 
 
Figure)5.27.)Potential)hypoxiaFselective)effect)of)doxazosin)(0F100)µM,)2.5)h)) in)PCF
3)cells.)Resazurin) reduction)was)used)as)an) indicator)of)cell) survival) following)24)h)
drugFfree)recovery.)Data)are)expressed)as)percent)of)untreated)normoxic)or)hypoxic)
control)(mean)±)SEM)for)normoxia)[n=4],)mean)for)hypoxia)[n=1]) )
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SUMMARY)
 
The present study demonstrates that prazosin, but not tamsulosin, radiosensitises 
hypoxic prostate cancer cells.  This effect is likely to occur via ROS-mediated inhibition 
of mTOR signalling and subsequently downstream suppression of HIF-1α expression 
and activity. Acute prazosin treatment stimulated autophagy and apoptosis in hypoxic 
and irradiated cells.  While there was no correlation between autophagy and LNCaP 
cytotoxicity, autophagy may act synergistically with prazosin-induced down-regulation 
of HIF-1α to restore PC-3 sensitivity to irradiation.  
  
 206 
 
  
 207 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER$6:$
FUTURE$DIRECTIONS$AND$PRELIMINARY$
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6.1$ BACKGROUND$
 
This exploratory chapter attempts to further uncover novel uses for doxazosin and 
prazosin as urogenital anticancer therapies.  The scope of the present experimental 
chapter assesses (1) the effects of these drugs on prostate stromal cells and whether 
these drugs alter stromal-cancer paracrine signalling; (2) investigate the potential 
synergism between prazosin and chemotherapeutic drugs in prostate cancer; and (3) the 
potential use of these drugs as intravesical treatment for non-invasive bladder cancer.   
)
HUMAN)PROSTATE)STROMA)AND)ALPHA1FADR)ANTAGONISTS)
Paracrine signalling between cancer-associated fibroblasts and prostate cancer cells is 
known to be reciprocal where the surrounding fibroblasts secrete growth factors 
(fibroblast growth factors) aiding in tumour establishment. This consequently drives a 
positive feedback loop where the tumour itself secretes factors, such as interleukin-6 
and TGF-β, to trigger induce further growth factor release from the reactive stroma 
(Gandellini et al., 2015, Giannoni et al., 2010).  
 
Prior to the revelation of the anticancer actions of doxazosin, prazosin and terazosin, 
these drugs were found to have a novel apoptotic effect on stromal cells in animal and 
human studies (Kyprianou, 2000, Turkeri et al., 2001), which was suggested to account 
for their sustained therapeutic effect for BPH clinically (Kyprianou et al., 2000). 
However, these findings preceded the current understanding of the significance of 
stromal-neoplastic interactions; and until recently, the relationship between antagonist-
mediated stromal cytotoxicity and the consequences for prostate cancer development 
was unknown.    
 
There have been several reports of alteration of stromal behaviour in response to α1-
ADR antagonist treatment.  Doxazosin and terazosin (25 mg/ day) were reported to alter 
the expression of the fibrosis-related gene and reduce basic fibroblast growth factor in 
the prostates of Wistar rats (Delella et al., 2012, Mitropoulos et al., 2009). Interestingly, 
one study demonstrated that the cytotoxic non-quinazoline naftopidil, but not silodosin 
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or tamsulosin, was effective in disrupting the stromal-cancer interactions of murine 
xenograft tumours (Hori et al., 2011). More specifically, the authors found that 
treatment with naftopidil reduced both stromal cell proliferation and secretion of the 
tumourigenic factor IL-6. It is known that these soluble factors (fibroblast growth 
factors and IL-6) promote the proliferation, metastasis and apoptosis-resistance of 
prostate tumours (Kwabi-Addo et al., 2004, Giannoni et al., 2010). While the relevance 
of these findings to the clinical anticancer effect of α1-ADR antagonists are less-direct, 
it can be hypothosised that α1-ADR antagonist-mediated suppression of secreted of 
fibroblast growth factors, either by indirect gene regulation or reduced number of 
stromal cells, may contribute to clinical anticancer findings.   
 
Despite the clinical significance, the relative cytotoxic potencies of α1-ADR antagonists 
on prostate stromal cells have largely been neglected. Furthermore, whether these drugs 
are able to alter paracrine signalling between stromal and prostate cancer cells was 
previously unknown.  
 
 
 !
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CHEMOTHERAPY)AND)Α1FADR)ANTAGONISTS)
The radiosensitising actions of prazosin on hypoxic prostate cancer cells shown in 
Chapter 5 raised the question whether prazosin may also enhance the cytotoxic potential 
of chemotherapies. For many cancers, chemotherapeutic agents are frequently combined 
with other drugs to maximize response and improve survival outcomes. Particularly in 
prostate cancer, docetaxel-based combinations are of significant interest to combat the 
resilient nature of castration-resistant prostate cancer (CRPC). Clinically investigated 
docetaxel-combinations such as anti-angiogenesis, anti-apoptotic inhibitors, and other 
cytotoxic agents were met with mixed results (Galsky and Vogelzang, 2010). Of 
particular interest, quinazoline-based doxazosin and prazosin are reported to have 
similar anti-cancer mechanisms as the aforementioned cytotoxic drugs used in 
combination with docetaxel including inhibition of EGFR (Hui et al., 2008) and Src 
(Isgor and Isgor, 2012), suppressing tumour angiogenesis (Keledjian et al., 2001), 
downregulating pro-survival Bcl-2 family proteins, and increasing pro-apoptotic protein 
expression (Chiang et al., 2005, Lin et al., 2007, Garrison and Kyprianou, 2006). 
Moreover, these drugs make attractive anti-cancer agents as they are safely used in 
clinical settings and have already been shown to have clinical anti-cancer activity 
(Harris et al., 2007, Keledjian et al., 2001, Tahmatzopoulos et al., 2005). While 
tolerable doses of doxazosin or prazosin would have little efficacy against advance 
stage prostate cancer, in combination with chemotherapeutics like docetaxel, these 
drugs may enhance prostate cancer chemosensitivity.  
 
To date, little is known about the anticancer activity of quinazoline-based doxazosin or 
prazosin in combination with chemotherapeutics against cancer. One study conducted 
by Cal and colleagues (2000) evaluated doxazosin in combination with the cytotoxic 
drugs doxorubicin, etoposide, or paclitaxel for synergistic activity in prostate cancer 
cells. Doxazosin plus doxorubicin or etoposide resulted in synergistic effect. In contrast, 
doxazosin-paclitaxel treatment produced an antagonistic effect, reducing the cytotoxic 
potential of either drug alone (Cal et al., 2000). However, a growing body of evidence 
indicates that synergistic activity may occur via schedule-dependent mechanisms. 
Studies in other cell lines have demonstrated schedule-dependent anti-proliferative 
effects of the EGFR inhibitors, erlotinib and gefitinib, in combination with 
chemotherapeutics, including docetaxel (Morelli et al., 2005, Xu et al., 2003a) (Kassouf 
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et al., 2006, Mahaffey et al., 2007). Of particular interest, the quinazoline structure is 
common to geftinib and erlotonib, as well as, doxazosin, prazosin and terazosin (as 
reviewed in Chapter 4 and Figure 4.1). Likewise, it was previously reported that 
doxazosin suppressed EGFR/ERK signaling activity in breast cancer cells to a similar 
extent as geftinib and erlotinib(Hui et al., 2008). These findings pointed to novel EGFR 
inhibiting properties of quinazoline-based doxazosin. Studies evaluating the cytotoxic 
profile of chemotherapeutics in combination with EGFR inhibitors demonstrated greater 
synergism when the chemotherapeutic agent was administered first, followed by the 
EGFR inhibitor (Xu et al., 2003a, Morelli et al., 2005, Kassouf et al., 2006).  
 
The effects of doxazosin, prazosin or terazosin in combination with chemotherapeutic 
agents are only speculative and require investigation. Therefore, the present study aimed 
to identify whether prazosin may have novel synergistic effects in combination with 
chemotherapeutic agents, such a docetaxel, in prostate cancer cells lines.  
)
 !
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BLADDER)CANCER)AND)Α1FADR)ANTAGONISTS)
Non-muscle invasive (organ-confined) bladder cancer accounts for nearly 70-80% of 
diagnosed urothelial tumours (Hendricksen and Witjes, 2007, Shelley et al., 2011), 
which is most commonly treated by a combination of transuretheral tumour resection 
(TURBT) and adjunct immune- or chemo-intravesical therapy to delay or prevent 
recurrence in moderate- to high-risk patients. In contrast to traditional systemic 
delivery, intravesical therapy involves administration of high concentrations of 
anticancer agents directly into the bladder, coming in direct contact with the bladder 
urothelium to target residual tumour cells (Figure 6.1) (Babjuk et al., 2013).  
 
 
 
Figure)6.1.)Illustration)of)intravesical)therapy.)Image)provided)courtesy)of)Cancer)
Research)UK)(2015).)
 
  
 214 
In current practice intravesical therapy is carried out using Bacillus Calmette-Guerin 
strains or the chemotherapeutic alkylating agents, gemcitabine and mitomycin C. 
However, due to frequent disease recurrence and maintenance therapies (Avritscher et 
al., 2006), bladder cancer has the highest lifetime cost per patient compared to all 
cancers in the Westernised world (Sievert et al., 2009). Specifically, it is estimated that 
45% of patients will develop disease recurrence following initial treatment within a 12-
month window. It can be deduced that this high economic burden can be addressed in 
part by the reduction of intravesical drug costs or by improving treatment efficacy, 
thereby minimising treatment failure and subsequent salvage therapies.  
 
Similar to prostate cancer, therapeutic concentrations of α1-ADR antagonists reportedly 
reduce the relative risk of developing bladder, increase apoptosis and decrease tumour 
vascularity of bladder tumours compared to unexposed men (Martin et al., 2008, 
Tahmatzopoulos et al., 2005). While only a handful, in vitro studies mirror findings in 
prostate cancer models showing comparable toxicity of supratherapeutic concentrations 
of these drugs in bladder cancer cell lines (Siddiqui et al., 2005, Gotoh et al., 2012) 
While supratherapeutic doses are unlikely to be tolerable systemically, high 
concentrations of these drugs might be safely used intravesically. 
 
To date, few studies have investigated the cytotoxic effect of α1-ADR antagonists on 
bladder cancer cells.  Furthermore, there are no published studies comparing the 
cytotoxic potency of these drugs and chemotherapeutic agents. The findings of this 
preliminary study will provide important insights for the potential use of 
doxazosin/prazosin as a novel intravesical therapy for the treatment of superficial 
bladder cancer. 
  
 215 
6.2$ AIMS$
 
The overall aim of this study to was to investigate additional novel uses of doxazosin 
and/or prazosin for in the treatment of urogenital cancers.    
 
The specific aims were to: 
1.' Investigate the relative cytotoxic potencies of various α1-ADR antagonists in 
human prostate WPMY-1 stromal cells 
 
2.' Examine the effects of indirect 2-D co-culture consisting of prostate stromal 
WPMY-1 and prostate cancer LNCaP and PC-3 cells, and to investigate whether 
the cytotoxic effects of prazosin on prostate cancer cells were altered by the 
presence of stromal cells. 
  
3.' Determine the relative sensitivity of prostate cancer cells to docetaxel and 
cabazitaxel, and investigate whether prazosin has synergistic actions when 
combined with docetaxel in a cellular model of castrate-resistant disease. 
 
4.' Examine the cytotoxicity of doxazosin and mitomycin C and compare the 
relative cytotoxic potencies of these drugs in bladder cancer T24 cells. 
 !
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6.3$ MATERIALS$AND$METHODS$
 
AIM)1:))CYTOTOXIC)POTENCY)OF)Α1FADR)ANTAGONISTS)IN)PROSTATE)
STROMAL)CELLS)
 
Human prostate stromal WPMY-1 cells were grown and maintained as previously 
described in Chapter 2 (General Methods).  Stromal cells were seeded at 3.0x103 trypan 
blue-excluding cells/ well in a 96-well plate and allowed to attach for 24 h. Culture 
medium above the cells was replaced with fresh medium containing either alfuzosin, 
doxazosin, prazosin, silodosin or tamsulosin (0-100 µM), and incubated for 24 – 72 h. 
Following appropriate treatment time, cell survival was determined using resazurin 
reduction as described in Chapter 2 (General Methods). 
'
 !
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AIM)2:)PRAZOSIN)TREATMENT)OF)PROSTATE)STROMALFCANCER)COFCULTURE)
 
Use of Indirect 2D co-culture model using Corning® Transwell ® inserts has previously 
been used to investigate the effects of paracrine signalling between stromal and prostate 
cancer cells (Li et al., 2011). In this preliminary experiment, Corning® Transwell® 0.4 
µm pore polyester membrane (6.5 mm) inserts were obtained from Sigma-Aldrich (Cat. 
No. CLS3470) and used as described below and in Figure 6.2. All solutions and drugs 
used were described previously in Chapter 2. 
 
PLATE PREPARATION AND SEEDING OF CELLS 
Prior to use, Corning® Transwell® inserts were incubated with 200 µL of sterile 
complete culture medium overnight at 37˚C to equilibrate the membrane. WPMY-1 
cells were seeded on the insert membrane at a density of 1.7x104 trypan blue-excluding 
cells per insert. WPMY-1 cells were grown to confluence by incubating at 37˚C for 72 
h. Two-days before the experiment, prostate cancer LNCaP cells were seeded in a 24-
well plate (separate from WPMY-1) at a density of 3.0x105 trypan blue-excluding cells 
per well and allowed to grow undisturbed for 48 h. 
)
Figure)6.2.)Illustration)of)Transwell®)2D)coFculture)system)used.)
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TREATMENT OF CO-CULTURE 
On the day of the experiment, Inserts containing confluent WPMY-1 cells were placed 
in wells containing LNCaP cells. Empty cell free inserts above LNCaP cells were 
included as negative controls. Spent medium was removed and replaced with fresh 
medium containing either vehicle or prazosin (1-30 µM) in both the upper (100 µL) and 
lower chambers (500 µL) of the Transwell® system. Cells were treated for 72 h and 
changes in cell survival or proliferation were determined by resazurin reduction assay.  
 
 !
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AIM)3:)PRAZOSIN)AND)CHEMOTHERAPY)COMBINATION)TREATMENT))
RELATIVE'CYTOTOXIC'POTENCY'
Prostate cancer cells were grown and maintained as previously described in Chapter 2 
(General Methods). PC-3 and LNCaP cells were seeded at 3.0x103 and 5.0x103 trypan 
blue-excluding cells/ well in a 96-well plate and allowed to adhere for 24 or 48 hours, 
respectively. Following appropriate incubation time, medium above the cells was 
replaced with fresh complete culture medium containing either docetaxel or cabazitaxel 
(0-1 µM) for 24 – 72 h. 
 
COMBINATION'TREATMENT'
For combination treatment of prazosin with docetaxel, cells were seeded as described 
above. Following appropriate incubation for cell attachment, culture medium above the 
cells was replaced with medium containing either single agent prazosin or docetaxel 
according to the schedules (A-C) shown in Figure 6.3. Concentrations used for 
combination treatments were based on pre-determined time- and cell type-dependent 
IC50 values. Each drug was used at their respective IC50 (nM) x 1, 0.5 and 0.25 for all 
treatment durations and will be indicated where appropriate throughout the Results 
section. Following appropriate treatment time, cell survival was determined using 
resazurin reduction as previously outlined in Chapter 2 (General Methods).  
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Figure)6.3.)Prazosin)and)chemotherapeutic)agent)(docetaxel))combination)
treatment)schedules.) )
(h)'
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AIM)4:)COMPARISON)OF)DOXAZOSIN)AND)MMC)TOXICITY)IN)BLADDER)
CANCER))
Mitomycin C (MMC) is a DNA cross-linking (alkylating) agent isolated from 
Streptomyces caespitosus bacterial strain (Figure 6.4). In clinical settings, MMC is 
instilled intravesically at a concentration of 40mg per 20 ml of sterile water (5.98 mM) 
and is retained in the bladder for 2 hours (Au et al., 2001). For this experiment, MMC 
was obtained from Sigma-Aldrich. Stock solutions were made in DMSO and stored at -
20˚C protected from light. 
 
 
Figure)6.4.)Chemical)structure)of)mitomycin)C.)
 
CELLS'AND'DRUG'TREATMENT'
Human bladder cancer T24 cells were used to investigate the effects of doxazosin on an 
in vitro model of bladder cancer, as well as compare the relative cytotoxicity of 
doxazosin to the intravesical chemotherapeutic MMC. The T24 cell line is a stable 
model of a grade 3 transitional cell (urothelial) carcinoma (Bubenik et al., 1973, Kato et 
al., 1978) and has been used previously to examine the cell-based effects of intravesical 
treatment (Kang et al., 2013, Kang et al., 2015). 
  
To compare the cytotoxic potency of MMC to that of doxazosin, bladder T24 cancer 
cells were seeded at 1.0X104 trypan blue-excluding cells/well and incubated overnight 
(>24 h) for attachment. Culture medium above the cells was replaced with fresh 
complete medium containing either doxazosin (0-100 µM) or mitomycin C (MMC; 0-
10 mM) for either 2 h (clinical duration) or 24 – 72 h continuous treatment. To mimic 
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intravesical treatment, cells that received 2 h treatment were washed with PBS and 
incubated for a further 24 – 72 h in drug-free complete growth medium at 37ºC. 
Following appropriate incubation, cell survival was determined using resazurin 
reduction (Chapter 2, General Methods).  
 
STATISTICAL)ANALYSIS)
Data were analysed and graphs were drawn using GraphPad Prism (ver. 6 for Mac 
OSX). Where appropriate, the relative IC50 value for each drug was determined for the 
concentration resulting in 50% of maximal reduction in cell survival (resazurin 
reduction) and IC50 values were obtained determined using non-linear regression. 
Statistical significance was determined using either one-way or two-way ANOVA as 
appropriate. Specific post hoc tests are indicated throughout the relevant portions of the 
Results section.  
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6.4$ $RESULTS$
)
AIM)1:)RELATIVE)CYTOTOXIC)POTENCY)OF)Α1FADR)ANTAGONISTS)ON)
WPMYF1)CELLS)
 
To investigate whether α1-ADR antagonists also have cytotoxic effects on human 
prostate stromal cells, WPMY-1 cells were treated continuously for 24-72 hours with 
alfuzosin, doxazosin, prazosin, silodosin, tamsuolsin or terazosin and cell survival was 
determined by resazurin reduction. As shown in Figure 6.5, all of the investigated 
antagonists were cytotoxic over the concentration range tested on WPMY-1 cells. 
Overall, these cytotoxic effects were more pronounced in WPMY-1 cells compared to 
prostate cancer LNCaP or PC-3 cells (Chapter 3).  Similar to findings in prostate cancer 
cells, 100 µM doxazosin and prazosin significantly reduced cell survival at all time 
points, with 100 µM completely abolishing cell survival at 72 h (P<0.001). In contrast 
to previous findings in prostate cancer cell lines (Chapter 3), alfuzosin and tamsulosin, 
were able to significantly reduce prostate stromal cell survival by 71.2% (± 6.62) and 
79.7% (± 4.52) at 72 h, respectively (P<0.001 for both vs. untreated control) (Figure 
6.5 C). Unlike findings in prostate cancer cells, terazosin was significantly less 
cytotoxic than alfuzosin and tamsulsoin at all time points, except for alfuzosin at 48 h, 
where these drugs demonstrated a similar reduction in cell survival (P=0.064).  
Interestingly, silodosin (10-30 µM) had a time-dependent hormetic effect on WPMY-1 
cells, with 30 µM enhancing cell survival by approximately 6 % (± 3.5), 17.5% (± 8.9) 
and 21.5 % (±14.8) at 24, 48 and 72 h respectively (P=0.015) for 48 and 72 h). 
However, 100 µM silodosin also modestly, yet significantly, decreased cell survival 
after 72 h treatment (P=0.009).  
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.  
Figure) 6.5.) Human) prostate) stromal) WPMYF1) cells) were) treated) with) alfuzosin,)
doxazosin,)prazosin,)silodosin,)tamsulosin)or)terazosin)for)24)(A),)48)(B))or)72)h)(C).)
Cell) survival) was) determined) by) resazurin) reduction) assay.) Data) are) expressed) as)
percentage)of)untreated)control)(mean)±)SEM,)n≥4).)
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The relative IC50 values were only obtained for doxazosin, prazosin, tamsulosin 24-72 
h) and alfuzosin (72 h) as determination of silodosin and terazosin IC50 values resulted 
in ambiguous results due to incomplete dose response curve. As shown in Table 6.1 & 
Figure 6.6, all three drugs were statistically equipotent at 24 h, however doxazosin and 
prazosin were more potent than tamsulosin at 48 and 72 h, respectively.  At 24 hours, 
the relative cytotoxic potency was found to be: doxazosin = prazosin = tamsulosin > 
alfuzosin > terazosin > silodosin. The potency order was the same at the other time 
points, except doxazosin was more potent than both tamsulosin and prazosin at 48 h, 
and doxazosin > prazosin > tamsulosin at 72 h. 
 
 
Table 6.1 Relative IC50 values (95% CI) (µM) 
 24 h 48 h 72 h 
Alfuzosin Ambiguous Ambiguous 69.5 (59.0-81.8) 
Doxazosin 70.0 (38.0 – 129) 
10.2 
(7.39 – 14.2) 
11.3 
(7.82 – 16.3) 
Prazosin 36.6 (33.1 – 40.6) 
24.4 
(16.1 – 36.9) 
19.7 
(11.7-33.3) 
Silodosin Ambiguous Ambiguous Ambiguous 
Tamsulosin 100.8 (33.6 – 303) 
61.3 
(50.1 – 74.9) 
58.1 
(51.7 – 65.2) 
Terazosin Ambiguous Ambiguous Ambiguous 
  
 226 
 
Figure) 6.6.) Comparison) of) WPMYF1) pIC50) values) of) tamsulosin,) doxazosin) and)
prazosin)at)24) (A),)48) (B))and)72)h) (C).)pIC50) values)were)determined)by)nonFlinear)
regression) and) data) are) represented) at) the)mean) ±) SEM) (n≥4).) Statistical) analysis)
was) determined) using) oneFway) ANOVA) with) Tukey’s) post) hoc) test.) +P<0.05,)
++P<0.01) and) +++P<0.001) vs.) tamsulosin.) ##) P<0.01) vs.) prazosin) and) ^^^P<0.001) vs.)
doxazosin.  
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AIM)2:)EFFECT)OF)PRAZOSIN)ON)WPMYF1)AND)LNCAP)COFCULTURES)
Next, it was investigated whether indirect co-culture of WPMY-1 with AR-positive 
LNCaP prostate cancer cells would alter the proliferation of prostate cancer cells and/or 
cell survival in response to prazosin treatment. To investigate this, cells were indirectly 
co-cultured using Transwell® tissue culture inserts, and were treated for 72 h with 
prazosin (0 – 30 µM). Resazurin reduction was used as an index of cell survival. As 
shown in Figure 6.7, co-culture with WPMY-1 modestly enhanced untreated LNCaP 
cell survival by approximately 12% at 72 h.  In this experimental model, there was no 
significant change in LNCaP sensitivity to prazosin in the presence of stromal co-
culture (Figure 6.7). While further investigation may be necessary, these preliminary 
findings suggest that prostate-stromal paracrine signalling does not alter prazosin-
induced cytotoxicity of AR-positive LNCaP cells. 
 
 
 
)
)
Figure) 6.7.) Comparison) of) cell) survival) following) 72) h) prazosin) treatment) between)
LNCaP)monoFculture)and)coFculture)with)human)stromal)WPMYF1)cells.)Cell)survival)
was) determined) using) the) resazurin) reduction) assay.) Data) are) expressed) as)
percentage)of)LNCaP)untreated)control)(mean)±)SEM,)n=3).))
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AIM)3:)EFFECT)OF)PRAZOSIN)IN)COMBINATION)WITH)DOCETAXEL)
 
CYTOTOXIC'POTENCY'OF'DOCETAXEL'AND'CABAZITAXEL'TREATMENT'
Docetaxel is the current standard of care therapy for castrate-resistant prostate cancers. 
The new chemically similar taxane-based agent, cabazitaxel is currently used as a 
salvage therapy following docetaxel treatment failure. To determine the relative 
cytotoxic potency of docetaxel and cabazitaxel, PC-3 and LNCaP prostate cancer cells 
were treated continuously for 24 – 72 h. Cell survival was then determined using 
resazurin reduction. Overall, these drugs reduced PC-3 and LNCaP cell survival in a 
concentration- and time-dependent fashion (Figure 6.8).  However, in both cell lines, 
cytotoxicity to docetaxel and cabazitaxel plateaued at approximately 10 nM at all time 
points, except for LNCaP where concentrations greater than 0.1 nM had no further 
effect at 72 h.  The relative IC50 values for docetaxel and cabazitaxel are shown in 
Tables 6.2 and 6.3 for PC-3 and LNCaP cells, respectively. Under the conditions tested, 
the cytotoxic potencies of these drugs were similar. Therefore, the first-line 
chemotherapeutic docetaxel was used for preliminary investigations of synergistic 
activity in combination with prazosin. 
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Figure) 6.8.) PCF3) (left)) and) LNCaP) (right)) cell) survival) following) 24,) 48) or) 72) h)
continuous) treatment) with) cabazitaxel) or) docetaxel) (0F1µM).) The) resazurin)
reduction) assay) was) used) as) an) index) of) cell) survival.) Data) are) represented) as)
percentage)of)untreated)control)(mean)±)SEM,)n=6).) )
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Table 6.2 PC-3 relative IC50 values (95% CI) 
 24 h 48 h 72 h 
Docetaxel 
(nM) 
2.40 
(1.7 – 3.4) 
0.97 
(13.0 – 16.6) 
0.97 
(9.8 – 21.3) 
Cabazitaxel 
(nM) 
1.4 
(0.6 – 3.3) 
0.60 
(0.37 – 0.97) 
0.46 
(0.27 – 0.79) 
 
 
Table 6.3 LNCaP relative IC50 values (95% CI) 
 24 h 48 h 72 h 
Docetaxel 
(nM) 
1.03 
(0.2 – 5.1) 
0.07 
(0.01 – 0.53) 
0.02 
(0.01 – 0.03) 
Cabazitaxel 
(nM) 
0.11 
(0.6 – 3.3) 
0.023 
(0.37 – 0.97) 
0.003 
(0.002 – 0.005) 
 
 !
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PRAZOSIN'AND'DOCETAXEL'COMBINATION'TREATMENT'
Next, it was investigated whether prazosin may have a synergistic effect when 
combined with docetaxel. Since chemotherapy regimens are classically reserved for 
castrate-resistant disease, AR-negative PC-3 cells were used for clinical relevance. 
Prostate cancer PC-3 cells were treated according to the treatment schedule shown 
previously in Figure 6.3 (Methods section). Briefly, cells were exposed to prazosin 
before, after or concurrently with docetaxel at the concentrations shown in Table 6.4. 
Following appropriate treatment time, cell survival was determined using resazurin 
reduction assay.  
 
As shown in Figure 6.9, none of the investigated schedules (A, B and C) were found to 
enhance cytotoxicity in PC-3 cells to levels that were significantly greater than single-
agent treatment with either prazosin or docetaxel.  
 
 
 
Table)6.4.)Concentrations)used)according)to)treatment)schedule)
Schedule 
Prazosin 
(µM)* 
Docetaxel 
(nM) 
A 
14, 28, 55 0.2, 0.48, 0.97 
B 
C 5, 11, 21 0.2, 0.48, 0.97 
Schedules: [A] Prazosin 24 h, docetaxel 48 h; [B] 
chemotherapy 48 h, prazosin 24 h; [C] prazosin + 
chemotherapy 72 h. *Values were rounded to nearest whole 
number.  
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Figure) 6.9.) Human) ARFnegative) PCF3) cell) survival) following) treatment) with) either)
singleFagent) prazosin) or) docetaxel) (0,) 0.25,) 0.5,) 1) X) IC50)) or) in) combination) in) a)
schedule) dependent) manner.) Schedules) were) (A)) 24) h) prazosin) followed) by) 48) h)
docetaxel;) (B))48)h)docetaxel) followed)by)24)h)prazosin;)and) (C))72)h)simultaneous)
prazosin) and) docetaxel) combination.) Cell) survival) was) determined) by) resazurin)
reduction.) Data) are) expressed) as) percentage) of) untreated) control) (mean) ±) SEM,)
n"3).))
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AIM)4.)COMPARE)CYTOTOXIC)POTENCIES)OF)MMC)AND)DOXAZOSIN)IN)T24)
BLADDER)CANCER)CELLS)
 
CONTINUOUS'TREATMENT'
To compare the relative cytotoxic potencies of doxazosin and the clinically used bladder 
cancer chemotherapeutic MMC, T24 cells were treated with doxazosin (0-100 µM) or 
MMC (0-10 mM) for 24, 48 or 72 h. Cell survival was determined at each time point 
using the resazurin reduction assay. As demonstrated in Figure 6.10, both MMC and 
doxazosin induced time-dependent reduction in T24 cell survival. However, maximal 
effect was observed only after 48 h continuous exposure in doxazosin treated cells.  At 
72 h, concentration greater than 0.1 mM and 1 µM of MMC and doxazosin, 
respectively, were capable of significantly reducing T24 cell survival compared to 
untreated control (P<0.001). Furthermore, doxazosin was found to be more potent than 
MMC at all time points investigated (Figure 6.11). Relative IC50 values for each drug 
and time point are detailed in Table 6.5.  For both MMC and doxazosin, comparisons of 
the time point cytotoxic potencies was significantly different between 24 h vs. 48 h or 
72 h (P<0.01 for all).  However, there was no significant difference in potency between 
48 vs. 72 h for either drug. In comparing the IC50 values, doxazosin was found to be 
between 7- and 36-times more potent than MMC at all time points (P<0.001).  
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Figure) 6.10.) TimeFdependent) reduction) of) T24) cell) survival) following) MMC) or)
doxazosin) treatment.) Resazurin) reduction) assay) was) used) as) an) index) of) cell)
survival.) Data) are) expressed) as) percentage) of) untreated) vehicle) control) (mean) ±)
SEM,)n=6).)
!
)
Figure)6.11.)Comparison)of)pIC50)values)between)MMC)and)doxazosin) following)24,)
48)and)72)h)treatment)of)T24)bladder)cancer)cells.)pIC50)values)were)determined)by)
nonFlinear) regression) and) were) represented) as) the) mean) ±) SEM) (n=6).) Statistical)
significance) was) determined) using) a) twoFway) ANOVA) with) Tukey’s) post) hoc) test.)
###)P<0.001)vs.)MMC.)
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Table)6.5.)IC50)values)for)continuous)MMC)or)doxazosin)treatment)in)T24)bladder)
cancer)cells)
 
 Relative IC50 values (95% CI) (µM) 
Drug 24 h 48 h 72 h 
MMC 1402 
(672.0 – 2925) 
223 
(148 – 334) 
109 
(74.2 – 159) 
Doxazosin 38.1 
(28.5-50.9) 
14.6 
(13.0 – 16.6) 
14.5 
(9.8 – 21.3) 
)
)
 !
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CLINICAL'DURATION'TREATMENT'AND'DRUG8FREE'RECOVERY'
Intravesical therapy is unique to bladder cancer, where high concentrations of cytotoxic 
agents are instilled into the bladder. This therapy is advantageous in the sense that it 
provides means for direct targeting of the tumour with doses that would be intolerable 
systemically. To mimic intravesical treatment, cells were treated acutely (2 h) with 
doxazosin or MMC followed by 24 – 72 h drug free recovery. Cell survival was then 
determined by the resazurin reduction assay.  As shown in Figure 6.12, both doxazosin 
(100 µM) and MMC (1-10 mM) were effective in reducing T24 survival following 2 h 
treatment and drug-free recovery (P<0.05-0.001 for all time points). Interpolation of the 
clinically relevant MMC dose (6 mM) following 72 h drug-free recovery revealed an 
approximate 85% (95% CI = 78.4-90.3) reduction in T24 survival, which was slightly 
greater than doxazosin at one- one-sixtieth of the concentration (100 µM, 58% ±[7.3]).   
Table 6.6 details the relative IC50 values for doxazosin and MMC at all time points.  
However, the IC50 values between doxazosin and MMC could not be compared 
statistically as the dose-response for doxazosin curve was incomplete, resulting in 
ambiguous values. Therefore, T24 cell survival was compared between MMC and 
doxazosin treatment at 100 µM.  This concentration was chosen, because T24 cells 
displayed cytotoxicity at 100 µM for both drugs (Figure 6.13). At 100 µM, doxazosin 
was significantly superior to MMC in reducing cell survival at all time points 
(P<0.001). Specifically, doxazosin (100 µM, 2 h) was at least twice as toxic to T24 
survival compared to MMC (100 µM, 2 h) treatment following 24 – 72 h drug-free 
recovery. These novel findings indicated that doxazosin may be more effective than the 
current intravesical chemotherapy agent mitomycin C. 
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Figure) 6.12.) T24) cell) survival) following) 2) h) treatment) with) MMC) (0F10) mM)) or)
doxazosin)(0F100)µM))followed)by)24)–)72)h)drugFfree)recovery.)Resazurin)reduction)
assay) was) used) as) an) index) of) cell) survival.) Data) are) expressed) as) percent) of)
untreated)control)(mean)±)SEM,)n=6).)
 
 
)
)
Table)6.6.)IC50)values)for)2)h)treatment)with)MMC)or)doxazosin)and)24)–)72)h)
recovery)in)T24)bladder)cancer)cells)
)
 Relative IC50 values (95% CI) (µM) 
Drug  24 h 48 h 72 h 
MMC 4054 (293.5 – 56000) 
2341 
(725 – 7557) 
2130 
(1310 – 33760) 
Doxazosin > 100 Ambiguous 
> 100 
Ambiguous 
> 100 
Ambiguous 
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)
Figure)6.13.)Comparison)of)T24) cell) survival) after)2)h) treatment)with)100)µM$MMC)
or)doxazosin)followed)by)24,)48)or)72)h)drugFfree)recovery.)Resazurin)reduction)was)
used) as) an) index) of) cell) survival.) Data) are) expressed) as) percentage) of) untreated)
control)(mean)±)SEM,)n=6).)Statistical)significance)was)determined)using)a)oneFway)
ANOVA)with)Tukey’s)post)hoc)test.)###)P<0.001)vs.)MMC.)
  
24 48 72
0
50
100
150
Drug-free recovery time (h)
C
el
l S
ur
vi
va
l
(%
 o
f u
nt
re
at
ed
 c
on
tro
l)
MMC
Doxazosin
##
#
##
#
##
#
 239 
6.5$ DISCUSSION$
 
The aim of this study was to investigate additional uses for doxazosin or prazosin as 
potential therapies for urogenital cancers. Specifically, it was investigated whether α1-
prazosin may possess novel effects on prostate stromal-cancer paracrine signalling or 
synergistic actions in combination with chemotherapy (docetaxel). Furthermore, 
doxazosin was compared to MMC chemotherapy to uncover a potential novel use of α1-
ADR antagonists for bladder cancer intravesical therapy.  
)
ALPHA1FADR)ANTAGONISTS)AND)PROSTATE)STROMAL)CELLS)(AIMS)1)&)2))
Consistent with previous literature, the findings in this study show cytotoxic effects of 
α1-ADR antagonists on prostate stromal cells. While the cytotoxic actions of doxazosin 
on prostate stroma are known (Kyprianou et al., 2000), the effects of other drugs such as 
prazosin, tamsulosin and silodosin at therapeutically relevant and supratherapeutic 
concentrations were previously unknown. Unlike findings in prostate cancer cells, the 
classically lesser-toxic agents such as the quinazoline alfuzosin and non-quinazolines 
silodosin and tamsulosin were found to induce significant toxicity to WPMY-1 cells in 
a time- and concentration-dependent manner.  Furthermore, the cytotoxic effect of 
alfuzosin and tamsulosin (quinazoline and non-quinazoline, respectively) (100 µM) 
were similar to doxazosin and prazosin at all time points (24-72 h).  Although the 
expression profile of α1-ADR subtypes in WPMY-1 cells is currently unknown, the 
enhanced cytotoxic potency of these drugs (including non-quinazolines silodosin and 
tamsulosin) suggests antagonism of α1-ADR might contribute to WPMY-1 cytotoxicity. 
These findings challenge previous reports of α1-ADR-independence, as well as, 
quinazoline-dependence. The potential involvement of α1-ADR antagonism in cell 
cytotoxicity is discussed in the General Discussion (Chapter 7). Therefore, it can be 
inferred that mechanisms driving the cytotoxic activities of these drugs may differ from 
prostate cancer models (as shown in Chapter 4).   
 
Since stromal-tumour interactions play an important role in prostate tumourigenesis, it 
was investigated whether prazosin may alter these interactions, specifically paracrine 
signalling, in attempts to provide insight into the differences between in vitro potency 
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and clinical anti-tumour efficacy of these drugs.  The present study did not identify any 
significant changes to prazosin-induced cytotoxicity on prostate cancer cell survival 
during co-culture with stromal cells.  However, further optimisation of the co-culture 
methodology used here may be required. More specifically, the lack of effect of stromal 
paracrine signaling on prostate cancer cells cannot be ruled out until findings are 
confirmed with the incorporation of a positive control.  These findings may conflict 
with a previous report (Hori et al., 2011) that cytotoxic naftopidil reduced stroma-
tumour interactions in vivo. However, it is proposed these effects are likely mediated by 
disruption of direct physical interactions as opposed to altered cell-to-cell paracrine 
signalling. Further investigation and optimisation of 2-D, as well as 3-D co-culture 
models (Fong et al., 2016) may provide further insight to the changes in the prostate 
cancer-stroma tumour microenvironment triggered by prazosin or other quinazolines 
such as doxazosin and terazosin.  
)
PRAZOSIN)AND)CHEMOTHERAPY)TREATMENT)OF)PROSTATE)CANCER)(AIM)3))
It was found that, unlike radiotherapy, prazosin does not appear to have synergistic 
effects in prostate cancer cells when combined with docetaxel. These preliminary 
findings are the first report of attempts to enhance chemotherapeutic sensitivity through 
the addition of prazosin in prostate cancer cells. No evidence was found of synergy 
between prazosin and docetaxel cytotoxicity.  At this time the reasons behind the lack of 
synergy between these drugs is only speculative, but may be due to incompatible cell 
death mechanisms or p-glycoprotein pump-mediate efflux of docetaxel and prazosin 
(described in more detail below). Further studies investigating other quinazoline 
antagonists such as doxazosin for cytotoxic synergy with docetaxel or cabazitaxel in 
prostate cancer cells would be particular interest.  
 
The pharmacodynamics between doxazosin and docetaxel remain unclear, but the lack 
of synergistic effect may be due to incompatible cell death mechanisms between these 
agents. In one study evaluating doxazosin and the taxane paclitaxel found a similar lack 
of synergistic cytotoxicity (Cal et al., 2000). It was reasoned that paclitaxel-mediated 
stabilisation of microtubules may have prevent the cytotoxic actions of doxazosin. 
Therefore, it can be reasoned that administration of doxazosin, or other quinazoline α1-
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blockers, and taxane chemotherapy such as docetaxel or cabazitaxel may exhibit 
reduced potency compared to either agent alone. Synergism may be achieved through 
schedule-dependent treatment protocols as investigated in the present preliminary study. 
However, further investigations are required to fully elucidate the effect of the 
combination of these drugs in vitro.  
 
It is known that docetaxel is a substrate of p-glycoprotein pumps (Shirakawa et al., 
1999), which act to detoxify the cell and are particularly important in driving innate and 
acquired chemoresistance (Zhang et al., 2015b). A review of the literature reveals that 
prazosin is also a substrate of these p-glycoprotein pumps and is commonly used to 
monitor p-glycoprotein pump activity in vitro (Shapiro et al., 1999, Rautio et al., 2006).  
As mentioned previously, it is unknown whether the prazosin-p-glycoprotein pump 
interaction contributed to the lack of appreciable synergistic effect. However, one study 
has reported that PC-3 cells do not express p-glycoprotein (O'Neill et al., 2011), further 
complicating the rationalisation for the observed lack of synergistic activity between 
prazosin and docetaxel in the present study.  
 
Doxazosin was reported to inhibit p-glycoprotein and ATP-binding cassette (ABC) G2 
transporter, which has been shown to reduce efflux of radiolabelled drugs and 
significantly enhanced the sensitivity of cells overexpressing these transport proteins to 
paclitaxel and mitoxantrone by 18- and 38-fold (Takara et al., 2009a, Takara et al., 
2012). Interestingly, reversal of mitoxantrone resistance in cells over-expressing 
ABCG2 transporter was also accomplished by other α1-ADR antagonists such as 
naftopidil and prazosin, but not terazosin (Takara et al., 2012). Overall, these effects 
have been largely attributed to direct inhibitory interactions of these drugs with the 
transport pump as opposed to altered protein expression (Takara et al., 2009b, Takara et 
al., 2012). While the present preliminary findings demonstrated no change in cytotoxic 
potential of docetaxel in prostate cells, the literature suggests that these drugs might be 
useful in reversing acquired chemotherapy resistance, particularly in the event of 
docetaxel-treatment failure mediated by aberrant efflux pump activity. Further in vitro 
investigations using cellular models of castrate-resistance and acquired docetaxel-
resistance (O'Neill et al., 2011), coupled with in vivo models, would be of significant 
interest to continue to elucidate the synergistic effects of doxazosin/prazosin in 
clinically relevant settings. 
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DOXAZOSIN)AND)BLADDER)CANCER)(AIM)4))
This exploratory chapter identified potential use for doxazosin as a novel intravesical 
therapy for bladder cancer. It was found that in both continual treatment 24-72 h and 2 h 
(clinical duration) followed by 24-72 h recovery, doxazosin demonstrated superior 
reductions in cell survival compared to the commonly used intravesical therapy, 
mitomycin C (MMC).  
 
While previous literature has described the cytotoxic potential of doxazosin and 
prazosin on a plethora of urogenital cancers (Tahmatzopoulos et al., 2005, Sakamoto et 
al., 2011, Gotoh et al., 2012), this is the first attempt to assess the feasibility of using 
these drugs for anticancer clinical applications, such as intravesical therapy.  These 
findings are particularly important as supratherapeutic concentrations of these drugs are 
unlikely to be both safe and tolerable for cancers which require systemic treatment. On 
the contrary, intravesical treatment carries little risk of systemic exposure, allowing high 
concentrations of drugs to be administered safely and effectively directly to the bladder 
tumour. Of particular interest, bladder cancer is also documented to express functional 
EphA2 receptors and expressional levels are strongly-associated with advanced disease 
(Abraham et al., 2006). In contrast to the non-specific cytotoxicity of mitomycin C and 
gemcitabine, the novel EphA2 agonist doxazosin may selectively target bladder cancer 
cells by restoration of anoikis mechanisms (Petty et al., 2012). Furthermore, this novel 
action may prevent tumour cells from embedding in the urothelium following TURBT. 
However, this doxazosin-mediated effect in bladder cancer is currently unknown and 
requires further investigation. Taken together, these findings suggest that the 
supratherapeutic anticancer potential of doxazosin may be advantageous as intravesical 
therapy for non-muscle invasive bladder cancer.   
 
In future investigations, evaluating the cytotoxic effect of clinically relevant 
concentration of MMC (6 mM) in comparison to supratherapeutic concentrations of 
doxazosin (" 30 µM) may provide further insight to clinical benefit of these drugs 
intravesically.  Since doxazosin is not currently available to Australian patients, whether 
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prazosin is able to elicit a similar anti-bladder cancer effect as doxazosin would be of 
significant interest to the Australian community. Therefore, further in vitro studies 
comparing prazosin to common intravesical chemotherapeutics, as well as elucidation 
of the underlying cytotoxic mechanisms in bladder cancer cells is needed. Likewise, use 
of in vivo bladder cancer models to assess the efficacy of doxazosin/prazosin and MMC 
would be beneficial to explore the clinical relevance of the present findings. 
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CHAPTER$7:$
GENERAL$DISCUSSION$
 $
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The overall aim of this study was to expand upon the current understanding of the 
anticancer effects of various α1-ADR antagonists, including the underlying signalling 
molecular mechanisms, in vitro. This study also investigated whether these drugs may 
enhance efficacy of currently used prostate cancer treatments, such as radiotherapy and 
chemotherapy.  
!
RELATIVE)CYTOTOXIC)POTENCIES)AND)UNDERLYING)MECHANISMS)OF)Α1F
ADR)ANTAGONISTS)IN#VITRO)
In Chapter 3, this thesis compared the relative cytotoxic potencies of alfuzosin, 
doxazosin, prazosin, silodosin, terazosin and tamsulosin, as well as the cell death 
mechanisms underlying the actions drugs in prostate cancer cell lines. Overall it was 
found that prazosin and doxazosin were generally equipotent in their cytotoxic actions 
on AR-positive LNCaP and AR-negative PC-3 cells. Moreover, LNCaP cells were 
found to be more sensitive to the cytotoxic effects of these drugs. These findings were 
consistent with current literature, which reported that quinazoline derivatives (such as 
prazosin and doxazosin) have greater cytotoxic effects than non-quinazolines 
(tamsulosin and silodosin). Additionally, it was found that distinctly separate cell death 
mechanisms regulate the cytotoxic response in AR-positive LNCaP and AR-negative 
PC-3 cells. In LNCaP cells, it appears that these α1-ADR antagonists primarily trigger 
apoptotic cell death; however, prazosin possessed greater apoptotic potential than 
doxazosin. While autophagy was found to be elevated in both cell lines following 
treatment with doxazosin and prazosin; it appears that autophagy only contributed to the 
cytotoxicity of these drugs in PC-3 cells. In contrast, PC-3 toxicity was found to involve 
autophagic mechanisms which was similarly induced by both doxazosin and prazosin 
treatment. As previously mentioned in Chapter 4, these findings are supported by prior 
literature that demonstrated a paradoxical role for autophagy in PC-3 and LNCaP cells; 
acting as a cytoprotective or cytotoxic mechanism, respectively (Pickard et al., 2015).  
 
Elucidation of the molecular mechanisms underlying cytotoxic activity of doxazosin, 
prazosin and terazosin remains incomplete. Separate studies have reported a plethora of 
α1-ADR independent molecular effects ranging from modulation of receptor tyrosine 
kinases (EGFR, VEGFR and EphA2) (Hui et al., 2008, Petty et al., 2012, Park et al., 
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2014a), to activation of TGF-β/Smad-signalling (Partin et al., 2003), direct DNA 
interactions (Arencibia et al., 2005) and inhibition of the cell cycle (Lin et al., 2007). 
Unlike reports of !1-ADR-independence in cancer cell lines, quinazoline-dependent 
cytotoxic effects of the investigated antagonists remain to be fully elucidated. For 
example, the non-quinazoline naftopidil was found to have a similar potency to 
doxazosin and prazosin (Gotoh et al., 2012). Likewise, silodosin and tamsulosin were 
found to be nearly as potent as doxazosin and prazosin in WPMY-1 prostate stromal 
cells (Chapter 6). As such, the observed quinazoline-dependent prostate cancer cell 
toxicity may in fact be an coincidental finding, secondary to !1-ADR independence. 
Either way, it is unlikely that a singular mechanism regulates the cytotoxic actions of 
doxazosin/prazosin. As such, the collective findings of this study presented in Chapters 
4 and 5 in combination with the current literature has led to the following hypothesised 
in vitro cytotoxic mechanism (Figure 7.1). Furthermore, the results of this thesis 
suggest that these cytotoxic mechanisms occur independent of the !1-ADRs in vitro.   
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Figure) 7.1.) Proposed) α1FADRFindependent) cytotoxic) mechanism) of) prazosin) and)
doxazosin) in) prostate) cancer) cell) lines.) Activation) is) represented) by) the) lines)with)
arrows.)Inhibition)is)represented)by)bluntFended)lines.)
 
 
In Chapter 5, prazosin was found to trigger the accumulation of intracellular ROS. 
High-levels of ROS is cytotoxic (in most cases) and eventually leads to oxidative stress 
by overwhelming the innate anti-oxidant capabilities of the cell. Consequently, 
oxidative stress can result in catastrophic outcomes for the cell, causing either apoptosis 
or cell cycle arrest in a cell type- and stimulus-dependent manner. On the other hand, 
low to moderate levels of ROS are known to participate directly or indirectly in redox 
signalling cascades driving a plethora of cellular responses. By directly modulating 
cysteine residues of signalling kinases, ROS promote phosphorylation-independent 
activity of receptor tyrosine kinases and signalling nodes including EGFR and ERK1/2. 
Specific to the proposed mechanism, ROS are known to indirectly promote the 
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activation of the energy-sensing kinase AMPK by two mechanisms. Firstly, intracellular 
ROS deplete ATP stores and increase AMP:ATP radio leading to the activation of the 
LKB1/AMPK axis. Secondly, ATM is responsible for orchestrating cellular response to 
DNA damage, including ROS-mediated genotoxic stress, resulting in cytosolic 
activation of LKB1 and AMPK (Alexander et al., 2010a). As mentioned previously, 
quinazoline-based doxazosin or prazosin has been reported to activate AMPK in rodent 
cardiac cells (Yang et al., 2011a). Together with the present findings, it can be 
hypothesised that prazosin (and possibly doxazosin) activates AMPK through the 
accumulation of intracellular ROS, and subsequent sequestering of mTOR/p70S6K 
signaling cascade.   
 
As reviewed previously in Chapters 3 and 4, in its active state mTORC1 blocks 
autophagy through inhibition of the Ulk complex, while also stimulating cell growth 
signalling through inhibition of 4E-BP and activation of p70S6 kinase (p70S6K). 
Importantly, S6 ribosomal protein is a substrate of p70S6K with growth promoting 
actions (Iwenofu et al., 2008). In the absence of mTORC1 activity, S6 ribosomal kinase 
activity would be suppressed, which was precisely what occurred in Chapter 4. Both 
mTOC1 and p70S6K were found to be suppressed in independent studies evaluating 
doxazosin and prazosin in vitro (Yang et al., 2011a, Park et al., 2014a, Park et al., 
2014b). While these studies used non-prostate cancer cellular models (human ovarian 
cancer and rat embryonic ventricular myoblast), it can be assumed that with the 
presence of appropriate molecules or proteins, signalling mechanisms will be conserved 
between cell types. However, differences may exist in cellular responses to these 
signalling pathways, which will inevitably be regulated by the presence or absence of 
downstream effectors.  This proposed signalling pathway is further supported by the 
results presented in Chapter 5, where prazosin was found to inhibit another downstream 
target of mTORC1, HIF-1α. Activation of mTORC1 triggers hypoxia-independent 
accumulation of HIF-1α, which has been proposed to occur via the transcription activity 
of p70S6K and 4E-BP1 (Dodd et al., 2015). In the present study, prazosin exposure 
suppressed HIF-1α accumulation in PC-3 cells, but less so in LNCaP cells. These 
findings are supported by previous literature, which have demonstrated doxazosin-
mediated inhibition of HIF-1α levels in ovarian cancer cells (Park et al., 2014a).  The 
importance of HIF-1α inactivation in normoxic conditions is unclear, but it may be one 
such mechanism by which prazosin enhances the radiosensitivity of hypoxic prostate 
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cancer cells. This effect will be further explored at a later point in this Chapter.  In 
summary, it is proposed that doxazosin and prazosin elicit their cytotoxic effect to some 
degree by inhibition of the mTOC1/p70S6K pathway. In addition, autophagy is likely to 
be triggered as a consequence of mTORC1 inhibition, which either contributes to or 
protects against cell death in a cell-dependent manner.   
 
As mentioned previously, the proposed cytotoxic mechanisms are likely to occur 
independent of the alpha1-ADR since the highly potent !1-antagonist, tamsulosin was 
unable to induce cell death or cytotoxic mechanisms in prostate cancer PC-3 and 
LNCaP cell lines.  While these findings are consistent with previous literature (Benning 
and Kyprianou, 2002), it remains unclear if !1-ADRs play and important role in the 
anticancer effect of these drugs in vivo and in clinical settings. 
))
 !
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PROPOSED)ANTIFTUMOUR)MECHANISMS)OF)Α1FADR)ANTAGONISTS)IN)
CLINICAL)SETTINGS)
The anticancer potency of α1-ADR antagonists is well documented to differ between 
observations in vitro, animal models and clinical settings.  However, the “elephant in 
the room” has yet to be addressed in the current literature. The supratherapeutic 
concentrations required to induce anti-tumour effects in vitro ( > 10 µM) are well above 
therapeutic concentrations identified in human plasma (33 – 391 nM) (Ahtoy et al., 
2002, Zhao et al., 2009, Korstanje et al., 2011). Therefore, an unknown mechanism 
must exist that acts to enhance the cytotoxic potency of these drugs on hyper-
proliferative cells in vivo and in clinical settings. Four such proposed and potentially 
intertwined mechanisms include: blockade of endogenous α1-ADR stimulation, ion 
channel interactions, effects of tumour hypoxia on receptor density, and stromal-
epithelial interactions.   
'
BLOCKADE'OF'Α18ADR'STIMULATION'
Many studies have attempted to describe the expression profile of α1-ADR subtypes in 
prostate cancers. Unfortunately, the majority of prior investigations have used antibody 
detection methods (Thebault et al., 2003, Katsogiannou et al., 2009), which have 
relatively recently been shown to often be non-specific (Jensen et al., 2009, White et al., 
2013), making these methodologies questionable in characterising specific α1-subtype 
expression. Despite this, the literature continues to provide strong evidence for the role 
of α1-ADRs in the modulation of prostate tumourigenesis.   Two separate studies 
reported antibody-detected α1A-expression in prostate cancer AR-positive LNCaP and 
androgen-independent PC-3 and DU145 cells (Thebault et al., 2003, Katsogiannou et 
al., 2009). In one of these studies, it was also demonstrated that chronic stimulation of 
LNCaP cells with the α1-ADR agonist phenylephrine enhanced cell proliferation in 
vitro, which could be abrogated in the presence of prazosin (Thebault et al., 2003). A 
separate study reported the presence of α1D-subtype adrenergic receptors in AR-
negative PC-3 cells by antibody detection, and was loosely confirmed by the presence 
of α1D-subtype mRNA expression as detected by RT-PCR analysis of human benign 
and malignant prostatectomy tissue specimens (Morelli et al., 2014). Likewise, it was 
found that cancerous tissues possessed a greater expression of α1D-ADR compared to 
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non-cancerous prostate samples. These two studies also report the co-involvement of 
TRP receptors with α1-ADR in regulating prostate cancer proliferation (Morelli et al., 
2014, Thebault et al., 2003). Supporting previous findings (Thebault et al., 2003), 
parallels between α1D-ADR and transient receptor potential (TRP) vanilloid-1 (V1) 
expression were observed in in vitro and in human prostate cancer specimens (Morelli 
et al., 2014). Briefly, the TRP family are plasma membrane calcium non-voltage gated 
channels that have been associated with increased tumourigenic potential (Liberati et 
al., 2014).  Furthermore, stimulation with noradrenaline was found to enhance AR-
negative PC-3 proliferation, in a α1D and TRPV1 dependent manner, however 
functionality of both α1D and TRPV1 was required for maximal proliferative effects in 
PC-3 cells. These reports are supported by earlier work by Thebault et al. (2003), which 
showed that in addition to prazosin-mediated blockage of α1-ADR, TRP channel 
inhibition also suppressed the proliferative effect of chronic phenylephrine stimulation 
in LNCaP cells. The cellular mechanism regulating the proliferative effects in prostate 
cancer described above is likely to involve TRP-mediated influx of calcium ions (as 
review in Chapter 1). As shown in Figure 7.2, α1-ADRs associate with TRP channels 
to promote calcium influx and subsequent signalling pathways to promote cell 
proliferation, thereby contributing to prostate cancer tumourigenesis (Deliot and 
Constantin, 2015). 
 
Unlike in vitro studies, in vivo α1-ADRs are under constant stimulation by circulating 
catecholamines. Dysregulation of these mechanisms in prostate cancers may exhibit a 
tumourigenic effect. Previously, it was demonstrated that metastatic castrate-resistant 
prostate cancer tissues have a greater expression and activation of TRPV2 compared to 
primary tumours (Monet et al., 2010). This effect was postulated to be a result of 
androgen-deprivation, which indirectly increased TRPV2 expression, and subsequently, 
metastatic potential of prostate cancer cell lines. Taken together, blockade of 
endogenous α1-ADR stimulation and downstream TRP channel-mediated calcium 
influx, may reduce prostate cancer proliferation, and even delay progression to castrate-
resistant state. While this mechanism is likely to negatively affect cell proliferation, it is 
unknown if inhibition of α1-ADR/TRP/calcium-signalling will result in apoptosis. 
Therefore, this mechanism alone does not fully encompass the apoptotic effects seen in 
animal and human studies. 
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)
Figure) 7.2.) Proposed) signalling)mechanisms)of) plasma)membrane) calcium) channels)
in) regulating) prostate) cancer) cell) cycle) and) proliferation) (Deliot) and) Constantin,)
2015).) In) the) case) of) α1FADRs) (right),) stimulation) by) catecholamines) promotes)
TRPCFmediated)calcium)influx,)resulting)in)activation)of)NFAT.)NFAT)translocates)to)
the)nucleus) and) inFturn)promotes) cell) cycle)progression)by) interactions)with) cyclin)
E.)Figure)reprinted)with)permission)from)copyright)holder.)
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ION'CHANNEL'INTERACTIONS'
Ion channels, particularly voltage gated sodium and potassium channels are known to 
play a role in cell proliferation, tumourigenesis, invasion and metastasis of several 
cancers, including prostate cancer (Fraser et al., 2014). In addition to the presumed 
indirect effects of α1-ADR antagonists on the calcium channel TRP via interaction with 
α1-ADRs, doxazosin and prazosin have previously been reported to inhibit potassium 
and sodium channels at therapeutic concentrations (Obata and Yamanaka, 1999, 
Thomas et al., 2004).  
 
A cluster of studies by the Thomas research group demonstrated that doxazosin, 
prazosin and terazosin bound to and inhibited the human ether-a-go-go-related gene 
potassium (hERG K+) channels resulting in apoptotic cell death in various cell lines 
(Thomas et al., 2004, Thomas et al., 2008, Staudacher et al., 2014). At this time, hERG 
K+ channels are not well documented in prostate cancer cells. However, over expression 
of these channels has been previously identified in androgen-independent DU145 
cancer cells, and indirect down-regulation of hERG expression was associated with 
increased prostate cancer apoptosis in vitro (Ji et al., 2015). Whether these potassium 
channels exist in other cellular models of prostate cancer, such as PC-3 and LNCaP, 
remains to be elucidated.  
 
A search of the literature also reveals an incidental report of sodium channel blocking 
properties of prazosin (Obata and Yamanaka, 1999). In contrast to benign prostate cells, 
it has been demonstrated that over-expression of functional sodium channels was 
characteristic of prostate cancer in vitro (Diss et al., 2001, Shan et al., 2014), which may 
function as a tumourigenic mechanism by promoting cancer cell motility and thus 
metastasis (Fraser et al., 2003).  In theory, inhibition of sodium channels in prostate 
cancer might delay development of advanced metastatic disease. Despite a lack of 
substantial evidence for inhibitory interactions of prazosin on sodium channels, 
revisiting this area would provide significant insight to the mechanisms contributing to 
the anticancer effects clinically.  
 
 '
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TUMOUR'HYPOXIA8MEDIATED'MODULATION'OF'RECEPTOR'ACTIVATION'AND'EXPRESSION''
As described in Chapter 5, hypoxia is well documented to promote tumourigenesis 
through HIF-1α stabilisation, which in turn, promotes angiogenesis. Importantly, 
hypoxia promotes radioresistance of tumours, particularly in prostate cancers, by 
suppressing irradiation-induced ROS formation and HIF-1α-mediated survival and 
adaptation.  In addition, hypoxia is reported to alter the activation and expression of 
various tyrosine kinase receptors associated with tumourigenesis, metastasis and 
invasion, including EGFR and EphA2 (Vihanto et al., 2005, Gluck et al., 2015). 
Particularly, overexpression of EGFR has been strongly associated with tumour hypoxia 
(HIF-1α) in vitro and histological studies of resected tumour specimens (Hoogsteen et 
al., 2012, Weber et al., 2012).   Less is known about the impact of hypoxia on the 
expression of Eph receptors, particularly EphA2. One study suggests that these 
receptors are up-regulated in hypoxic conditions (Cercone et al., 2009). If in fact 
doxazosin/prazosin act by actions on EGFR or EphA2 (Hui et al., 2008, Petty et al., 
2012), it can be hypothesised that the cytotoxic potency of these drugs would be 
enhanced in hypoxic solid tumours. In other words, the cytotoxic outcome effect of α1-
ADR antagonists in theory would be proportional to the number of receptor inhibited, 
producing a greater effect in hypoxic tumours compared to well-vascularised tissues. 
However, clinically, it is likely to be more complex than proposed, as hypoxia triggers a 
plethora of survival and adaption mechanisms. For example, hypoxia induced resistance 
to the EGFR antagonist gefitinib (similar quinazoline structure to doxazosin) by 
increasing activity of insulin-like growth factor 1 receptor in lung cancer cells 
(Murakami et al., 2014). Nevertheless, the effect of hypoxia is likely to be an important 
aspect to the clinical efficacy of α1-ADR antagonists as anticancer agents and warrants 
further investigation. 
 
 )
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THERAPEUTIC)VALUE)OF)DOXAZOSIN)AND)PRAZOSIN)FOR)PROSTATE)CANCER)
The findings presented in Chapter 5 demonstrated that doxazosin/prazosin enhanced the 
sensitivity of hypoxic PC-3 and LNCaP cells to radiotherapy.  This effect was likely to 
occur independent of α1-ADR antagonism since the highly selective α1-ADR 
antagonist, tamsulosin, had no effect on the sensitivity of prostate cancer cells irradiated 
under either normoxic or hypoxic conditions. However, clinically, α1-antagonism may 
also be beneficial to radiotherapy treatment outcomes. It was previously reported in 
separate studies that rats pre-treated with α1-ADR agonist or a combination of both 
muscarinic and α1-ADR agonists prior to irradiation of non-cancerous salivary glands, 
demonstrated significantly reduced irradiation-induced tissue damage (Xiang et al., 
2013, Coppes et al., 2001).  In the case where α1-ADR activity acts to promotes 
tumourigenesis, it is unknown whether the antagonism of physiologically relevant 
stimulation of α1-ADR will enhance radiosensitivity of prostate cancer tumours. 
However, it poses an attractive mechanism where α1-ADR antagonists such as prazosin 
might improve radiotherapy outcomes by mitigating treatment-associated LUTS, 
inhibiting α1-ADR-mediated tumourigenesis and selectively targeting hypoxic prostate 
cancer cells.  
 
In contrast to radiotherapy, the combination of α1-ADR antagonist prazosin and 
chemotherapeutic agents did not appear to have a synergistic effect. On the contrary, the 
combination may actually possess an antagonistic effect that is cytoprotective. While 
further investigations are required, this suggests that the clinical benefit of combination 
therapy may be clinically beneficial for men treated with radiotherapy, whereas these 
drugs should be used with caution in men treated with docetaxel or cabazitaxel for 
prostate cancer.  
 
Clinical trials highlight the importance of autophagy in relation to prostate cancer, with 
modulators of autophagic activity, such as silencing of autophagy-related genes or 
pharmacological modulators of autophagy, possessing clinical efficacy although in a 
patient/disease-specific manner (Armstrong et al., 2013). The present study 
demonstrated that doxazosin and prazosin induced autophagy in both prostate cancer 
cell lines and contributed to the cytotoxic response in PC-3 cells. Nonetheless, there is 
no current evidence to suggest that clinically relevant doses of doxazosin or prazosin are 
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effective in inhibiting mTOR, thereby inducing autophagy in vivo. The results do 
suggest that these drugs may be useful in modulating autophagy and subsequent 
sensitivity to anticancer therapies as described by previous studies (Lin et al., 2010, 
Morikawa et al., 2012, Ling et al., 2014, Pickard et al., 2015).  However, it is 
acknowledged that for some prostate cancers autophagy may act as a pro-survival 
mechanism and theoretical induction of autophagy by doxazosin or prazosin may be 
disadvantageous (Bennett et al., 2013), although this may be overcome through the 
addition of autophagy inhibitors (Pickard et al., 2015).   
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EXPERIMENTAL)LIMITATIONS)AND)FUTURE)INVESTIGATIONS)
While the present study further advances the current understanding of the cytotoxic 
actions as well as the cell death mechanisms of doxazosin and prazosin, it is 
acknowledged there are experimental limitations that should be addressed in future 
studies.  Likewise, the present findings have also raised a number of questions with 
potential for further investigation. 
 
The evaluated concentration range chosen was based on a logarithmic scale to 
encompass a wide range of clinically-relevant and supratherapeutic doses. Prostate 
cancer cells were then treated with these concentrations for 24 – 72 h.  To further the 
understanding of the cytotoxic effects of these drugs, a supratherapeutic dose-response 
curve containing several concentrations between 10 and 100 µM may be beneficial to 
more accurately determine IC50 values. If within solubility limits of the drugs, 
concentrations greater than 100 µM for the lesser toxic alfuzosin, terazosin, silodosin 
and tamsulosin would further clarify relative cytotoxic potency between these drugs.  
 
Treatment times investigated (24 – 72 h) were based on typical cell culture treatment 
protocols used within the present laboratory. However, the clinical relevance of these 
treatment durations are limited since the clinical dosing of these drugs is 1-2 times daily 
for months to years. Therefore, extended treatment (> 72 h) in vitro may continue to 
close the gap between in vitro and clinical observations. Cell cultures treated beyond 72 
h may require additional optimisation to prevent the negative effects of long term cell 
culture such as acidifying of the medium, culture medium evaporation and the loss of 
medium nutrients.  
 
Two-dimensional cell culture is the current standard for pre-clinical investigations of 
drug cytotoxicity and molecular mechanisms. However, in recent years it has been 
acknowledged that the clinical relevance of 2-D culture is limited since it poorly mimics 
true physiological conditions. To close the gap between the cytotoxicity of doxazosin 
and prazosin observed in vitro and clinical findings, additional investigations utilising 
prostate cancer and stromal cell 3-D co-cultures would be of significant importance. 
Although the present study did not find an appreciable effect using 2-D indirect co-
cultures, direct 2-D or 3-D co-cultures (scaffolding or MatriGel®) may be useful in 
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further exploring the anticancer effects of these drugs. The use of direct (2-D or 3-D) 
co-cultures more accurately mimics the tumour microenvironment, which allows the 
cultured prostate tumours to interact directly with stromal cells and/or the extracellular 
matrix as they would physiologically. Furthermore, 3-D cultures also, to some degree, 
can replicate characteristic tumour hypoxia and acid imbalances which are crucial to 
tumourigenesis (Choi et al., 2014). To the best of my knowledge, no current published 
literature has employed direct 2-D or 3-D co-culture technique for investigating the 
anticancer effects of doxazosin, prazosin or tamsulosin in prostate cancer or stromal 
cells. However, some limitations exist in the use of direct (2D and 3D) co-cultures. To 
accurately examine the potential proliferative effects of direct prostate stromal-cancer, 
as well as, the cytotoxic effects of these drugs, the stromal and cancer cells must be 
labeled and changes measureable. One such way is to use viral vectors to induce stable 
expression of green or red florescent proteins to distinguish and quantify changes in 
stromal or epithelial cell number. However, these techniques can be time consuming 
and costly. Furthermore, genetic modification may have unsolicited effects of cell 
proliferation or cytotoxic response, further removing the in vitro experiment from 
clinical relevance. Despite these limitations, the effect of these drugs on 2-D co-culture 
or 3-D tumour development and their cytotoxic potencies in established tumours would 
be of great interest.  
 
In Chapter 4, changes in protein expression and phosphorylation of several cell stress 
and RTK signaling targets in response to doxazosin and prazosin were investigated. 
This was the first reported instance of using an array to assess the underlying cytotoxic 
mechanisms of these drugs following 24 h exposure in vitro. While these experiments 
provided a plethora of data, further studies investigating the identified targets of interest 
are required. One limitation of these array kits is the lack of a total protein expression 
control making changes in phosphorylation in protein difficult to interpret.  In the 
current study, changes in protein phosphorylation status were merely correlated with 
changes in protein activation. While, the manufactures’ optimisation data provided with 
the array kits suggest that phosphorylation indeed equates to activation; determination 
of total target protein in conjunction with phosphorylated protein is required to ascertain 
activation. For example, apparent changes in phosphorylation may in fact be due to 
changes in expression or elimination of target proteins. The use of Western blotting or 
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ELISA methods would be useful to measure both total and phosphorylated protein 
expression of the identified doxazosin/prazosin protein targets.  
 
Another limitation of the array experiments conducted in Chapter 4 was the single 
investigated time-point (24 h). While it was the intention of the present study to 
investigate the sustained cytotoxic molecular mechanisms at 24 h to coincide with the 
apoptosis and autophagic data (24 h) presented in Chapter 3, future studies investigating 
time-dependent phosphorylation (activation) of the identified targets and related 
signaling pathways.  This might clarify apparent discrepancies between findings in the 
literature and those presented in Chapter 4. For example, Hui et al. (2008), reported 
inhibition of EGFR following acute treatment with doxazosin, whereas the present 
study found no significant change to EGFR phosphorylation following 24 h doxazosin / 
prazosin exposure in prostate cancer cells.  As discussed in the Chapter 4, EGFR 
activation by doxazosin / prazosin is likely to be an early signaling event which may not 
be sustained at 24 h.  Future time course studies (5 minutes to > 24 h) using Western 
blotting or ELISA methods would be useful to further characterise the time-dependent 
effect of these drugs on the molecular targets of doxazosin / prazosin. As a last measure, 
the use of pharmacological inhibitors or small interfering RNA-mediated gene 
knockdown in combination with Western blotting and the resazurin reduction assay 
would be useful to confirm the proposed cytotoxic mechanisms of doxazosin and 
prazosin.   
 
In Chapter 5 the fluorescent probe DCF was used to investigate the changes in 
intracellular reactive oxygen species following irradiation in the presence or absence of 
prazosin and environmental oxygen. While the present DCF data suggests prazosin 
enhances ROS in the presence or absence of irradiation, further investigation is required 
to confirm findings. As described in Chapter 5 Methods section, it is known that the 
DCF assay can be adversely affected by light, which was controlled for throughout the 
study. However, DCF-DA has been reported to not be a direct indicator of intracellular 
ROS, but in fact DCF-DA oxidation is dependent on ROS-mediated mitochondrial 
release of redox-active iron and/or cytochrome c (Karlsson et al., 2010). Additional 
studies using a more specific ROS probe, such as the mitochondrial superoxide 
indicator MitoSOX Red or Amplex Red Hydrogen Peroxide assays. Optimisation of 
ROS experiments will be required to overcome the challenge of treating and irradiating 
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in glass vessels (petri dishes or glass 96-well plates) and subsequent fluorescence 
reading of intracellular or extracellular ROS production or release, respectively.   
 
In the experiments presented in Chapter 5 it was found that prazosin had 
radiosensitising actions on hypoxic prostate cancer cells. Whether this effect is specific 
to prazosin, or if it may extend to doxazosin, or the modestly cytotoxic terazosin, is 
unknown. Additionally, it is unknown if the observed prazosin-mediated 
radiosensitisation of hypoxic prostate cancer cells can be replicated in other 
experimental models such as 3D cultures (single cell line or co-culture). To more 
closely mimic clinical conditions, treatment with therapeutic concentrations with 
combination of a typical therapeutic irradiation regimen would be useful for the 
understanding of whether these drugs may possess clinical benefit. Pending studies with 
3-D co-cultures, in vivo murine models also may help to identify to potential clinical 
relevance. For example, mice xenografted with AR-negative PC-3 prostate cancer cells 
could be treated with therapeutically-relevant doses of prazosin, doxazosin or 
tamsulosin and evaluated for frequency of metastasis and irradiation disease response in 
the presence or absence of these drugs. Furthermore, murine PC-3 tumour 
immunohistochemistry (or similar studies) for molecular targets previously identified 
(e.g. mTOR, HIF-1!) following drug treatment in the presence or absence of irradiation 
may help to further elucidate the anticancer mechanisms in vivo, and potentially 
clinically.   As an adjunct to present study, a retrospective review of patient records 
conducted by a colleague at Griffith University (B. Spencer, Gold Coast, Australia) is 
currently underway investigating whether treatment with α1-ADR antagonists may 
prevent or delay radiation therapy biochemical failure. The findings of this novel study 
will guide further experimental investigations as well as potential prospective clinical 
trials.  
 
Based on the preliminary findings presented in Chapter 6, the significant cytotoxic 
effect of acute doxazosin treatment on bladder cancer cells warrants further 
investigation. Likewise, unpublished data from our lab suggests that prazosin has a 
similar cytotoxic profile to doxazosin in these cell lines (P. Singh, Bond University, 
Australia), indicating these drugs may be useful as an alternative intravesical treatment 
where extremely high concentrations can be used with minimal organ-confined toxicity. 
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Of particular interest is in vivo modelling of bladder cancer and intravesical treatment 
with doxazosin/prazosin. Rodent models of bladder cancer can be induced using 
carcinogens such as N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) or transplanted via 
transurethral instillation of human bladder cancer cell lines including T24s (Zhang et al., 
2015a). Although BBN-induced rodent bladder cancer is histologically and genetically 
similar to human bladder cancers, these tumours are more similar to human invasive 
bladder genotype making this experimental model undesirable for evaluation of non-
invasive bladder cancer (Williams et al., 2008). In addition to evaluating the anticancer 
effects if intravesical doxazosin/prazosin, patterns of urination and assessment of 
released chemical mediators (e.g. ATP) might provide insight to any treatment-related 
bladder toxicity. 
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CONCLUDING$REMARKS$
 
The findings presented in this thesis demonstrate that doxazosin and prazosin exhibited 
the greatest cytotoxic potency of the investigated antagonist, possessing apoptotic and 
autophagic effects in prostate cancer cells. However, cell death mechanisms were found 
to be predominantly cell-type dependent, with these drugs inducing apoptotic cell death 
of LNCaP cells, and autophagic cell death in PC-3 cells. Furthermore, prazosin was 
found to sensitise hypoxic prostate cancer cells to irradiation, which likely involved 
ROS-mediated induction of autophagy in PC-3, and enhanced apoptosis in LNCaP 
cells.  Mechanistic investigations implicated the inhibition of mTORC1/p70S6K-
signaling as a novel mechanism underlying the cytotoxic effect of these drugs, as well 
as the radiosensitising effect of prazosin in hypoxic prostate cancer cells.  Preliminary 
findings in bladder cancer T24 cells also demonstrated sustained cytotoxic effects 
following acute doxazosin exposure, which were significantly greater than the currently 
used chemotherapeutic mitomycin C. 
 
In conclusion, these findings expand the current understanding of the mechanisms 
contributing doxazosin/prazosin-mediated prostate cancer toxicity in vitro. While 
further investigations are required, this thesis proposes a novel use for these drugs to 
improve the clinical treatment efficacy of radiotherapy for prostate cancer, or as 
intravesical agents for bladder cancer. 
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